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The maturation of many secreted proteins in Saccharomyces cerevisiae involves the
cleavage of a precursor polypeptide after pairs of basic residues by a specific
protease (Kex2p) at a late stage in the secretory pathway. The aim of this project
was to determine the order of processing events and the importance of ordered
processing in the maturation of a multi-subunit protein toxin (the Kluyveromyces
lactis killer toxin) in the S. cerevisiae secretory pathway. The involvement of Kex2p
in the maturation of the K. lactis killer toxin was confirmed and the cleavage event
was shown to most likely occur at a late stage in the secretory pathway. In order to
determine whether the timing of Kex2 processing was critical for efficient
maturation and secretion of secretory proteins an attempt was made to localise the
Kex2 activity to the endoplasmic reticulum (ER) and thus cause premature Kex2
processing of secretory proteins. In order to localise Kex2 activity to the ER,
various constructs were made based on an active portion of the Kex2p that can be
secreted. Various sequences were fused to the C-terminus of this truncated Kex2p in
an attempt to localise Kex2 activity to the ER. A truncated Kex2 polypeptide with the
60 C-terminal amino acids of yeast protein disulphide isomerase (PDI) added to
create a Kex2-PDI hybrid protein was more efficiently retained within the cell than
any of the other constructs, including a truncated Kex2p with the yeast HDEL
retention signal added to the C-terminus. The implications of these results are
discussed in the thesis.
Analysis of the effect of the different Kex2 constructs on the processing and assembly
of the K. lactis killer toxin was hampered by the complexities of the toxin system and
technical difficulties. Therefore in order to determine the activities of the various
Kex2 constructs in vivo the production of the peptide mating pheromone a factor was
measured. Suprisingly the efficiently retained Kex2-PDI hybrid protein exhibited
the lowest in vivo activity in this experiment. Assuming that the Kex2-PDI hybrid
protein is localised to the ER as predicted, the results suggest that Kex2p localised in
the ER cannot facilitate the efficient maturation of secretory proteins into an active
secreted form. Possible reasons for this are discussed in the thesis.
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In eukaryotic cells, secretory proteins must be accurately transported between a
series of membrane bounded organelles, and eventually to the cell surface where they
are released. Secretory proteins released at the cell surface differ from the cognate
primary translation products due to modifications made to the proteins in the
secretory pathway during transport. The following sections attempt to give a broad
view of the eukaryotic secretory pathway and processes that take place in this
pathway based on current knowledge. Aspects of the secretory pathway particularly
relevant to this project will be discussed in greater detail. Secretion of proteins
from the yeast Saccharomyces cerevisiae will be discussed separately as it is the
experimental organism used in this project.
1.1 The secretory pathway of mammalian cells: a brief overview.
Proteins that enter the secretory pathway are synthesised on polysomes attached to
the rough endoplasmic reticulum (RER) (Siekevitz and Palade 1960) and are
translocated across the endoplasmic reticulum (ER) membrane. Translocated
secretory proteins move from the ER to the Golgi complex where they are packaged
into secretory vesicles and transported to the plasma membrane. As well as proteins
destined for the cell surface and secretion, other classes of protein enter the
secretory pathway, both soluble and membrane bound. Lysosomal proteins and
proteins resident in the different organelles of the secretory pathway all enter the
secretory pathway in the same way as secreted proteins, but do not usually reach the
cell surface. The correct localisation of proteins that enter into the secretory
pathway is necessary to maintain the integrity and function of the cell.
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1.1.1 Translocation of proteins across the ER membrane.
Proteins to be translocated across the ER membrane possess a specific signal
sequence, usually located at the extreme amino terminus of the protein (Blobel and
Dobberstein 1975). There is no consensus signal sequence but a number of features
are commonly found. They are:- the presence of 1-3 positively charged amino acids
in the amino terminal region, followed by a long hydrophobic sequence consisting of
14-20 amino acids and ending in a glycine or an alanine at the carboxy terminus of
the signal peptide (von Heijne 1985). The signal sequence of a nascent polypeptide,
upon emergence from the ribosome, is recognised by the signal recognition particle
(SRP) (Walter and Blobel 1981) through its 54K component (Krieg et al 1986). In
the absence of membranes SRP can induce an arrest of elongation of the polypeptide
in vitro (Walter and Blobel 1981). Interaction of SRP with its receptor in the ER
membrane (docking protein) (Meyer et al 1982, Gilmore et al 1982) causes SRP to
be released from the ribosome (Gilmore and Blobel 1983) and from the signal
sequence (Wiedmann et al 1987a). The signal sequence is then found in the close
proximity of a 35K integral glycosylated membrane protein of the ER (Wiedmann et
al 1987b). The actual process of passage of the polypeptide across the phospholipid
bilayer is still poorly understood. A ribosome receptor and a proteinaceous tunnel to
provide a hydrophilic environment for the passage of the polypeptide chain have
been postulated (Blobel and Dobberstein 1975) but not yet identified. Proteins will
usually pass through the ER membrane into the lumen of the ER unless a second
hydrophobic region which can anchor the protein in the membrane is present (for
review see Rapoport and Weidmann 1985).
1.1.2 Modifications in the ER.
Polypeptides translocated across the ER membrane are acted upon by a number of
enzymes on the luminal side of the membrane. As the protein enters the lumen of the
ER the signal sequence is usually removed by signal peptidase (Baker efa/ 1986,
Evans et al 1986). A high mannose oligosaccharide core unit is transferred to
selected asparagine residues located in the sequence Asn-X-Ser/Thr where X can be
any amino acid except proline (see fig. 1.1). The efficiency of this N-linked
glycosylation is dependent on the conformation of the peptide chain as it enters the
lumen of the ER, as potential glycosylation sites may no longer be accessible once the
protein has folded (for review see Kornfeld and Kornfeld 1985). Some modifications
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to the N-linked oligosaccharide occur in the ER (see fig. 1.1 and section 1.1.5).
Another type of modification that takes place in the ER is the formation of disulphide
bonds by thiol oxidation and disulphide exchange which is catalysed by the enzyme
protein disulphide isomerase (PDI) (Freedman 1984). PDI has also been implicated
in a number of other processes that take place in the ER. As well as existing as a free
monomer, PDI is an essential subunit of prolyl-4-hydroxylase, an enzyme that
catalyses the modification of prolyl residues in newly synthesised collagen
(Pihlajaniemi et al 1987). PDI also binds to the Asn-X-Ser/Thr acceptor sequence
for N-linked glycosylation and is an important component of oligosaccharide
transferase (Geetha Habib et al 1988). As well as making these covalent
modifications to polypeptides, proteins present in the ER may be involved in helping
proteins to fold and assemble correctly (see later sections).
1.1.3 Transport between the ER and the Golai
Electron microscopic studies have suggested that small vesicles transport proteins
from the RER to the Golgi apparatus. Regions of the RER free of ribosomes are
thought to be nascent transport vesicles but may also represent vesicles that are
fusing with the ER (Farquarh and Palade 1981, Saraste and Kuismanen 1984).
Vesicles responsible for transport of proteins between the ER and Golgi have been
described biochemically (Lodish et al 1987). More recently, cell-free systems have
been developed that reconstitute ER to Golgi transport of newly synthesised
glycoproteins (Haselback and Schekman 1986, Balch et al 1987). In these cell-free
systems, movement to the Golgi apparatus is monitored by the action of a Golgi
oligosaccharide processing enzyme on the glycoprotein from the donor ER vesicles. It
has been discovered that for the donor glycoprotein to be modified by the Golgi
enzymes, energy in the form of ATP, cytosolic proteins and membrane proteins are
required. However, in these cell free systems vesicular intermediates of transport
between the ER and Golgi have not been detected and promiscuous fusion of ER and
Golgi vesicles may be occurring that does not occur in vivo.
1.1.4 The Golai complex.
The Golgi complex consists of at least three functionally and compositionally distinct
compartments (or cisternae) that operate in succession to construct the
oligosaccharide chains on transported glycoproteins (see fig. 1.1)(Dunphy and
4
Rothman1985) and sort out proteins destined for lysosomes, the cell surface or
secretory granules. The Golgi complex is also the site of processes such as O-linked
glycosylation (for review see Kornfeld and Kornfeld 1985), sulphation (Huttner
1988), phosphorylation of lysosomal enzymes (von Figura and Hasilik 1986) and
proteolytic processing of prohormones (for review see Thomas et al 1988).
Transport between adjacent cisternae of the Golgi complex is thought to be mediated
by the budding and fusion of vesicles (for review see Pfeffer and Rothman 1987)
that requires energy and protein components in a cell-free system (Malhotra et al
1988) in a similar fashion to transport between the ER. and Golgi apparatus.
Vesicular transport between membrane bounded compartments in a cell allows the
compartments to be separate from one another and able to contain different
intra-compartmental environments. Conditions such as pH, ionic strength and
protein content can be varied from compartment to compartment. This
compartmentalisation of organelles allows the wide variety of modifications that are
needed for the maturation of proteins in the secretory pathway to occur in an ordered
fashion.
1.1.5 N-linked olvcosvlation.
Most proteins that are synthesised in the ER become glycosylated. The elaborate
series of covalent modifications that take place in the ER and Golgi apparatus are well
established and the structure of the oligosaccharide moiety indicates to which
enzymes in the processing pathway the glycoprotein has been exposed. In many cases
this information can be used to infer which compartment the glycoprotein has
reached during transport through the secretory pathway (for review see Kornfeld
and Kornfeld 1985)
The first step in the synthesis of N-linked oligosaccharides is the transfer of the
precursor GIC3MangGlcNAc2 (Glc = glucose, Man = mannose, and GlcNAc =
N-acetylglucosamine) from its lipid donor to an asparagine residue on a nascent
polypeptide in the RER, (fig. 1.1: reaction 1). The terminal Glc is removed (reaction
2) and then the two inner Glc residues are removed (reaction 3). The specific
glucosidases that catalyse these reactions are located in the membranes of the RER, as
is a specific a-mannosidase which catalyses the removal of at least one a1,2-linked
5
Fig. 1.1 N-linked alvcosvlation.
This figure is a diagrammatic representation of N-linked glycosylation through the
secretory pathway. The enzymes that catalyse the reactions are:-
oiigosaccharyltransferase (1), a-glucosidase I (2), a-glucosidase II (3), ER 1,2
mannosidase (4), N-acetylglucosaminylphosphotransferase (I), N-acetylglucosam-
ine-1-phosphodiester a-N-acetylglucosaminidase (II), Golgi a-mannosidase I (5),
N-acetylglucosamiyitransferase I (6), Golgi a-mannosidase II (7), N-acetylglucos-
-aminyltransferase II (8), fucosyltransferase (9), galactosyltransferase (10) and











Man residue (reaction 4). Once transported to the Golgi apparatus, further
modifications take place. In the c/'s-Golgi, lysosomal enzymes undergo a specific Man
phosphorylation (reactions I and II). The high Man oligosaccharides on
non-lysosomal glycoproteins can be further trimmed by a Golgi mannosidase
(reaction 5) to yield a Man5GlcNAc2 structure in the cis or medial Golgi cisternae.
In the medial cisternae oligosaccharides destined to become complex type structures
are processed by the addition of GlcNAc (reaction 6) followed by the removal of two
Man residues (reaction 7) and subsequent addition of another GlcNAc residue
(reaction 8). At this stage fucose may be added to the innermost GlcNAc residue
(reaction 9). In the trans-Golgi outer chain galactose and sialic acid residues are
added (reactions 10 and 11). Other terminal sugar additions are also thought to
occur at this late stage.
1.1.6 Proteolytic processing
Small peptide hormones and neurotransmitters are usually synthesised as larger
precursor proteins that undergo proteolytic cleavage to produce mature bioactive
peptides (Thomas et al 1988). The peptides in precursor proteins are usually
flanked by pairs of basic residues ie Lys-Lys, Arg-Arg or Lys-Arg and diverse
enzymes have been implicated in the processing at such sites (Loh et al 1987,
Clamagrand efa/1987, Gluschankof 1987 , Davidson 1987, Marx 1987). Although
proteases with the required specificities for cleavage have been isolated from
mammalian cells their exact physiological roles have not been identified. The Kex2
protease of the yeast Saccharomyces cerevisiae has been much studied and has been
shown to have a physiological role in prohormone processing which will be discussed
in later sections. After cleavage at pairs of basic amino acid residues, flanking amino
acids are usually removed by a carboxypeptidase B-like enzyme or a similar
aminopeptidase (Thomas et al 1988).
1.1.7 The problem of protein sorting
The problem of how proteins in eukaryotic cells reach their final destinations so that
the subcellular organelles of a cell can be formed and maintained has been the subject
of a lot of recent attention. A pattern is emerging to suggest that the proteins
themselves contain the signals that direct them to the appropriate locations in the
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cell. As has already been mentioned, proteins that are to be translocated across the
ER membrane contain structural motifs that facilitate this transfer (von Heijne
1985). Similarly mitochondrial proteins contain sequences that allow them to be
incorporated into this organelle (Horwich et al 1985, Schatz 1987). The targetting
sequences mentioned above are primarily located in the amino-terminal
(N-terminal) region, but other targetting sequences may occur elsewhere in the
protein. The structural motifs that allow a protein to enter into the nucleus are short
linear sequences located at internal positions within the protein (Dingwall et al
1982, Kalderon efa/1984). Also the attachment of mannose-6-phosphate, a signal
required for transport of proteins to the lysosome in mammalian cells is not
necessarily confined to the N-terminal end (Kornfeld 1986, von Figura and Hasilik
1986) and peroxisomal targetting sequences have been identified in the carboxy
terminal (C-terminal) region of a protein (Miyazawa et al 1989, Gould et al
1 989).
Proteins that are destined for secretion, and proteins that constitute structural and
functional components of the secretory organelles have somehow to be distinguished
from one another as they all enter the secretory machinery by being translocated
across the ER membrane. It was originally suggested that proteins destined for
secretion contained specific sequences that targetted them to be secreted (Lodish et al
1983). However, the view now more widely held is that secretion occurs by a bulk
flow mechanism and proteins that are to be prevented from being secreted are
somehow selectively retained.
One striking piece of evidence to suggest that secretion occurs by default comes from
experiments performed by Wieland efa/(1987). Their experiments showed that a
synthetic tripeptide consisting of the consensus glycosylation sequence
Asn-Tyr-Thr, esterified to make it membrane permeable can enter cells, be
glycosylated in the ER (thus making it membrane impermeant) and can then be
rapidly secreted. Furthermore the data from these experiments suggests that at least
some of the secreted tripeptide passes through the normal secretory and the Golgi
apparatus, as the appropriate modifications to the attached oligosacccharide take
place.
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1.1.8 Retention of proteins
Resident proteins of the various secretory organelles must somehow avoid export by
the bulk flow pathway of secretion. It is easy to imagine how membrane proteins
that are residents of secretory organelles may escape export by bulk flow by being
held in position by interactions between their cytoplasmic domains and other
cellular structures. In fact it has been shown that short cytoplasmic sequences serve
as retention signals for transmembrane proteins in the ER , (Nillson et al 1989,
Poruchynsky and Atkinson 1988) although the proteins with which they interact
have not yet been identified. For truly soluble proteins in the lumen of secretory
organelles, retention represents a greater conceptual problem. If these proteins are
soluble and easily diffusible it would seem that they will tend to be secreted by the
bulk flow as are secretory proteins. There must therefore be some way of
preventing this class of proteins from being secreted if the integrity and function of
the cell is to be maintained.
The following sections attempt to describe mechanisms by which proteins may be
localised to organelles by specific and non-specific means. The organelle that will be
concentrated upon is the ER, as the majority of work has been carried out on ER
retention.
1.1.9 Different proteins are secreted at different rates.
Although secretory proteins are thought to be secreted by a bulk flow default
pathway, different proteins are secreted at different rates from the cell. The
halftime of exit of proteins from the ER varies from about 15 minutes for some
viral glycoproteins (Quinn efa/ 1984 , Copeland efa/ 1988) and some serum
proteins to 2 hours or more for some other serum proteins (Fries et al 1984 ,
Lodish efa/ 1983, Yeo et al 1985). Wieland et al estimated the halftime for the
secretion of the synthetic tripeptide Asn-Tyr-Thr from tissue culture cells to be
about 10 minutes, although whether this is a true reflection of the rate of bulk flow
has been questioned (Rose and Doms 1988). However it seems reasonable to assume
that the bulk flow rate is close to the rate of transport of the most rapidly secreted
proteins as no positive secretion signals have been found for any protein. The most
likely reason why specific proteins are secreted more slowly than expected from the
rate of bulk flow is that these proteins are retarded in their progress through the
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secretory pathway by interactions with other elements of the pathway, with the ER
appearing to be the organelle in which the majority of such interactions take place.
Some of these interactions will be discussed in the following sections.
1.1.10 Protein folding and assembly in the ER.
The correct folding of monomeric proteins and the correct folding and assembly of
multimeric proteins is necessary for their efficient transport to the cell surface
(for review see Hurtley and Helenius 1989). This is probably because unfolded
proteins tend to bind other proteins in the ER or form insoluble aggregates that are
unable to enter transport vesicles. The folding of proteins in vitro is often slow and
inefficient but proteins fold in vivo into the correct conformation rapidly and
efficiently due, at least in part to several resident ER proteins. In addition these
resident ER proteins may bind to aberrantly assembled proteins to prevent their
export. For example protein disulphide isomerase (PDI) interacts with unfolded
proteins and catalyses the formation of disulphide bonds, which are often required
for the correct folding of a protein. Other proteins such as CD-co or TRAP (Alarcon et
al 1988, Bonifacino et al 1988), the collagen binding protein colligin (Hughes et al
1987) and the abundant ER protein GRP94 (Sorger and Pelham 1987, Lee 1987)
may also have roles to play in protein assembly and the prevention of premature
export of proteins. However, perhaps the protein most widely implicated in
protein folding and assembly in vivo is BiP (also known as GRP78). The following
sections discuss the possible functions of BiP.
1.1.11 The role of BiP
A major resident ER protein is the soluble protein BiP which is also known as
glucose-regulated protein (GRP78). BiP has been found tightly associated in the ER
with newly synthesised proteins that are incompletely assembled, have mutant
structures or are incorrectly glycosylated . BiP was originally found associated with
unassembled immunoglobulin heavy chains before their assembly with light chains,
thus preventing transport to the Golgi apparatus (Bole et al 1986). BiP can be
released from its association with heavy chains in vitro by incubation in the
presence of ATP (Munro and Pelham 1986). BiP is found bound to mutant or
malfolded forms of influenza haemagglutinin (HA) (Gething et al 1986), to a
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derivative of SV40 T antigen that is fused to a signal sequence to allow it to enter the
ER (Sharma et al 1985), in an in vitro translation translocation system to
unoxidised (but not to disulphide bonded) prolactin and to unglycosylated but not
glycosylated invertase (Kassenbrock et al 1988). Proteins that are inhibited in
glycosylation tend to fold poorly (Leavitt et al 1977) and BiP is found associated
with many proteins that have had their glycosylation inhibited (Bole et al 1986,
Gething efa/1986, Dorner et al 1987 , Hendershot et al 1988).
It has been suggested that the associations with BiP are all hydrophobic in nature
(Pelham 1986 and 1989) which could mean that BiP recognises hydrophobic
regions of misfolded proteins that are normally buried or masked by glycosylation in
the correctly folded protein. However, in contrast with this view, it has been
reported that both hydrophilic and hydrophobic peptides are bound by BiP (Flynn et
al 1989). Many of the known substrates for BiP are aberrant proteins but BiP may
also have a role to play in the correct maturation and folding of normal proteins in
the secretory pathway. One example that has already been mentioned is the
binding of BiP to immunoglobulin heavy chains that are not aberrant, before their
assembly with light chains (Bole efa/ 1986). Also BiP has been observed bound
transiently to several human serum glycoproteins expressed in CHO cells. The
transient binding of BiP to secretory proteins is probably one of the reasons for the
different half times of secretion for different proteins. Some proteins may stay in
the ER longer than others because of difficulty in folding into a structure able to
avoid the binding of BiP by hydrophobic interactions and therefore have a longer half
time for secretion.
1.1.12 The action of BiP
The association of BiP with aberrant proteins and transiently with normal proteins
has been described in the previous section but the mode of action has not been
discussed . The immunoglobulin heavy chain binding protein BiP is a member of the
evolutionary conserved HSP-70 family of heat shock proteins (Hutton efa/ 1987).
Like hsp70, BiP binds ATP tightly and the hydrolysis of ATP allows it to be released
from at least some of the substrates which it binds (Munro and Pelham 1986,
Dorner et al 1987, Kassenbrock et al 1988). One model for the action of BiP and
other members of the HSP-70 family is that they act as reversible detergents,
binding to hydrophobic surfaces and using the energy from ATP hydrolysis to change
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the conformation of the protein to a non-binding state (Pelham 1986). This would
have the effect of keeping unfolded or unassembled proteins in solution, avoiding
aggregation or precipitation into permanently non-functional complexes because of
hydrophobic interactions, and thus allow them to achieve their final tertiary or
quaternary structures by using the energy of ATP hydrolysis.
Although the main function of BiP is probably to promote the normal folding and
assembly of proteins it may also rescue misfolded proteins from their misfolded
fate by using the energy from ATP hydrolysis to change the proteins conformation,
and thus allow them another chance to fold correctly. BiP may also function to stop
the exit of misfolded proteins from the ER until they either fold correctly or are
degraded. Association with BiP may be one of the reasons for the inefficient secretion
of many proteins expressed in heterologous eukaryotic cells. In summary it appears
that BiP has an important role to play in enabling proteins to reach a transport
competent conformation and in preventing the exit of aberrant proteins.
1.1.13 Degradation of proteins in the ER.
Large numbers of proteins in the ER are transport-incompetent for some of the
reasons mentioned previously, so the question arises of how the cell disposes of them
as it would be reasonable to assume that the accumulation of aberrant proteins in
the ER would be deleterious to the cell. Although misfolded proteins are inherently
more sensitive to proteases than correctly folded proteins, they often have a
relatively long half-life in the ER (Corless et al 1987, Hurtley et al 1989). Often a
lag period followed by a rapid degradation phase is seen which possibly suggests that
to be degraded, proteins need to be moved to a specific compartment away from the
ER. It has been suggested that degradation of some unassembled and misfolded proteins
probably occurs in the ER itself (Lippincott-Schwartz et al 1988), although the
identity of the degradative enzymes in the ER is not known. Degradation of some other
aberrant proteins may take place in lysosomes as their degradation is blocked by
inhibitors of lysosomal degradation (Davis and Hunter 1987). Further studies are
needed to determine where and how the degradation of the wide
variety of retained proteins occurs and how these processes are controlled.
1 3
1.1.14 Retention of luminal ER proteins
The previous sections have described how aberrant proteins and proteins en route
through the secretory pathway may be held up in the ER, but there are proteins in
the lumen of the ER that are resident there and necessary for its function.
A mechanism must therefore exist to prevent these luminal ER proteins from leaving
the cell with other secretory proteins.
The first indication that a specific mechanism for the retention of luminal ER
proteins came from the observation that that PDI and BiP have a common C-
terminal tetrapeptide, KDEL, (Lys-Asp-Glu-Leu) (Munro and Pelham 1986). It has
now been determined that luminal ER proteins from a variety of species have this
C-terminal sequence or a related sequence such as HDEL (Saccharomyces cerevisiae)
(Rose et al 1989) RDEL (rat colligin), KEEL (mouse ERp72) (Pelham 1989) or
DDEL (Kluyveromyces lactis) (Lewis et al 1990) . Although there is some
divergence in the C-terminal sequence in different organisms, the similarity
suggests that these C-terminal tetrapeptides may act as retention signals for the ER.
The importance of the KDEL sequence for retention of proteins in the ER has been
shown in experiments in which altered proteins were expressed in COS cells. The
removal of KDEL from BiP caused it to be slowly secreted from COS cells and the
addition of the KDEL tetrapeptide to the C-terminus of lysozyme (a protein that is
normally secreted) caused it to accumulate in the ER of COS cells (Munro and -
Pelham 1987). Furthermore experiments in which the C-teminus of lysozyme was
changed to KDAS or KDELGL resulted in the secretion of lysozyme suggesting that
KDEL is required at the extreme C-terminus of a protein for the protein to be
efficiently retained.
The addition of the SEKDEL sequence to the C-termini of two secretory proteins, rat
growth hormone (rGH) and human chorionic gonadotropin (hCGa), does not prevent
them from being secreted but only retards the proteins in their progress through
the secretory pathway. Thus it seems as if the addition of the C-terminal KDEL
sequence is sufficient to prevent the secretion of certain proteins but for others it
merely increases the half time for secretion (Zagouras and Rose 1989). In either
case it appears that KDEL does have a role to play in at least slowing the exit from the
cell of proteins containing this sequence.
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1.1.15 How does the KDEL sequence function?
Experimental data suggests that the KDEL sequence is involved in the specific
retention of resident ER proteins, so the question is "how is this sequence promoting
the retention of these proteins?" One simple explanation of the function of the
C-terminal KDEL sequence could be that the sequence is recognised by an integral
membrane protein (a KDEL receptor) present in the ER, thus preventing exit of
proteins containing this sequence. However, KDEL-containing proteins are very
abundant in the ER and no membrane protein has been described that is present in
sufficient quantity to bind all of the KDEL-containing proteins and immobilise them
in the ER. To try to explain the apparent excess of KDEL-containing proteins
compared to putative receptor, a model was proposed in which KDEL receptors
captured proteins with the C-terminal KDEL sequence from a post-ER salvage
compartment and then returned them to the ER (Warren 1987, Munro and Pelham
1987). The receptor would not need to be present in stoichiometric amounts as it
would not be functioning to bind the KDEL containing proteins permanently but would
only associate with them transiently until the KDEL-containing protein was returned
to the ER.
One piece of evidence that suggests that KDEL-containing proteins are not
continuously and tightly bound to a component of the ER comes from micro-injection
experiments (Ceriotti and Coleman 1988). These experiments show that the
presence of a KDEL tail on BiP does not significantly alter its rate of diffusion in the
ER compared with that of BiP bearing the unrecognised KDELGL C-terminus. Both
of the BiP constructs diffuse more rapidly than an integral membrane protein
haemaglutinin but more slowly than albumin, a protein that is secreted. It has been
shown that proteins with the KDEL signal can leave the ER transiently since the
modification of the oligosaccharide side chains by the addition of UDP-GlcNAc to
mannose residues, occurs in a cathepsin D (normally a lysosomal protein) hybrid
protein bearing the C-terminal KDEL sequence (Pelham 1988). The
phosphotransferase that catalyses the addition of UDP-GlcNAc is thought to reside not
in the ER but in a smooth-membraned compartment close to, but possibly distinct
from the cis Golgi. The KDEL-containing cathepsin D was not transported to
lysosomes as normal cathepsin D would be, but was found to have accumulated in the
ER. The removal of the GlcNAc from the oligosaccharide (see fig. 1.1) of the
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cathepsin D hybrid was not observed, suggesting that the hybrid protein does not
penetrate far into the Golgi stack before being returned to the ER. The
oligosaccharides on GRP94, glucosidase II and of colligin which are all thought to be
luminal ER proteins are of high mannose type and do not appear to have been exposed
to the Golgi mannosidase I which is thought of as a cis Golgi marker. Thus it appears
that separation of resident ER proteins may occur in a salvage compartment that
contains phosphotransferase but lacks N-acetylglucosaminidase and Golgi
mannosidase I.
For the retrieval model to be correct the putative salvage compartment should have a
luminal environment distinct from that of the ER, one that promotes the binding of
KDEL to its receptor. Conversely the environment of the ER should allow the release
of the KDEL-containing protein by its receptor, thus allowing the receptor to return
to the salvage compartment to recover more KDEL-containing protein. Many of the
organelles in a cell contain distinct proteins that are considered to be markers of that
particular organelle. There are now possible marker proteins described for the
salvage compartment. A 58K glycoprotein has been localised by immunoelectron
microscopy to the cis face of the Golgi, to the vesicles and tubules associated with it
and occasionally to the adjacent transitional regions of the ER (Saraste et al 1987).
A 53K non-glycosylated protein that exists as a hexamer has also been found
localised to smooth vesicles and tubules between the ER and the Golgi (Schwiezer et
al 1988). These two proteins are both membrane proteins and are possible
candidates for markers of the putative salvage compartment.
1.1.16 The recycling mechanism.
It has recently been shown that the movement of proteins between the salvage
compartment and the ER is probably mediated by vesicular movement along
microtubules. This return to the ER from post ER compartments has been termed
retrograde transport as movement is in the opposite direction from that associated
with secretion (Lippincott-Schwartz et al 1990). The involvement of microtubules
in retrograde transport has been shown by experiments performed by
Lippincott-Schwartz eta/(1990). A temperature block results in the accumulation
of a unique 53K antigen in the salvage compartment. At 16°C retrograde transport
back to the ER is inhibited while flow from the ER to the salvage compartment
continues. At 16°C the antigen can be seen to be leaving the salvage structures
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identical to those seen in experiments using Brefeidin A to fuse the salvage
compartment to the Golgi cisternae (Lippincott-Schwartz era/ 1990). Electron
microscopy shows that the necklaces consist of vesicles and tubules that are being
transported along microtubules. If the temperature block is released the 53K
protein leaves the salvage compartment and can be transiently detected in the ER .
Treatment of cells with microtubule depolymerising drugs inhibits the flow of the
53K antigen from the salvage compartment to the ER but not from the ER to the
Golgi.
1.1.17 The KDEL receptor.
Conventional approaches to identifying the KDEL receptor using affinity columns did
not prove to be encouraging. An alternate approach of generating anti idiotypic
antibodies has proved to be more promising (Vaux et al 1990). The strategy in
raising anti idiotypic antibodies to the KDEL receptor is as follows;- antibodies are
raised against peptides containing the KDEL signal. Antibodies against the KDEL
binding site of these anti KDEL antibodies can then be raised. If the KDEL binding site
of the anti KDEL antibodies mimics the binding site of the native KDEL receptor, the
antibodies raised against the KDEL binding sites of these anti KDEL antibodies should
also recognise the native KDEL receptor. Anti idiotypic antibodies raised using three
slightly different variations of the above strategy (Vaux et al 1990) have been found
to recognise a 72 K integral membrane protein in all vertebrate species tested. To
show that the 72 K protein is likely to be the KDEL receptor, it has been shown that
antibodies raised against the anti 72K protein antibodies can recognise peptides
ending in KDEL. It therfore appears as if the 72K protein is a good candidate for the
KDEL receptor.
When used to examine the subcellular location of the KDEL receptor the anti idiotypic
antibodies showed the same distribution as the salvage compartment markers
(described in section 1.1.15) and the redistribution of the KDEL receptor when a
16°C temperature block is introduced is the same. These observations suggest
further that the 72K protein is the KDEL receptor and is recycled between the ER
and the salvage compartment.
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1.1.18 Is the C-terminal KDEl sequence sufficient to localise
proteins to the ER :-The possible roie of calcium.
Although the KDEL signal has been shown to be involved in the recycling of proteins
to the ER, it cannot be ruled out that other mechanisms may also exist separately or
in combination with the KDEL retention system to localise luminal ER proteins to the
ER. As has been mentioned previously it is possible for proteins containing the
C-terminal signal to be secreted albeit at a slower rate (Zagouras and Rose 1989),
which suggests that the retention system may not be 100% efficient. It is possible
however that the folding of these engineered proteins does not allow efficient
recognition of the KDEL sequence.
The possibility of calcium ions playing a role in the retention of luminal ER proteins
(reticuloplasmins) came from the observation that agents that perturbed the level of
cellular calcium caused reticuloplasmins to be secreted (Booth and Koch 1989). A
number of possible roles for the involvement of calcium in the sorting of
reticuloplasmins have been proposed. One model has been proposed in which
relatively high calcium levels promote binding of KDEL-containing proteins to the
KDEL receptor in the salvage compartment and relatively low levels of calcium
facilitate their release in the ER (Kelly 1990). If this model is correct then the site
of action of the calcium-perturbing agents would be the salvage compartment.
Another aspect of the KDEL based retention system is the requirement of vesicles
containing the reticuloplasmins to return to the ER. Calcium ions have been shown to
be necessary for the transfer of material from the ER to the Golgi (Beckers and
Balch 1989), therefore it is possible that they are also needed for the retrieval
pathway, and that perturbation of cellular calcium may favour secretion of
reticuloplasmins. One problem with the above models is that they do not explain how
an increase in reticuloplasmin synthesis during stress responses actually decreases
their secretion. There has been a suggestion that the level of reticuloplasmins may
actually affect the sorting mechanism.
The protein concentration in the ER has been estimated to be as much as 100 mg/ml
(Koch 1987). Proteins in other compartments at comparable concentrations do not
necessarily exist as freely diffusible monomers or oligomers but aggregate to form a
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matrix or a gel. For example, in the sarcoplasmic reticulum calsequestrin is thought
to form a matrix stabilised by calcium ions that concentrates the protein in the
region of transverse tubules (Messner 1975) . In the bacterial periplasm proteins
and proteoglycans form a gel that provides stability and controls diffusion of proteins
in that space (Hobot et al 1984). Booth and Koch (1989) suggest that the ER is made
up of a gel matrix of reticuloplasmins and that true secretory proteins are part of an
additional mobile phase. When vesicles bud from the ER they would preferentially
sample the fluid phase and exclude the majority of the immobile reticuloplasmins.
Some reticuloplasmins would inevitably escape this bulk sorting and need to be
retrieved by a more specific system ie the KDEL system. If this matrix is stabilised
by calcium, then calcium perturbing-agents would destabilise the matrix and
reticuloplasmins would leave the ER in vesicles in greater amounts than usual. The
high concentration of KDEL-containing proteins leaving the ER could saturate the
retrieval system and a large proportion of the reticuloplasmins would be secreted
along with normal secretory proteins.
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1.2 Yeast as an experimental organism
The yeast Saccharomyces cerevisiae is a unicellular eukaryote that has been widely
used as an experimental eukaryote for a number of reasons. It is amenable to both
classical genetic and to molecular genetic techniques using recombinant DNA
technology (Struhl 1983). In fact virtually all of the molecular genetic techniques
that can be used in bacterial systems can also be applied to Saccharomyces
cerevisiae. Saccharomyces cerevisiae has many of the features of higher eukaryotic
cells. For example the genetic material is confined to the nucleus in the form of
chromatin and organised on many chromosomes each of which has a centromere, two
telomeres and multiple sites of DNA replication. The yeast transcription and
translation processes have typical eukaryotic features, the proteins are typically
eukaryotic and the macromolecular structures resemble those of higher eukaryotes
(eg 80S ribosomes). Also the membrane bound organelles in yeast;-RER, Goigi,
nucleus, mitochondria and lysosomes-all resemble the organelles of higher
eukaryotes.
The biology of yeast involves the fusion of haploid cells of opposite mating types
to form diploid zygotes which in appropriate conditions can undergo fairly typical
meiosis. Both the haploid and diploid forms of S. cerevisiae can be grown
vegetatively in defined medium. The amenability to genetic manipulation and the
typically eukaryotic features make S. cerevisiae useful for studying many of the
basic questions in eukaryote biology including ; gene expression, DNA replication,
recombination, chromatin structure, the cell cycle, control of cell type and the
secretory pathway.
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1.2.1 Analysis of the veast secretory pathway
Stages of the yeast secretory pathway have been defined by the isolation and
characterisation of temperature-sensitive mutants in which protein export is
blocked at the restrictive temperature. At the restrictive temperature these
secretion-defective mutants (sec mutants) accumulate organelles and also various
precursor forms of the secreted enzyme invertase (Esmon et al 1981), the
vacuolar enzyme caboxypeptidase Y (CPY) (Stevens eta/ 1982), the mating
pheromone a factor (Julius efa/ 1984), and the S. cerevisiae killer toxin (Bussey
et al 1983), which relate to their position in the secretory pathway.
Yeast cells that are temperature sensitive for secretion become dense during
incubation at the non-permissive temperature of 37°C due to the accumulation of
secretory proteins intracellular^. This property was observed for the original sec
mutants and used to isolate further secretory mutants by sedimentation of
mutagenised cells on a Ludox gradient (Novick et al 1980). Colonies derived from
these dense cells were screened for conditional growth and conditional secretion of
invertase and acid phosphatase. The sec mutants that accumulated a large
intracellular pool of invertase at 37°C (Class A sec mutants) were found to fall into
23 complementation groups. Many of the sec mutants secreted their invertase on
return to the permissive temperature of 26°C. Electron microscopy (EM) of all of
the sec mutants (with one exception) revealed the temperature dependent
accumulation of membrane-enclosed secretory organelles (see table 1.1). Novick et
al 1980 described these organelles as being intermediates in the secretory pathway
whose soluble contents are destined for secretion by exocytosis and membranes for
incorporation into into the plasma membrane by fusion.
A set of 10 of the secretory mutants appeared to accumulate membrane-enclosed
vesicles of 80-100 nm diameter which were proposed to represent secretory
vesicles before fusion with the plasma membrane. A set of 9 secretory mutants
accumulated a more extensive network of ER than seen in wild type cells and a subset
of 4 from this group accumulated small 40 nm vesicles as well as ER. Two of the sec
mutants accumulated structures consisting of two curved membranes with an
electron-transparent lumen thought to represent the Golgi complex but termed the
Berkeley body (Bb). The sec 19 and sec 11 mutants could not be placed into any of
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Table 1.1 The class A sec mutants












sec11 12 no organelle accumulated
serf2 4 BR
serf3 4 BR
serf4 4 Berkeley bodies
sec15 2 SV
serf 6 2 BR
serf 7 1 ER, small vesicles
serf 8 2 ER, small vesicles
serf 9 1 ER, Berkeley bodies, and SV
sec20 1 BR
sec21 1 BR
sec22 4 ER, small vesicles
sec23 1 BR
Twenty three complementation groups have been identified by Novick etal (1980). Some
of these groups have many representatives but others have only one; this distribution
suggests that there are other sec A complementation groups that have not been discovered.
the above groups as sec 19 accumulated all three types of organelle and sec 11 did not
appear to accumulate any organelle under restrictive conditions.
The order of events in the yeast secretory pathway was elucidated by the
characterization of haploid double sec mutants with respect to the structure of
invertase and the amplification of one or more of the secretory organelles mentioned
above (Novick efa/1981). The morphology of the exaggerated organelles
accumulated in these double sec mutants at 37°C allowed the order in which the SEC
gene products are required, to be assessed. By looking at the precursor forms of
invertase accumulated the order of events in the processing of invertase could be
deduced. The results were consistent with the following model;- secretory proteins
enter the ER where initial glycosylation steps take place. Nine or more SEC gene
products plus energy are required to transfer the secretory proteins to a Golgi-like
structure where further glycosylation steps occur. Two or more SEC gene products
plus energy are required to package the nearly fully glycosylated proteins into
secretory vesicles that are then transported to the bud of the cell. Ten or more SEC
gene products plus energy are then needed for the fusion of these secretory vesicles
with the plasma membrane.
1.2.2 Biogenesis and secretion of a factor
Saccharomyces cerevisiae is capable of existing as three cell types;- two haploid
cell types designated a and a which can fuse together to form an a/a diploid,-the
third cell type. The process of a and a mating is initiated by the reciprocal exchange
of diffusible oligopeptide pheromones called a and a respectively (for review see
Herskowitz 1986).
The mating pheromone a factor is 13 amino acid residues long, encoded by two genes
MFa1 and MFa2 which both encode multiple copies of the a factor peptide. MFa1 has
4 copies of the a factor peptide and MFa2 has two copies. Both genes give rise to
large precursor polypeptides. The mature a factor peptides are generated by
proteolytic processing of the large precursor polypeptides in the secretory pathway.
MFa1 encodes a 165 amino acid precursor polypeptide (pre-pro a factor) which
has the following features:- a pre-sequence of 20 amino acids which is the signal
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sequence, a 60 amino acid pro-sequence that contains 3 consensus sites for N-linked
glycosylation and an N-terminal region which encodes 4 copies of the mature a factor
peptide. The 4 repeat sequences are separated by the spacer sequences
Lys-Arg-GIu/Asp-Ala-Giu-Ala (see fig. 1.2 and Kurgan and Herskowitz 1982).
The biogenesis of a factor has been assessed with the aid of the sec mutants blocked at
various stages of the secretory pathway (Julius et al 1984). The pre-pro a factor
is directed into the secretory pathway by its signal sequence which is removed by
signal peptidase (Waters et al 1988). The species of pro a factor accumulated in a
sec 18-1 mutant at 37°C (blocked in ER to Golgi transport) has a molecular weight
of around 25K which is consistent with the addition of 3 N-linked core
oligosaccharides at the consensus positions in the pro region, onto the pro a factor.
Limited digestion with endoglycosidase H of the a factor accumulated in sec18-1
cells at 37°C and treatment of sec 18-1 cells with tunicamycin (which blocks the
synthesis of N-linked glycosyl chains) (Mahoney and Duskin 1979) give results
consistent with the addition of three N-linked oligosaccharides to pro a factor
(Julius efa/ 1984).
Proteolytic processing of pro a factor is thought to occur during transit through the
Golgi apparatus as no proteolyticaily processed a factor can be detected in a sec 18-1
mutant at 37°C. The first cleavage of pro a factor is thought to be carried out by the
Kex2 protease at pairs of basic residues in the spacer peptides to release four
pheromone repeat units (see fig. 1.1) (Julius efa/ 1984). The Glu/Asp-Ala
residues at the amino terminus of each peptide are removed by
dipepfidylaminopeptidase-A (Julius et al 1983), and the carboxy terminal Lys-Arg
residues are removed sequentially by Kex1 exoprotease (Dmochowska et al 1987,
Aschetter and Wolf 1987) (for review see Fuller et al 1988). The proteolytic
processing events must be initiated after the position in the secretory pathway at
which SEC7 exerts its effect as material accumulated in a sec7 mutant at 37°C shows
little evidence of being processed. Processing of a factor must be completed before
SEC1 exerts its effect as mature a factor accumulates in a sed mutant at 37°C. The
three enzymes responsible for the proteolytic processing of pro a factor have
been identified, biochemically characterised and the structural gene for each
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Figl .2 Biosynthesis of the mating pheromone a factor
This diagram shows the post-tranlational processing of the MFa1 gene product -
prepro-a factor. This processing pathway has been elucidated by biochemical and
immunocytochemical identification of processing intermediates and by analysis of
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enzyme has been isolated (see Bussey 1988 for review). The processing of a factor
is similar to the processing of prohormones in higher eukaryotes and is the first
example of a eukaryotic protein in which all of the intermediates of processing and
the enzymes responsible for processing have been identified.
1.2.3 N-linked alvcosvlation in veast
In the yeast Saccharomyces cerevisiae the early steps in the synthesis of N-linked
glycans are identical to those found in animal cells (for review see Kukuruzinska et
al 1987). The differences occur only in the later processing steps, or in the
modifications that the carbohydrate chains undergo in the Golgi. The events that take
place in the lumen of the ER are identical to those that take place in higher
eukaryotes, ie the transfer of GIC3MangGlcNAc2 from a dolichol pyrophosphate
carrier onto selected asparagine residues followed by the stepwise removal of 3
glucose residues and 1 mannose residue (see fig. 1.1). Once these processing events
have taken place the glycoproteins are transported in an energy-dependent manner
from the ER to the Golgi presumably via specific vesicles. In the Golgi the processing
of yeast oligosaccharides diverges from that of animal cells. Outer chain
modifications to N-linked carbohydrates still proceed in sequential fashion in yeast,
but unlike complex-type oligosaccharides in animal cells the modifications are
composed principally of mannoses added in specific linkages by different mannosyl
transferases. These mannosyl transferases function in the Golgi apparatus to add
mannose residues to core oligosaccharide units in a1-6, a1-2 and a1-3 carbon
linkages, where the attachment of mannobiose phosphate in diester linkages also
occurs (for review see Ballou 1982).
Mutations that interfere directly with the addition of outer-chain mannose residues
do not necessarily prevent subsequent processing events in the secretory pathway,
therefore intermediates in the processing of oligosaccharides are difficult to identify
using mutants of this type. The use of sec7 mutant cells to accumulate glycoprotein
intermediates in transit allows identification of reactions that precede and follow
this Golgi-specific block (Franzusoff and Schekman 1990). In sec7 cells at the
restrictive temperature of 37°C there were no a1-3 mannose linkages detectable in
glycoproteins but a1-2 and a1-3 mannose linkages could be detected. Thus it
appears that a1-2 and a1-6 linkages occur in a separate compartment or
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compartments in the Golgi apparatus before that in which the a1-3 linkages occur.
These experiments suggest that the yeast Golgi apparatus has at least 2 functionally
seperate compartments which require the Sec7p for transport between the two.
In mammalian cells, one way in which proteins are thought to be targetted to
lysosomes is by the recognition of a mannose-6-phosphate marker on their N-linked
oligosaccharides (Kornfeld et at 1986). Alternative targetting signals must also
exist in mammalian cells (Owada and Neufeld 1982, Wakeed et al 1982 and 1988).
In yeast, inhibition of glycosylation does not prevent targetting to the vacuole
(analogous to lysosome) (Hasilik and Tanner1978, Schwaiger et al 1982), thus
targetting of proteins to the yeast vacuole is not dependent on modifications to their
oligosaccharides. Specific sequences in yeast CPY appear to direct it to the vacuole
(Johnson et al 1987).
1.2.4 Retention of soluble ER proteins in veast.
As has been discussed in earlier sections the powerful genetics of Saccharomyces
cerevisiae has been used to identify processes taking place in the yeast secretory
pathway and the gene products involved at various stages of the secretory pathway.
Many of the processes taking place are analogous to those occurring in higher
eukaryotes. The first indication that yeast may have a similar system to that of
higher eukaryotes for the sorting of resident ER proteins came from the fact that
yeast BiP contained the C-terminal tetrapeptide HDEL which is a similar motif to the
KDEL sequence (Pelham et al 1988). Yeast PDI also has this HDEL motif at the
C-terminus (Dr. R.Freedman personal communication). Antibodies to the HDEL
sequence also recognise other yeast proteins (Hardwick et al 1990).
Pelham et al (1988) showed that an invertase-HDEL fusion protein was retained
within yeast cells whereas an invertase-KDEL fusion protein was not efficiently
retained. Thus it appears that HDEL is the ER retention signal in yeast and not KDEL.
The yeast HDEL sequence, as in mammalian cells, is thought to act as a recycling
signal (Pelham et al 1988):- Yeast glycoproteins receive the same oligosaccharide
chains in the ER as animal cell glycoproteins. Some are then modified by the addition
of 100 or more mannose residues with specific linkages. This outer-chain
modification is considered a Goigi function as a sec 18 mutant at the restrictive
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temperature of 37°C blocks this modification. The invertase fusion protein bearing
the HDEL signal, and at least one endogenous ER protein is subject to this outer-chain
modification which suggests that such proteins can reach the Golgi and still be
retrieved. The outer-chain glycosylation occurs more slowly with HDEL-tagged
proteins than with similar proteins lacking the HDEL sequence, thus exposure of ER
proteins to the outer-chain modifying enzymes is probably a rare event and as with
higher eukaryotes retrieval may usually be from a pre-Golgi or very early Golgi
compartment.
Recent experiments in which pre-pro a factor was tagged at its C-terminus with the
HDEL sequence (Dean and Pelham 1990) show that fusion protein accumulates
intracellular^ in a Sec18-dependent manner with ER and Golgi-specific
modifications in the ER as shown by subcellular fractionation. The Golgi-specific
modifications to the a factor construct consist of a1-6 mannose linkages but no
a1-3 linkages were detectable. The addition of a1-6 linkages has been shown to be an
early Golgi event and addition of a1-3 linkages to be a later event (Franzusoff and
Schekman 1989) which suggests that retrieval is from an early Golgi compartment.
The yeast retention system appears to be saturable as overexpression of the a factor
HDEL fusion proteins results in the secretion of BiP which is not normally secreted
(Dean and Pelham 1990).
1.2.5 The veast HDEL receptor
Powerful selection and screening methods have been developed to select a number of
mutants defective in retaining HDEL-containing proteins (Pelham et al 1988).
These mutants are named erd mutants for ER retension defective and analysis of the
mutants defines two genes- ERD1 and ERD2. The function of the ERD1 gene product is
not clearly understood but it has been suggested that it is required for the correct
binding of the HDEL receptor to its ligands (Hardwick et al 1990). The ERD2 gene
product appears to be the putative HDEL receptor itself (Semenza efa/1990, Lewis
et al 1990). The ERD2 gene encodes a 26K integral membrane protein whose
abundance determines the efficiency and capacity of the retention system. Also the
cloning of the Kluyveromyces lactis ERD2 gene into Saccharomyces cerevisiae
changes the specificity of retention of proteins in S. cerevisiae to that found in K.
lactis, ie S. cerevisiae will retain proteins with either HDEL or DDEL at the
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C-terminus, as does K. lactis. Proteins with DDEL at the C-terminus are not
normally retained in S. cerevisiae. The ERD2 gene product is also essential for
growth, which suggests it may have a function other than that of receptor. It has been
suggested that the ERD2 gene product may be needed to form the recycling vesicles
and, if absent, soluble or membrane proteins involved in vesicular trafficking couid
not return to the ER and reduce the secretory pathway to a trickle. It is interesting to
note that the putative KDEL receptor in mammalian cells identified by Vaux et al
(1990) and the putative HDEL receptor in yeast have very different molecular
weights.
1.2.6 The Kex2 protease of Saccharomvces cerevisiae
The Kex2 protease (Kex2p) is an endopeptidase that cleaves at the carboxyl side of
Lys-Arg or Arg-Arg residues (for review see Fuller 1988). It is required for the
maturation of Saccharomyces cerevisiae killer toxin (Bostian et al 1984) and the
mating pheromone a factor (Julius et al 1984). The predicted amino acid sequence of
the Kex2p contains a domain homologous to the subtilisin class of serine proteases
(Mizuno et al 1988), a serine/threonine-rich domain thought to be a site of
extensive O-linked glycosylation (Sudhot et al 1985) and a transmembrane domain
that is thought to anchor it in the membrane.
Kex2p is present in very low amounts in yeast as is the case for many membrane
proteins but studies in which Kex2p is overexpressed reveal that, Kex2p is
membrane bound but solubilised by detergents, is able to cleave peptide substrates
at Arg-Arg or Lys-Arg sites and is inhibited by EDTA and EGTA but is fully
reactivated by calcium ions (Fuller et al 1989). Also Kex2p can be labelled
specifically with 125l labelled Tyr-Ala-Lys-Arg chloromethylketone. Mutant
enzymes lacking as many as 200 C-terminal amino acid residues can still be
specifically labelled, and retained calcium dependent protease activity (Fuller et al
1 989).
The subcellular location of Kex2p has been suggested to be the Golgi for a number of
reasons: The processing of pre-pro a factor and pre-pro killer toxin by Kex2p
occurs at a kinetically late step in the secretory pathway (Julius et al 1984, Bussey
efa/1983). No significant levels of Kex2p have been found in enriched fractions of
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secretory vesicles or at the surface of intact cells and therefore it is likely that the
enzyme functions within the Golgi complex. Kex2 processing is now thought to occur
in late Golgi after the sec7 block and after a1-2 and a1-6 mannose addition to
oligosaccharides (Franzusoff and Schekman 1989, Dean and Pelham 1990). It has
been reported that immunofluorescence microscopy detects Kex2p in the same
subcellular location as Sec7p, in structures that may represent Golgi apparatus
(cited in Franzusoff and Schekman 1989 as unpublished data).
1.2.7 The killer toxin of Kluvveromvces lactis
Killer strains of the yeast Kluyveromyces lactis secrete a protein toxin which
inhibits the growth of sensitive yeasts. The production of the toxin is dependent on
the presence of two linear double stranded DNA plasmids, k1 and k2 of sizes 8.9kb
and 13.4kb respectively (Gunge et al 1981, Wesolowska et al 1982). The linear
plasmids can be transferred to Saccharomyces cerevisiae although only to p° strains
as the linear plasmids are not stably maintained in strains containing mitochondrial
DNA (p° strains of yeast lack mitochondrial DNA and are petite mutants). Active
toxin indistinguishable from that secreted from Kluyveromyces lactis is secreted
from Saccharomyces cerevisiae strains harbouring the linear plasmids. Yeast cells
harbouring the linear plasmids are not sensitive to the toxin as the plasmids also
confer immunity upon the cells containing them. Both k1 and k2 have been sequenced
and have been shown to have 4 and 10 open reading frames (ORFs) respectively.
Functions have been assigned to at least 6 of the products of the ORFs (for review see
Stark et al 1990). The plasmid k2 is thought to function in the maintenance of both
of the linear plasmids in the cell by encoding transcription factors etc, as it is
possible to find cells with k2 alone but not with k1 alone. The plasmid k1 has been
shown to encode the structural genes for the toxin (Stark and Boyd 1986) (see fig.
1.3).
1.2.8 Structure of the toxin
The toxin secreted from linear plasmid-containing strains of yeast consists of 3
subunits, a, (3 and y with molecular weights of 99K, 30K and 27K respectively
(Stark and Boyd 1986). The a subunit is glycosylated with a single core N-linked
oligosaccharide but neither of the smaller subunits appears to be glycosylated. The
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Fig. 1.3 The linear plasmid k1 and the toxin polypeptides that it
encodes
(A) The linear plasmid k1 has four open reading frames (ORF's). ORF2 and ORF4
encode the toxin polypeptides. ORF2 encodes a 130 K primary translation product
(the a(3 precursor) which is processed in the secretory pathway to give rise to the
mature a and p subunits. The ap precursor polypeptide contains 3 potential Kex2
cleavage sites. It is known that the N-terminus of the mature a subunit starts
immediately after a potential Kex2 cleavage site as does the N-terminus of the p
subunit. The exact C-terminus of the a subunit is not known, there are two
possibilities:- It is possible that the cleavage at the potential Kex2 site that creates
the N-terminus of the p subunit creates the C-terminus of the a subunit. If however
all of the potential Kex2 cleavage sites are cleaved a small 'spacer peptide' will be
excised from the precursor to create the C-terminus of the a subunit. Maturation of
the ORF4 primary translation product only involves the removal of the signal
sequence by signal peptidase.
(B) The mature toxin polypeptides are shown. However there is some doubt about
the a subunit due to not knowing its exact C-terminus. I have assumed that all the
potential Kex2 sites have been cleaved and thus there is only one possible site for
N-linked glycosylation. However if the 'spacer peptide' is not excised, as may be the
case there are four potenial sites for N-linked glycosylation each which could be the
actual site of glycosylation. The p subunit is not glycosylated even though it has
potential sites for N-glycosylation, this may be due to the unusually hydrophobic
nature of the p subunit. The y subunit contains no potential sites for N-glycosylation.
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structure of . the toxin is maintained by disulphide bonds:- The (3 and y subunits
are thought to be covalently attached by disulphide bonds to one another and the a
subunit is thought to contain at least one intramolecular disulphide bridge, as
implied by analysis on non-reducing SDS-PAGE (Tokunaga et al 1987). A
stoichiometry of 1:1:1 for the subunits is likely but this point still needs to be
clarified.
The a and p subunits of the toxin are produced as a large precursor (the ap
precursor) and proteolytically processed to give rise to the 2 mature subunits. The
S. cerevisiae Kex2 protease has been implicated in this processing as amino acid
sequencing of the mature subunits reveals that the N-terminal amino acids of the
mature subunits are those that would be predicted if cleavage of the ap precursor
were to take place at the C-terminal side of Lys-Arg residues (Stark et at 1986).
1.2.9 Toxin assembly.
The K.lactis toxin is structurally complex and therefore it is likely that specific
assembly steps are involved in its biogenesis. Evidence to support this is the fact that
the y subunit fails to be secreted in the absence of ap production even though the
leader peptide is functional in facilitating translocation into the lumen of the ER of
the y subunit (Tokunaga et al 1989) and can be used to direct secretion of
heterologous proteins (Tokunaga et al 1988). However if the S.cerevisiae proa
factor sequence is inserted in frame between the y subunit leader peptide and the
coding sequence of the mature polypeptide the y subunit is secreted (Tokunaga et
al 1989). This is interesting as the y subunit is the only example of a secreted yeast
protein that is neither glycosylated nor cleaved from a glycosylated precursor.
Secretion of the y subunit does not occur unless it associates with the other toxin
subunits or a factor pro-sequence is added. In either case the y subunit is being
associated with a glycosylated entity. There is some confusion as to the mode of action
of the toxin but the y subunit has been implicated as being the actual toxic subunit
(for review of possible modes of action see Stark et al 1990).
The K.lactis killer toxin has a number of features that make it attractive and
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interesting for the study of biogenesis of proteins in the yeast secretory pathway. It
is the only example of a multi-subunit yeast protein that is assembled from the
products of multiple transcripts and the mature subunits can be identified from one
another by mobility on SDS PAGE. Two of the subunits (P and y) are linked
covalently by disulphide bonds, therefore it should be possible to monitor the
assembly of the toxin by direct immunoprecipitation. One of the subunits (a) is
glycosylated and the precursor has other consensus sites for glycosylation. Also
proteolytic processing events should be easy to monitor because of large size
differences in the precursor and mature polypeptides.
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1.3 Outline of prqject-
At the outset, the aim of my project was to examine the biogenesis of secretory
proteins in yeast in order to further our knowledge of processes that take place in
the secretory pathway. The assembly and processing of the K.lactis killer toxin was
examined, since it is an unusual yeast protein (in that it is a multi-subunit secreted
protein), and may also provide information that can be related to the analogous
assembly of multi subunit secreted proteins in higher eukaryotic cells. As the
project progressed, the question as to whether the order of processing events was
important in the maturation of proteins was addressed. This was done by attempting
to re-locate a Golgi processing enzyme (Kex2 endoprotease) to the ER by the addition
of specific ER retention signals, and then examining the maturation of yeast
secretory proteins (i.e. mating pheromone a factor and K.lactis killer toxin) when
processed prematurely (if at all) by this abnormally located enzyme. The attempt to
relocate the Kex2 protease activity to the ER was also of interest as it provided






All chemicals were obtained from BDH Chemicals, Sigma Chemical Co, or Fisons Ltd,
Loughborough. The synthetic peptide substrate for the Kex2 assays (b-QRR MCA)
was obtained from Peptide Intitute Inc, Japan
2.1 Radiochemicals
[a-35S]-dATP (500 Ci/mmol) was obtained from New England Nuclear. [35S]
methionine (1115 Ci/mmol) and [a-32P]-dATP (>3000 Ci/mmol) was from
Amersham International pic.
2.2 Enzymes
All DNA modification enzymes including restriction endonucleases, phage T4 DNA
ligase and the Klencw fragment of DNA polymerase I were obtained from Bethesda
Research Laboratories (BRL). Zymolyase 100T was from the Seikagaku Kogyo Co,
Japan. Lysozyme was from Sigma Chemical Co.
2.3 Bacterial and veast strains
The strains of E. coli and S. cerevisiae are listed in Table 2.1, with their relevant
properties. Derivatives of these strains are not listed but are mentioned in the
relevant Chapters
2.4 Media
In general bacterial cultures were grown in complete medium (Luria broth, LB)
containing 0.1% (w/v) Bacto tryptone, 0.5% (w/v) Bacto yeast extract, and 0.5%
(w/v) NaCI. When appropriate the antibiotics ampicillin (100 pg/ml) or
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kanamycin (80 (ig/ml) were added to the media. When solid medium was required,
2% (w/v) Bacto agar was added to the above media.
Yeast cultures were grown in complete medium (YPD), containing 1% (w/v) Bacto
yeast extract, 2% (w/v) Bacto peptone and 2% (w/v) glucose; or minimal
(selective) medium (SD), 0.67% (w/v) Bacto yeast nitrogen base without amino
acids and 2% (w/v) glucose. When required the following nutrients were added:
histidine (20 pg/ml), leucine (30 pg/ml), tryptophan (20 pg/ml) and uracil (20
pg/ml). SD supplemented with 1% Casein hydrolysate (which lacks uracil and
tryptophan) was used in a number of experiments. Where appropriate the carbon
source used was 2% (w/v) galactose (YPG, SG) instead of glucose (YPD, SD). When
solid medium was required 2% (w/v) Bacto agar was added to the above media.
2.5 General manipulations of DNA
All standard techniques including restriction endonuclease cleavage, ligation,
extraction with phenol, and precipitation in ethanol were carried out as described by
Maniatis et al., (1982). Gel electrophoresis for visualising DNA fragments was
routinely carried out using 0.8% (w/v) agarose gels; the size of the DNA fragments
was estimated by comparison with a Pst I digest of phage X DNA.
2.6 Transformation of bacterial and veast cells
DNA was transformed into bacterial cells previously treated with CaCI2 as described
by Maniatis et al (1982). Yeast cells were made competent for transformation with
LiOAc following the protocol of Ito et al (1983).
2.7 Small scale preparation of genomic DNA from veast
The yeast strain was grown in YPD overnight to a high density (stationary phase of
growth). A total of 4.5 ml (3 x 1.5 ml) of culture was harvested in an Eppendorf
tube by centrifugation in a microfuge. The cell pellet was resuspended in 800 pi of
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BME buffer (0.9 M sorbitol, 0.05 M Na2HP04, containing 1 pi of p-mercaptoethanol
per ml of buffer). 25 pi of zymolyase (10 mg/ml) was added to the resuspended
pellet and mixed by inversion. Incubation was for 30-45 min at 37°C until
spheroplasts could be seen to be formed. The spheroplasted cells were pelleted by
centrifugation at low speed in a microfuge and resuspended in 100 pi of 1 M sorbitol.
800 pi of lysis buffer (0.1 M Tris HCI pH 9.7, 50 mM EDTA pH 8.5, 0.5% (w/v)
SDS) was added to the spheroplasts and incubated at 70°C for 20 min. After the 20
min incubation, 200 pi of 5 M KOAc was added, mixed and left on ice for 45 min. The
tubes were centrifuged in the microfuge at high speed for 10 sec and the supernatant
was carefully transferred to a clean Eppendorf tube without transferring any of the
precipitate. 0.55 ml of isopropanol was added to the supernatant and left at room
temperature for 5 min to precipitate the DNA. The DNA was pelleted by
centrifugation at high speed in a microfuge for 10 minutes. The DNA pellet was
washed once in 70% ethanol, dried and resuspended in 20 pi of TE (it was necessary
to heat the pellet at 65°C in order to resuspend it). 10 pi of this DNA was digested
and ran on 0.8% agarose gels for Southern analysis.
2.8 Southern hybridisation
Transfer of DNA from agarose gels to nitrocellulose filters, and the subsequent
hybridisation of a-[32P] radiolabeled probes to the filter,were carried out as
described by Maniatis (1982) using a method based on that of Southern (1975).
2.9 Preparation of radiolabeled DNA probes
The DNA fragment to be labelled was purified from an agarose gel (Maniatis et al
1982). Approximately 25 ng of purified DNA was labelled following the method of
Feinberg and Vogelstein (1983): DNA synthesis was primed on denatured DNA by
random hexadeoxynucleotide (obtained from Pharmacia) in the presence of the
Klenow fragment of E. coli DNA polymerase I and a-[32P]-dATP.
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2.10 DNA sequence analysis : Preparation of single stranded M13 DNA
A single M13 plaque was used to infect 20 pi of exponentially growing E. coli NM522
cells in a 30 ml polypropylene tube. After 5 minutes at room temperature, 1.5 ml of
2 x TY (1.6% (w/v) Bacto tryptone, 1% (w/v) Bacto yeast extract, 0.5% (w/v)
NaCI) growth medium was added and the cultures were incubated at 37°C overnight
(16 hrs). During the incubation the cultures were shaken vigorously to provide
adequate aeration. The cultures were transferred to 1.5 ml Eppendorf tubes and the
cells were harvested by high speed centrifugation in a microfuge. Supernatants were
decanted into fresh eppendorf tubes and single-stranded DNA was prepared from
these stocks. Bacterophage were precipitated by addition of 200 pi of 20% (w/v)
PEG 6000, 2.5 M NaCI solution to 900 pi of supernatant. After 60 minutes at room
temperature the phage pellet was collected by high speed centrifugation in a
microfuge and the pellet was resuspended in 200 pi TE buffer. This was extracted
twice by the addition of an equal volume of a 1:1 phenol: chloroform solution, after
which the DNA was precipitated out of the aqueous phase in the presence of 1/10
volume of 3 M NaOAc pH 5.5 and 2 volumes of ethanol at -20°C. The precipitated DNA
was collected by centrifugation at high speed in a microfuge for 10 minutes and the
pellet was resuspended in 20pl of TE buffer. 5 pi of this DNA was used as template in
a typical sequencing experiment.
The single stranded M13 DNA was sequenced using the dideoxy chain termination
method of Sanger et al (1977) in the presence of [a-35S]-dATP (Williams et al
1986). The sequencing reactions were performed as described in the BRL " M13
cloning/dideoxy sequencing instruction manual " using a BRL sequencing kit. The
sequencing reactions were electrophoresed on a 6% acrylamide gel (0.4 mm
thickness) containing 8 M urea.
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2.11 In situ Ivsis aels to detect linear DNA plasmids k1 and k2.
The yeast cells to be checked for the presence of the linear plasmids were grown
overnight in the appropriate medium (either YPD or supplemented SD if selective
growth required). 1 ml of each of the cultures to be tested were harvested by
centrifugation in a microfuge and the ceil pellet was washed with 1 ml of SE (1 M
sorbitol, 25mM EDTA). The cells were harvested again and resuspended in 50 pi SED
(SE containing 50 mM DTT) and then 5 pi of zymolyase (5 mg/ml) was added. The
cells were incubated at 37°C or until spheroplasts were formed. To check for the
presence of the linear plasmids the spheroplasts were lysed in an agarose gel (in
situ) to release their DNA content. The gel was poured using two sets of slot formers
taped back to back so that the two rows of slots were about 3 mm apart. The back slot
former was taped so that it created a single large slot. The leading wells were loaded
with the spheroplasts and the trailing well with the lysis buffer (1 ml lysis buffer=
0.9 ml 1% SDS, 0.1 ml gel loading buffer, 10 ml RNase A (10 pg/ml)). The samples
were electrophoresed overnight at 15 V. As the lysis buffer runs through the
spheroplasts it gently lyses them releasing the DNA content. The gels were observed
under UV illumination after staining in ethidium bromide solution (Maniatis et al
1 982)
2.12 Making radiolabeled veast extracts
For the labelling of the sec mutant strains of yeast posessing the linear plasmids
(MRY101, MRY102 and MRY103) 5 mis of the appropriate strain was grown at
26°C in labelling medium (SD + HUWLK, 5% (v/v) glycerol, 1% (w/v) BSA).
When the cells were at a density of approximately 2 x 107 cells/ml they were moved
to 37°C for 10 min to introduce the sec block. Once the sec block had been
introduced, 5 pi (50 pCi) of 35S-methionine was added to the culture and the cells
were placed back at 37°C for 90 mins. For the last 2 min of labelling 10 mM sodium
azide was added to the culture and the cells were placed on ice. The cells were
harvested in an Eppendorf tube by centrifugation in a microfuge (5 x 1 ml), and the
supernatants were discarded. The cell pellet was washed twice in water and then
resuspended in 50 pi of 1% SDS. 0.3 g of glass beads were added to the Eppendorf
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tube and the tube was vortexed (5 x 30 sec) to break the cells. 500 pi of lysis
solution (0.1% (w/v) SDS, 0.5% (w/v) sodium deoxycholate, 1% (v/v) Triton
X-100, in 1 x PBS) was added and the tube vortexed again. The mixture was placed
in a boiling water bath for 5 mins and then a hole was punctured in the bottom of the
Eppendorf with a needle. The Eppendorf was placed in a small Falcon tube and the
extract was forced through the hole in the Eppendorf tube into the Falcon tube by
centrifugation (1000 rpm for 2 mins in Beckman J2-21 rotor). 50 pi of 10 x
protease inhibitors (200 pi of 200mM PMSF prepared in isopropanol, 20 jllI of 1
mg/ml pepstatin prepared in methanol , 20 pi of 1 mg/ml antipain prepared in
water, 20 pi of 1 mg/ml leupeptin prepared in 3:1 methanol/DMSO, 20 pi of 1
mg/ml chymostatin prepared in 3:1 methanol/DMSO made up to 1 ml with water)
was added to the extract in the Falcon tube. The extract was transferred to an
Eppendorf tube and centrifuged for 10 minutes at high speed to get rid of unbroken
cells and cell debris. The supernatant was transferred to a clean Eppendorf tube.
Extracts prepared in this way were used in the immunoprecipitation experiments.
2.13 ImmunopreciDitation of labelled proteins.
50 pi of the labelled extract was placed into an Eppendorf tube containing 150 pi of
lysis solution (see above). 5 pi of serum (either immune or pre immune) was added
to the tube and the tube was placed on a rotating wheel overnight in the 4°C cold
room. The next morning 30 pi of Pansorbin fixed Staphylococcus aureus (Staph A)
cells (or 30 pi of protein A-sepharose) was added to the tube and incubated at 4°C on
the rotating wheel for a further 1 hr. The Staph A cells (or protein A-sepharose)
were pelleted in the microfuge and washed twice in HEN (100 mM Hepes NaOH pH
7.9, 10 mM EDTA, 1 mM NaCI, 1% (v/v) NP40), three times in LIT (0.5 M LiCI,
0.1 M Tris HCI pH 8.8, 0.1% (w/v) SDS, 1% (v/v) NP40) and then once again in
HEN (30 minutes for each wash on the rotating wheel at room temperature). The
final pellet was resuspended in 30 pi of protein sample buffer and boiled for 3
minutes. The immunoprecipitates were analysed on 10% polyacrylamide gels.
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2.14 Induction of transformed NM522 cells to produce protein A
fusion proteins
E. coli strain NM522 transformed with pKPRA (or plasmid derived from pKPRA)
was grown in 100 mi of selective medium (LB + Kanamycin) at 37°C to a density of
a600 = 0-3-0.5. When the cells had reached this density IPTG was added to a
concentration of 0.25 mM to induce cells to produce fusion protein from the lac
promoter. Induction was for 4 hrs at 37°C after which the cells were harvested and
inclusion bodies were prepared.
2.15 Induction q! transformed pop2136 cell? to produce
B-oalactosidase fusion proteins.
E. coli strain pop2136 transformed with a pEX plasmid (or a plasmid derived from
the pEX plasmids) was grown in 100 mis of selective medium (LB + ampicillin) at
30°C to a density of A600 = 0.4. When the cells had reached this density they were
moved to a 42°C shaking incubator to induce the cells to produce the fusion protein.
Induction was for 4 hrs at 42°C after which the cells were harvested and inclusion
bodies were prepared.
2.16 Preparation of inclusion bodies from E. coli
The purification of inclusion bodies from NM522 and pop2136 was the same even
though the method of induction was different. Although the fusion proteins in this
thesis all produced inclusion bodies when cells were induced for their expression, it
has to be noted that some fusion proteins do not appear to form inclusion bodies but
are apparently soluble in the cell, in which case it is of no use to purify inclusion
bodies. The inclusion bodies were purified by the following method: 100 ml of
induced E. coli culture was harvested by centrifugation and washed in 50 ml of 0.1 M
Tris HCI, pH 7.5. The cells were lysed by the addition of 1 mg/ml lysozyme,
incubation on ice for 20 mins and then sonication for 5 x 30 sec (between each
sonication the cells were placed on ice for 1 min to prevent excess warming). Cell
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debris was removed by centrifugation at 1000 rpm (in a Beckman JA-20 rotor) for
5 min. The supernatant was poured into a clean tube and the inclusion bodies were
pelleted by centrifugation at 18000 rpm (in a Beckman JA-20 rotor). The inclusion
bodies were resuspended in 0.5 ml 100 mM Tris HCI, pH 8, 150 mM NaCI, 6 mM
p-mercaptoethanol, 1% (w/v) SDS, 1% (v/v) Triton X-100. The pellets were
usually difficult to dissolve and therefore needed to be heated to 65°C to aid
solubilisation. 0.5 ml of protein sample buffer was added to the preparation; samples
were boiled for 5 min before analysis on polyacrylamide gels.
2.17 Preparation of concentrated supernatants and crude microsomes
from veast.
The yeast strains were each grown overnight in 100 ml of their selective media (SD
+ Casein amino acids) to stationary phase of growth. The cells were pelleted by
centrifugation at 1500g for 10 minutes and the supernatants were removed. The
supernatants from each of the strains were concentrated from 100 ml to
approximately 1.5 ml by filtration under pressure through an Amicon
ultrafiltration cell (YM 2 filter). The crude microsome preparation was as follows:-
The cell pellet was resuspended in 5 mis of 10mM Tris.HCI pH 7.3, 1mM EDTA,
150mM NaCI. An equal volume of glass beads was added to the cell suspension and
vortexed for 5 x 30 seconds to lyse the cells, placing on ice between each vortexing
for 1 min. A hole was punctured in the bottom of the tube containing the lysed
cell/glass bead suspension and this tube was placed into a larger centrifuge tube. The
lysed cell suspension was spun through the hole and into the larger centrifuge tube at
low speed (300 g) for 5 minutes. The supernatant in the larger centrifuge was
transferred to a clean centrifuge tube, leaving the pellet of cell debris and unlysed
cells behind. The supernatant was centrifuged at 38000g for 20 minutes to pellet the
microsomes. The supernatant from this spin was discarded and the microsome pellet
was resuspended in 100 nl of 50mM potassium acetate pH 5.0 , 1% (w/v) Brij 58.
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2.18 Gel electrophoresis of proteins.
Separation of proteins was by electrophoresis through polyacrylamide gels following
the basic procedures and buffer system of Laemmli (1970). The constitution of the
various buffers and solutions is given in Table 2.2. Electrophoresis was usually
carried out on the Hoeffer "tall mighty small" apparatus although larger slab gels 18
x 14 cm were also used in some case.10% (w/v) acrylamide separating gels with a
5% (w/v) stacking gel were routinely used.
Protein bands on gels were visualised by staining with Coomassie Brilliant Blue:-
The gel was first immersed in fixing solution (10% (v/v) acetic acid, 20% (v/v)
methanol) for 30 minutes with gentle agitation. Protein bands were then stained
with 0.25% (w/v) Coomassie Brilliant Blue dissolved in 50% (v/v) methanol,
7.5% (v/v) acetic acid for 10 minutes. Gels were destained by agitation in 10%
(v/v) methanol, 7% (v/v) acetic acid.
For fluorography, radioactive gels were fixed in 10% acetic acid, 20% (v/v)
methanol, washed extensively in water and then placed in 10 volumes of the fluor (1
M sodium salicylate) for 30 mins. The gels were then dried onto a piece of Whatman
3 MM chromatography paper, and exposed at -70°C to X-ray film (Amersham
hyperfilm).
2.19 Transfer of proteins onto nitrocellulose
Proteins separated on acrylamide gels were transferred onto nitrocellulose
membranes using a semi dry blotting procedure (The apparatus used was an LKB
semi dry blotter). The procedure used was as follows: Six pieces of 3 MM paper and
one piece of nitrocellulose were cut to the same size as the gel to be transferred. Two
pieces of 3 MM paper were soaked in anode buffer 1 (0.3 M Tris, 20% (v/v)
methanol, 0.1% (w/v) SDS, pH 10.4) and placed onto the anode plate. A piece of 3
MM paper soaked in anode buffer 2 (25 mM Tris, 20% (v/v) methanol, 0.1%
(w/v) SDS, pH 10.4) was then placed on top of the two pieces of 3MM soaked in
47
Table 2.2 Solutions and buffers used in polvacrvlamide ael
electrophoresis
A. Separating gel buffer
0.75 M Tris.HCI pH8.8, 0.2% (w/v) SDS
B. Stacking gel buffer
0.25 M Tris.HCI pH6.8, 0.2% (w/v) SDS
C. Acrylamide solution
44% (w/v) acrylamide, 0.8% (w/v) N;N'-methylene-bis-acry-
-lamide (bis)
D. Electrophoresis buffer
0.125 M Tris, 0.192 M glycine, 0.1% (w/v) SDS
(gives pH8.3 without adjustment)
E. Sample buffer
0.0625 M Tris.HCI pH6.8, 20% (w/v) glycerol, 4% (w/v) SDS,
5% (w/v) (3-mercaptoethanol
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anode buffer 1, followed by a piece of nitrocellulose soaked in anode buffer 2. The
gel, soaked in cathode buffer (25 mM Tris, 20% (v/v) methanol, 0.1% (w/v) SDS,
40 mM 6-amino-n-hexanoic acid, pH 9.4) was placed on top of the nitrocellulose
followed by three pieces of 3 MM paper soaked in cathode buffer. The cathode plate
was placed on top of the stack, sandwiching the stack together. Transfer was at 0.8
mA per cm2 of gel area for 1 hr (ie the current used was dependent on the size of the
gel). Care was taken when forming the stack, not to trap air bubbles between the
layers as this may have interfered with transfer. After the proteins had been
transferred for an hour the assembly was taken apart and the nitrocellulose was
treated for the next stage (ie treated for Western analysis or used as an affinity
strip).
2.20 Purification of fusion proteins from polvacrvlamide gels.
A double thickness (2 mm) 10% polyacrylamide gel (large format) was loaded with
the preparation of inclusion bodies containing the desired fusion protein (in this case
the protein A-Kex2 fusion protein) in a single well across the top of the gel. The
proteins in were separated by electrophoresis and then the gel was stained with
Coomassie brilliant blue. The protein band corresponding to the fusion protein was
cut out of the gel, fragmented and placed in dialysis tubing containing about 2 mis of
Tris-glycine buffer. The dialysis tubing was sealed and placed in a electrophoresis
tank containing Tris-glycine buffer. The protein in the gel slice was electroeluted at
125 V for 5 hours. The dialysis tubing was then placed in a beaker of water (5
litres) on a magnetic stirrer in the 4°C cold room overnight to dialyse. The next day
the liquid was removed from the dialysis tubing, frozen at a slant and then freeze
dried. The freeze dried sample was resuspended in 300 jj.1 of sterile water. The
sample was kept frozen until needed (ie for injection into rabbits or for gel
electrophoresis)
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2.21 Immunising rabbits with fusion protein.
Approximately 100 ng of purified fusion protein (Protein A-Kex 2 fusion protein)
was emulsified with an equal volume of Freunds complete adjuvant by vortexing
(total volume of sample + adjuvant = 1 ml). The emulsified material was taken up
into a 1 ml syringe and injected into rabbits. Two young New Zealand white rabbits
were each immunised with this amount of material by subcutaneous injection. Five
weeks after the initial immunisation a subcutaneous booster of 100 pg of fusion
protein emulsified with Freunds incomplete adjuvant was given to each rabbit. The
rabbits were boosted again in the same way five weeks after the first boost. Seven
days after each boost a 30 ml sample of blood was taken from each animal. A sample
of blood was also taken before immunisation with any fusion protein (pre-immune
serum). The blood samples were all treated in the same way to obtain serum: The
blood was allowed to clot by standing it at room temperature for 2 hrs in a Corex
tube and then at 4°C for a further 18 hrs. The serum was poured into a clean Corex
centrifuge tube leaving the majority of the clot behind and centrifuged at 5000 rpm
(in a Beckman JA-20 rotor) for 10 mins. The serum was passed through a 0.22 urn
Millipore filter an aliquoted into sterile Eppendorf tubes. The serum was stored
frozen at -20°C except for the stock in use which was stored at 4°C to prevent
continuous freezing and thawing. All experiments described were performed using
the serum prepared from the second boost.
2.22 Affinity purification of antibodies using antigen immobilised on
a nitrocellulose strip.
The sample containing antigen (In this case a preparation of inclusion bodies from
pEX-Kex transformed pop2136 cells) was separated on a 10% preparative slab gel
(the whole sample was loaded into a single well spanning the width of the gel) and
transferred onto nitrocellulose (Chapter 7). The nitrocellulose was stained in 0.2%
Ponceau S in 3% TCA for 5 minutes and then washed in water to remove the
background staining. The band corresponding to the antigen (in this case the
p-galactosidase-Kex2 fusion protein which was the largest and most abundant
protein on the blot) was carefully excised from the blot using a scalpel. The Ponceau
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S was removed from the affinity strip by washing in TBS several times (NB it is
important to be able to determine which side of the strip has the antigen bound to it,
especially once the Ponceau S is removed). The affinity strip was then incubated in
blocking buffer (3% BSA in TBS) for 90 minutes in order to block any non-specific
sites on the nitrocellulose and then washed in TBS. The affinity strip was placed
(antigen side up) onto parafilm in a container with a lid and the immune serum
(Kex2 antiserum) was placed onto the strip (as much as could be held on the strip by
surface tension). The lid was placed on the box and the strip was shaken gently at
room temperature for 2 hrs. The excess serum was removed from the strip and the
strip was washed three times for 5 minutes each wash in TBS to remove any unbound
antibodies that may have been present. The antibodies specifically bound to the
antigen were removed from the strip by placing elution buffer (0.2 M glycine.HCI,
pH 2.8) onto the strip (as much as could be held on the strip by surface tension) for
20 min. The elution buffer containing the eluted antibodies was removed from the
affinity strip and neutralised immediately by adding an equal volume of 0.1 M Tris
HCI, pH 8.5. These affinity purified antibodies were stored at 4°C after the addition
of 0.1% sodium azide to them. The Affinity strips were be re-used after washing in
TBS, and stored at 4°C in TBS, 0.1% sodium azide.
2.23 Detection of blotted proteins with antibodies (Western analysis)
Two different methods of detection were used in the experiments described in this
thesis. Both methods involve the detection of a second antibody conjugated to horse
radish peroxidase (HRP). In the earlier experiments the blots were developed with
4-chloro-1-naphthol and in later experiments the blots were developed with a
chemi luminescent reagent (Amersham ECL system) and detected by exposing X-ray
film to the blot
Detection with 4-chloro-1-naphthol
Once the proteins separated by electrophoresis had been transferred to nitrocellulose
the nitrocellulose blot was placed into blocking buffer (TBS + 0.5% (v/v) Tween
20) for 90 mins. Once blocked the blot was placed into TBS + 0.05% (v/v) Tween
20 containing primary antibody (the dilution and type of primary antibody was
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dependent on the particular experiment) and incubated at room temperature for 2
hrs. The blot was washed in TBS + 0.05% (v/v) Tween 20 (5 x 5 mins) and then
placed into TBS + 0.05% (v/v) Tween 20 containing second antibody ( a 1/2000
dilution of goat anti-rabbit HRP-conjugated IgG obtained from Sigma was routinely
used). The blot was washed in TBS + 0.05% (v/v) Tween 20 and then placed into
developing solution (25 ml TBS, 7 jj.I H202, 5 ml 4-chloro-1-naphthol (3 mg/ml)
in methanol). Developing was stopped by washing the blot copiously in water and
then placing in TBS.
Detection with ECL reagent
Once the proteins separated by electrophoresis had been transferred to nitrocellulose
the nitrocellulose blot was placed into ECL blocking buffer (TBS + 5% (w/v) non fat
dried milk (Marvel), 1% (v/v) Tween 20) for 1 hr. Once blocked the blot was
placed in ECL blocking buffer containing the primary antibody (the dilution and type
of primary antibody was dependent on the particular experiment). The blot was
washed in TBS + 0.1% (v/v) Tween 20 (5 x 5 mins) and then placed into ECL
blocking buffer containing second antibody (a 1/5000 dilution of goat anti-rabbit
HRP-conjugated IgG obtained from Sigma were routinely used). The blot was then
washed in TBS + 0.1% (v/v) Tween 20 (5 x 5 mins) after which it was ready to be
developed. Development of the blot was performed in the dark room as it is necessary
to expose the blot to X-ray film and develop the film in a short space of time. The
blot was placed in 20 mis of ECL reagent (prepared as described in the Amersham
booklet provided with the reagent) for 1 min. The blot was removed from the reagent
and excess reagent was removed (by letting it drip off for a few seconds). The blot
was wrapped in Saran wrap and placed antigen side up in an X-ray film cassette.
X-ray film was exposed to the blot in the cassette for 30 seconds and then developed.
The developed film was looked at and another film was exposed to the blot for a longer
or shorter time (depending on how the first film looked) before being developed.
Once the blot was placed in ECL reagent it was important to carry out subsequent
steps quickly as the ECL reagent fades. Blots could however be re-developed using
fresh ECL reagent if they are stored in TBS (ie without drying out). This method of
detection was preferable to detection with chloronaphthol as it was quicker to
perform, much more sensitive and a permanent record of the blot (the developed
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autoradiograph) was instantly made.
2.24 Permeabilisina veast cells with Brii 58.
Yeast cells permeabilised with Brij 58 were used as the source of internal Kex2p in
the in vitro assays for Kex2. 1 ml of yeast cells were pelleted by centrifugation in a
microcentrifuge for 5 min. The cell pellet was washed in 0.9% (w/v) NaCI,
harvested by centrifugation in a microfuge and the supernatant was discarded. The
cell pellet was frozen at -70°C for 30 min and then were allowed to thaw slowly on
ice. 0.9 ml of potassium acetate pH 5.0 followed by 0.1 ml of 10% (w/v) Brij 58
were added to the thawed pellet (the cells were left on ice for 30 minutes in order
for them to permeabilise). 5 p.l of the permeabilised cell suspension was used in each
assay for intracellular Kex2 activity.
2.25 In vitro assay for Kex2 activity
5 |il of the Kex2 source (either culture supernatant or cells permeabilised with Brij
58) was assayed in a 50 jil reaction mix in an Eppendorf tube as descibed by Fuller
et al (1988):- The reaction mix contained 200 mM sodium-hepes pH 7, 1 mM
CaCl2. 0.5 mM phenylmethylsulphonyl fluoride (PMSF), 0.1 mM
L-1-tosylamido-2-phenyl-ethyl chloromethyl ketone (TPCK), 1% (w/v) Triton
X-100 and 100 |iM t-butoxycarbonyl-Gln-Arg-Arg 4-methylcoumarin-7-amide
(bQRR-MCA). Reaction mixtures were incubated for 30 minutes at 37°C. The
reactions were terminated by the addition of 0.9 ml of 0.125 M ZnS04 and 0.1 ml of
a saturated Ba(OH)2 solution. The precipitate formed on the addition of Ba(OH)2 was
removed by centrifugation for 1 minute in a microcentrifuge. The 7
amino-4-methylcoumarin (AMC) released from bQRR-MCA due to cleavage after the
pair of Arginine residues (by Kex2p) was determined fluorimetrically [X
(excitation) = 385 nm, X (emission) = 465 nmj.
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2.26 Microtitre assay for K. lactis killer toxin
The yeast strain sensitive to the toxin (LL20) was grown in YPD and diluted in toxin
assay broth (18 ml YPD, 0.74 ml 0.5M citric acid, 1.26 ml 1.0 M Na2HP04) to a
cell density of 1 x 106 cells/ml. 20 pi of the supernatants of the cells to be tested for
toxin production were placed into the wells of a microtitre assay plate followed by
180 pi of diluted sensitive cells. The microtitre plate was incubated at 28°C for 24
hrs. Inhibition of growth was obvious in wells containing toxin by the apparent
density of cells in the wells. For a quantitative result the 200 pi of cells in the
microtitre assay wells were placed into a a cuvette containing 0.8 mis of water and
the A600 was measured. The lower the A600 the greater the inhibition due to the
presnce of the toxin (ie there is more toxin present in the supernatant).
2.27 Assays for «factor
Both of the assays for a factor are based on the inhibition of growth of a strain of
yeast that is sensitive to a factor (RC631).
Halo assay for secreted a factor
The growing yeast strain RC631 was inoculated to a density of 106 cells/ml into YPD
+ 0.8% (w/v) Bacto agar (no warmer than 50°C) and poured immediately ont YPD
plates to create a lawn of sensitive cells. The plates were dried in a 30°C incubator
and then the strains to be tested for a factor secretion were patched onto the seeded
lawn. The plates were incubated at 30°C for approximately 36 hrs, until the
sensitive strain of yeast had grown and the halos of inhibition of growth could clearly
be seen. The size of the halo is an indication of the amount of a factor being produced
by the seeded strain, with a large halo indicative of a large amount of a factor
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Microtire assay for secreted a factor
A growing culture of the sensitive yeast strain RC631 was diluted to a density of
approximately 105 cells/ml. 100 p.l of the supernatant (or a dilution of the
supernatant) to be tested for the presence of a factor was placed into the well of a
microtitre assay plate. This was followed by 100 jal of the diluted sensitive cell
culture. The microtitre assay plate was incubated overnight (18 hrs) at 30°C. The
density of the sensitive cells was measured by placing the 200 p.l of cells in the assay
well into a cuvette containing 800 |il of water and then measuring the A600. The
lower the A600 the greater the amount of a factor in the supernatant. Thus the
density to which the sensitive cells grew to could be used to estimate the relative
amounts of a factor in the media of different strains.
2.28 Processing veast cells for immunocvtochemistrv using LR white
resin.
The processing of all of the strains of yeast used for immunocytochemistry was by a
method obtained from Dr R. Wright, Biochemistry department, Barker Hall,
University of California, Berkeley (personal communication):-
Fixation of the yeast cells.
Gross morphological alterations and changes in the presence and/or location of
proteins has been reported when yeast are subjected to centrifugal forces. To avoid
any such affects in this method, the fixative is added directly to the growing culture
of yeast.
(1) A 1/10 volume of 10x prefixative solution (10% gluteraldehyde, 2% methanol
free formaldehyde, 0.4M potassium phosphate pH7) was placed into a centrifuge
tube.
(2) The early log phase yeast culture (50ml) grown in selective medium was poured
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rapidly into the fixative and allowed to sit at room temperature for 5 minutes.
(3) The cells were pelleted and resuspended in 1/10 volume of ice cold 1x
prefixative (1% gluteraldehyde, 1% methanol free formaldehyde in 0.04M
potassium phosphate pH7) and allowed to complete fixation for 30 minutes.
(4) Excess fixative was removed by three buffer washes (ie 0.04M potassium
phosphate pH7) leaving the cell suspension in each change of buffer for at least 5
minutes.
Periodate treatment
(1) The washed cell pellet was washed in 5 ml of freshly prepared 1% sodium
metaperiodate (aqueous) and allowed to incubate at room temperature for 15
minutes. The samples became clumpy at this point which is an advantage in later
stages. The cells were pelleted and washed once in phosphate buffer.
(2) The pellet was resuspended in 50mM ammonium phosphate to block free
aldehyde sites. After 15 minutes the cells were washed twice with distilled water.
Dehydration
(1) The cells were resuspended in 10ml of 50% ethanol and then "spun' in a conical
glass centrifuge tube for 5 minutes to pellet the cells (the use of glass is important
for maximising clumping of the pellet into aggregates of convenient size).
(2) The supernatant was replaced with 1ml of 70% ethanol. At this point the cells
formed firm pellets that could be gently dislodged with a pasteur pipette into small
fragments. Aliquots containing 10-20 small chunks were dispensed into eppendorf
tubes containing 70% ethanol. These aliquots can be stored at -20°C for several
months but in this case subsequent processing was carried out immediately.
(3) The tubes containing the samples were placed on a rotating drum for 5 minutes.
Dehydration was completed by subsequent incubations (5 minute rotations) in 95%
and 3 changes in 100% ethanol. For the 100% ethanol incubations a new bottle of
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ethanol was opened to ensure the absence of water.
Infiltration
(1) The last 100% ethanol incubation was replaced with a solution of 2 parts
ethanol to 1 part resin (LR white). The eppendorfs were returned to the rotator for
1 hr.
(2) The resin mix was replaced with a 1:1 resinrethanol mix and the samples were
rotated for 1 hr.
(3) The resin mix was replaced with a fresh 1:1 mix and the samples were rotated
uncapped overnight in a fume hood. The ethanol slowly evaporates thus increasing the
resin concentration gradually.
(4) The next day the residual resin was replaced with fresh 100% resin and the
samples rotated for an hour. The resin was changed and the samples placed under
vacuum (20 psi) for 15 minutes to degas, then they were placed back on the rotator
for 1 hr.
Embedding
(1) Small pellet fragments were removed from the eppendorf tubes using a tooth
pick and placed into gelatin capsules filled with resin.
(2) The sample was allowed to sink to the bottom of the capsule, positioned in the
centre and then placed under vacuum for 15 minutes.
(3) Polymerisation was accomplished by leaving the gelatin capsules in an incubator
at 45°C-50°C for 2 days.
Grid preparation and sectioning
Sections from the LR white resin blocks were cut by the Department of Pathology,
University of Edinburgh and placed onto gold EM grids. The sections were air dried on
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the grids for two days.
Immunolabelling
For this technique it is essential to use affinity purified antibodies derived from
polyclonal antiserum as when crude antiserum is used contaminating antibodies can
produce severe problems in interpretation. Background labelling of the cell wall,
vacuole and nucleus are especially problematical. As the affinity purified Kex2
antibodies appear to be specific for Kex2p in Western analysis it was decided that
these antibodies would be good enough to use as the primary antibody in
immunolabelling experiments of the different strains of yeast expressing the various
forms of the truncated Kex2p and of control strains.
Setting up the incubation chamber
(1) The incubation chamber consisted of a box with a tight fitting lid, of sufficient
size to contain all of the grids and solution droplets. Moist paper towels were placed
in the incubation chamber in order to maintain humidity throughout the labelling
steps.
(2) Parafilm was positioned in the box and small coloured adhesive dots (sticky
dots) labelled with the identity of the grid were placed down the left side of the
parafilm. Across the top of the parafilm 4 sticky dots were also positioned. The first
and third represented positions at which droplets of blocker would be placed. The
second represented the position of the droplet of primary antibody (affinity purified
Kex2 antibody) and the fourth the position of the droplet of secondary antibody (goat
anti rabbit gold conjugated antiserum:-10nm gold particles).
Reagents
PBST (140mM NaCI, 3mM KCI, 8mM Na2HP04, 1.5mM KH2P04 and 0.5% Tween
20) was used throughout the immunolabelling protocol for all washes and as the
vehicle for the blocker. The blocking solution was PBST containing 2% bovine
albumin. All solutions were filtered through a 0.22 p.m filter (Acrodisc) before use.
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Both primary and secondary antibodies were diluted in blocking solution. The best
dilution factor for the batch of affinity purified Kex2 antibodies was found to be
1/50 by using a dilution series. The gold conjugated second antibody was adjusted to
a525 = 0-13-
Experimental procedure for immunolabelling
(1) 20jj.I droplets of blocking solution were positioned at the appropriate positions
on the parafilm sheet. The appropriate grid was submerged in the blocking solution
and allowed to incubate for 15 minutes at room temperature.
(2) After blocking the grid was removed from the blocking solution, touched onto a
Kimwipe to remove excess fluid and then submerged in a 20|j.l droplet of primary
antibody for 2 hrs at room temperature.
(3) The grids were next washed 3 times for 5 minutes in PBST (0.5ml). The washes
were performed in a porcelein dish shaking at a speed so that the-solution was moving
as rapidly as possible without spilling.
(4) The grids were transferred from the washes to a second drop of blocking solution
for 15 minutes and the to a 20|xl drop of secondary antibody for 1 hr at room
temperature.
(5) Washes were performed as in (3) and after the final PBST wash the grids were
dipped 10 times into distilled water in a 5ml beaker with a rapid up and down
motion. This step was to remove salts that may crystallise on the grid and obscure
the view under the electron microscope. The grids were allowed to air dry for 2 days
before staining
(6) The grids were stained with 2% aqueous uranyl acetate for 1-5 minutes and in




Biogenesis of the K. lactis killer toxin.
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3.0 Introduction
The study of intermediates in the maturation of proteins in yeast has been aided
greatly by the use of conditional sec mutants, isolated by Novick et al (1980). These
sec mutants are blocked in secretion and, at the restrictive temperature of 37°C,
accumulate intermediate forms of proteins in specific organelles of the secretory
pathway (depending on the particular mutant). The processing events that these
intermediates have undergone are an indication as to those processing enzymes to
which they have been exposed.
The Kluyveromyces lactis killer toxin is secreted by strains of Saccharomyces
cerevisiae harbouring the linear DNA plasmids k1 and k2. It should therefore be
possible to use the well-established genetics of S.cerevisiae, and the sec mutants in
particular, to monitor the processing and assembly of the K.lactis killer toxin as has
been done for a factor (Julius et al 1984), invertase (Esmon et al 1981) etc. One of
the processing events that occurs in the maturation of the K.lactis killer toxin is the
proteolytic cleavage of the 130K ap precursor polypeptide to give rise to the mature
99K a and 30K p polypeptides. The Kex2p of S.cerevisiae has been implicated in the
this processing event as the cleavage of the ap precursor is known to be at the
carboxyl side of Lys-Arg sequence which is known to be cleaved by Kex2p in other
proteins (ie prepro a factor). Furthermore K.lactis possesses a functional
homologue (the K.lactis Kex1 protease) of the Kex2 protease of S.cerevisiae that was
isolated as being deficient in processing the K.lactis killer toxin, and which also has
sequence similarity to Kex2p (Tanguy-Rogeau et al 1988). In this chapter I will
describe experiments which verify the involvement of Kex2p in the processing of the
ap precursor of the toxin in S.cerevisiae. Also the timing of processing and assembly
of the toxin in the secretory pathway will be discussed.
3.1 Involvement of Kex2p in the processing of K.lactis killer toxin
S.cerevisiae strain F102-2 harbours the linear DNA plasmids k1 and k2 (for full
genotype see Table. 2.1) and secretes a functional killer toxin that inhibits the
growth of a sensitive strain of S.cerevisiae called LL20. To show the involvement of
Kex2p in the processing of the K.lactis killer toxin it was decided to replace the KEX2
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gene of F102-2 with a non-functional KEX2 gene which is disrupted with a
selectable marker, the LEU2 gene (kex2::LEU2). The kex2::LEU2 disruption was
obtained as a Bam Hl/Sph I fragment in a plasmid called pGA1070 (supplied by Dr.
G. Ammerer). The first step in this gene replacement was to digest the plasmid
pGA1070 with Bam HI and Sph I and purify the Bam Hl/Sph I fragment (fig. 3.1).
This purified fragment was transformed into F102-2 with selection for Leu+
colonies (untransformed F102-2 is Leu"). These Leu+ transformants should have
had their chromosomal copy of the KEX2 gene replaced with the kex2::LEU2
disruption from pGA1070 (fig. 3,1). The transformants were checked for the
replacement of the KEX2 gene with the kex2::LEU2 disruption by Southern analysis
of the chromosomal DNA of the transformants (fig. 3.2).
The Southern analysis (fig. 3.2) showed that three of the transformants (2, 5 and 6)
all appeared to have had the chromosomal copy of the KEX2 gene replaced with the
kex2::LEU2 disruption from pGA1070. Three of the transformants (1, 3 and 4)
appeared to possess both the normal chromosomal copy of the KEX2 gene and the
kex2::LEU2 disruption. This was possibly because the kex2::LEU2 disruption had
integrated somewhere in the chromosome but not at the KEX2 locus. Another
possibility was that when the transformants 1, 3 and 4 were being picked a mixture
of colonies with and without the gene replacement were picked instead of a single
colony. A third possibility is that the Bam Hl/Sph I fragment has somehow become
recircularised in the yeast and has a fortuitous origin of replication so that it can be
maintained in the cells under selection. Transformants 2, 5 and 6 were assumed to
be Kex2" as they unambiguously have the chromosomal copy of KEX2 replaced with
the kex2::LEU2 disruption.
Strain F102-2, together with the six transformants previously checked for
replacement of the normal chromosomal copy of the KEX2 gene with the kex2::LEU2
disruption, were tested to see whether they secreted active K.lactis killer toxin or
not:- 5ml cultures of F102-2 and the six transformants were grown overnight (16
hr) in YPD medium at 30°C. All of the cultures of yeast had reached stationary phase
by the next morning. 1ml of cells from each of the cultures was harvested by
centrifugation and the cells were kept. The supernatants from each of the spun
cultures was also kept and were assayed by microtitre assay (see Materials and
Methods) for K.lactis killer toxin activity. The harvested cells were checked for the
62
Fig 3.1 Replacement of the chromosomal copy of KEX2 in F102-2 with
a non functional disrupted KEX2 aene (kex2::LEU2).
The Bam Hl/Sph i fragment of pGA1070 (supplied by Gustav Ammerer) has the
majority of the KEX2 gene replaced with the LEU2 gene (kex2::LEU2) but the
flanking regions are intact. Yeast strain F102-2 was transformed with the
kex2::LEU2 disruption from pGA1070 with selection for Leu+ transformants.
Homologous recombination of the regions flanking the kex2::LEU2 disruption in the
Bam Hl/Sph I fragment and the regions flanking the chromosomal copy of the KEX2
gene results in the replacement of the chromosomal copy of the KEX2 gene with the
kex2::LEU2 disruption. The resulting strain with the recombinant chromosome was
named PWYS1 and does not contain a functional KEX2 gene. The restriction sites



































Fig 3.2 Southern analysis of F102-2 and F102 transformants.
Total DNA from F102-2 and F102-2 transformed with the kex2::LEU2 disruption
fragment was digested with Eco Rl and electrophoresed on a 0.8% agarose gel. The
DNA was blotted onto nitrocellulose. Southern analysis was performed using a
radiolabeled DNA probe. The DNA fragment used as the probe is shown in the figure
and consists of a 3.6 kb Eco Rl fragment of the KEX2 gene (purified from plasmid















The 3.6 kb band on the autoradiograph is indicative of the KEX2 gene. The 2.8 kb and
2.6 kb bands are indicative of the kex2::LEU2 disruption fragment being present
(when kex2::LEU2 is digested with Eco Rl, two fragments of 2.8 kb and 2.6 kb are
released; Both of them are recognised by the KEX2 probe).
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presence of linear plasmids by in situ lysis electrophoretic analysis (see Materials
and Methods).
The results of the killer toxin assay (Table 3.1) show that F102-2 and
transformants 1, 3 and 5 all secreted active killer toxin as they inhibited the growth
of LL20 the sensitive strain. Transformants 2, 5 and 6 did not appear to secrete
active killer toxin as they did not inhibit the growth of LL20. These results suggest
that when the normal KEX2 gene is present (ie in F102-2 and transformants 1, 3
and 4) the K.'.actis killer toxin is processed and secreted into the culture medium in
an active form. However when the normal chromosomal copy of the KEX2 gene is
replaced with the kex2::LEU2 disruption (ie in transformants 2, 5 and 6) to make
the strain Kex2", there is no detectable K.lactis killer toxin activity in the
supernatants. These results suggest that an active Kex2p is required for the
processing and/or secretion of K.lactis killer toxin from S.cerevisiae.
The in situ lysis gel (fig. 3.3) shows that F102-2 and all of the transformants
contained the linear plasmids and therefore were capable of producing K.lactis killer
toxin. The amount of DNA in each of the lanes varies even though approximately the
same amount of cells from each of the cultures were treated with zymolyase and
loaded onto the gel. It appears that lanes corresponding to F102-2 and transformants
1, 3 and 4 contained more linear plasmid DNA than transformants 2, 5 and 6. Thus
for some reason the Kex2" strains appear to have less linear plasmid DNA on the gel
than Kex2+ strains. One explanation could be that Kex2" mutants do not form
spheroplasts as readily as Kex2+ strains and therefore when placed into the wells of
the in situ lysis gel only a proportion of them are lysed and released their DNA
content into the gel. An interesting observation is that Kex2" mutants tend to clump
together when grown in liquid medium to a greater extent than Kex2+ strains. This
clumping could possibly effect the efficiency of spheroplast formation as all the cells
in the clump may not be accessible to digestion by zymolyase. Another possible
explanation for the differing DNA contents on the gel could be that Kex2" mutants are
more susceptible to lysis during spheroplast formation and a high proportion lyse to
release their DNA content before being loaded into the wells of the in situ lysis gel.
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TABLE 3.1 Results of the microtitre assays for secreted killer toxin in cell
supernatants
Supernatant from strain % of control growth
F102-2 2 2%
F102-2 transformant 1 24%
F102-2 transformant 2 1 00%
F102-2 transformant 3 29%
F102-2 transformant 4 28%
F102-2 transformant 5 103%
F102-2 transformant 6 1 02%
The results of the toxin assays of the cell supernatants from the different
strains are expressed as a percentage of the density to which LL20 (the toxin
sensitive strain) grows when no toxin is present (ie cell supernatant is
replaced with YPD in the microtitre assay). Hence a low percentage indicates
that active toxin was present in the cell supernatant and a high percentage
indicates that that very little (or no) active toxin is present in the cell
supernatant.
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Fig 3.3 In situ Ivsis analysis of F102-2 and F102-2 transformants
The strain F102-2 and F102-2 transformed with the kex2::LEU2 disruption
fragment were analysed by in situ lysis gel electrophoresis for the presence of the
linear plasmids k1 and k2.
Lane 1. F102-2 transformant n° 1
Lane 2. F102-2 transformant n° 2
Lane 3. F102-2 transformant n° 3
Lane 4. F102-2 transformant n° 4
Lane 5. F102-2 transformant n° 5




3.2 Processing and assembly of the K.lactis killer toxin in the
secretory pathway
The linear DNA plasmids k1 and k2 were placed in S. cerevisiae strains with
different genetic backgrounds by a method called cytoduction (Zakharov et al 1969).
Strains MRY101, MRY102 and MRY103 (M. Romanos and A. Boyd unpublished)
contained the linear plasmids in sec18, sec14 and sed backgrounds respectively.
These strains are all temperature sensitive for growth and should accumulate
specific secretory organelles at the restrictive temperature of 37°C because of their
sec genotypes. MRY101 should accumulate ER, MRY102 should accumulate Golgi and
MRY103 should accumulate secretory vesicles. It was intended to examine the
accumulation of intermediates in the processing and assembly of the K. lactis killer
toxin in these strains and by analysing the intermediates to deduce the order of
processing and assembly of the toxin.
3.3 Analysis of the toxin accumulated in MRY1Q1. MRY1Q2 and
MRY1Q3 at the restrictive temperature,
MRY101 is a sec18 mutant that contains the linear DNA plasmids k1 and k2. At the
permissive temperature of 26°C MRY101 secretes active killer toxin. However at
the restrictive temperature of 37°C MRY101 is arrested in growth and according to
its genotype should accumulate ER and ER forms of secretory proteins. Therefore ER
modified forms of the K.lactis killer toxin should be accumulated in MRY101 at
37°C. Analysis of the toxin accumulated in MRY101 at 37°C should indicate the
processing and assembly events that have taken place before the sec18 block.
Strain MRY101 was grown in 10 ml of labeling medium to a cell density of 2 x 107
cells/ml at 26°C. The culture was then shifted to 37°C in order to impose the sec18
block. After 10 minutes at 37°C radioactive label ([35S]-methionine) was added to
the culture and labelling allowed to proceed for 1 hr. After 1 hr the labelling was
stopped by addition of sodium azide and extracts were made from the labelled cells.
Immunoprecipitations using polyclonal antibodies to different subunits of the toxin
were carried out on the labeled cell extracts (For details of labelling, cell extract
and immunprecipitation protocols see Materials and Methods). An antibody specific
to the a subunit of the toxin (anti a antibody) and an antibody specific to the y
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subunit of the toxin (anti y antibody) were used to immunoprecipitate material from
MRY101 cell extracts labeled at 37°C. The material specifically immunoprecipitated
was run on a reducing 10% SDS PAGE, and processed for fluorography (see
Materials and Methods)
The fluorograph (fig. 3.4) shows that the a-specific antibody specifically
precipitates a protein of approximate molecular weight 130K. This protein is
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presumed to be the ap precursor of the toxin as it is the predicted size of the ap
precursor and the anti-a antibody should recognise the ap precursor as well as the
mature a subunit. The y specific antibody specifically precipitates a protein with an
approximate molecular weight of 30K. This protein is presumed to be the y subunit
of the toxin as it is in the correct size range to be the y subunit and is the only
subunit of the toxin that should be specifically precipitated by the anti-y antibody.
Pre-immune sera from both rabbits used in the preparation of the anti-a antibodies
and the anti-y antibodies do not specifically precipitate any polypeptides (fig. 3.4).
There does not appear to be any co-precipitation of the y subunit with the ap
precursor when anti-a antibodies are used in the immunoprecipitation and
conversely there does not appear to be any co-precipitation of the ap precursor with
the y subunit when anti-y antibodies are used in the immunoprecipitation. A number
of different methods for making labeled cell extracts in combination with different
methods for immunoprecipitation have been tried and co-precipitation of the ap
precursor and the y subunit has not been detected with any of them (data not shown).
The simplest explanation for this observation is that the y subunit is not covalently
attached to the rest of the toxin by the disulphide bond known to exist in the fully
assembled toxin until after the position in the secretory pathway at which sec 18
blocks secretion. This explanation would, however, go against the accepted view that
disulphide bonds form in the ER (Freedman 1984). Another explanation could be that
in making the cell extract or in the immunoprecipitation procedure the disulphide
bonds are reduced and the toxin falls apart. A third explanation, less likely given that
the antiserum is polyclonal is that the antibodies used only recognise free subunits
and not assembled toxin complexes. The fact that a 130K protein (the ap precursor)
is the only protein specifically precipitated using anti a antibodies indicates that the
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Fig. 3.4 Immunoprecipitations of toxin subunits from a sec18 mutant
labeled at the restrictive temperature.
Strain MRY101 was labelled at 37°C, extracts made and immunoprecipitations
performed as described in Materials and Methods. Immunoprecipitates were
precipitated either with Staphylococcus aureus (Staph. A) cells or protein
A-Sepharose (PAS). The antisera used in the immunoprecipitations were anti a
immune serum anti y immune serum (both raised against p-galactosidase fusion
proteins by M. Stark and A. Boyd unpublished). The pre immune sera (a-PI and
y-PI) came from the same rabbits in which the immune sera were raised, before
immunisation.
Lane 1. 14C-labelled marker proteins.
Lane 2. MRY101 extract immunoprecipitated with anti-a immune serum (Staph A)
Lane 3. MRY101 extract immunoprecipitated with a-PI serum (Staph A)
Lane 4. MRY101 extract immunoprecipitated with anti-y immune serum (Staph A)
Lane 5. MRY101 extract immunoprecipitated with y-PI serum (Staph A)
Lane 6. MRY101 extract immunoprecipitated with anti-a immune serum (PAS)
Lane 7. MRY101 extract immunoprecipitated with a-PI serum (PAS)
Lane 8. MRY101 extract immunoprecipitated with anti-y immune serum (PAS)








toxin being accumulated in MRY101 labeled at 37°C has not been proteolytically
processed by Kex2p to release the a and p subunits. This suggests that cleavage by
Kex2p does not normally occur until a position after that at which the sec18 block
has its effect, as expected. The ap precursor can also be specifically precipitated in
immunoprecipitations from MRY101 cell extracts labelled at 26°C using anti a
antibodies but the amount is much less than when labelling is at 37°C (data not
shown). The ap precursor precipitated from MRY101 cells labelled at 26°C could be
en route through the secretory pathway or the sec18 defect may affect exit from the
ER even at 26°C but to a lesser extent than the total block at 37°C. There is evidence
that sec18 mutants are defective, even at the permissive temperature by the
synthetic lethality of double mutants (Kaiser and Schekman 1990).
In situ lysis analysis of MRY103 revealed that it did not contain the linear plasmids
k1 and k2 as it was supposed to (data not shown). The strain still retained its
temperature sensitive phenotype which suggested that it was a sect mutant as
expected but the linear plasmids were not present. The reason for this is not known
but a possibility could be that the linear plasmids are not stably maintained in a sed
background and the plasmids are lost at a high frequency from the strain. Although
the original MRY103 (made by Dr M Romanos) contained the linear plasmids, during
routine re-streaking of the strain, colonies may have been selected that fortuitously
lacked the linear plasmids because of plasmid loss due to instability in a sed
background.
MRY102 is a sec14 mutant that contains the linear plasmids k1 and k2. At the
permissive temperature of 26°C this strain secretes active killer toxin. However at
the restrictive temperature of 37°C MRY102 is arrested in growth and according to
its genotype should accumulate Golgi and Golgi forms of secretory proteins. Therefore
Golgi-modified forms of the K.lactis killer toxin should be accumulated in this strain
at 37°C. Analysis of the toxin accumulated in MRY102 at 37°C should indicate the
processing and assembly events that have taken place before the sec14 block.
Labeling and immunoprecipitation experiments have been performed on MRY102
using exactly the same methods as with MRY101. No specific proteins were
precipitated with either the anti a or anti y antibodies (data not shown). The reason
for this is not known as the linear plasmids were present and the strain was
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temperature sensitive for growth.
3.4 Concluding remarks
In this chapter I have confirmed the involvement of Kex2p in the processing of the
K.lactis killer toxin by replacing the KEX2 gene with the kex2::LEU2 disruption and
showing that linear plasmid bearing strains with this disruption do not secrete
active killer toxin. Also I have demonstrated that cleavage of the a(3 precursor by
Kex2p has not occured before the stage in the secretory pathway at which sec 18
exerts its effect (ie before transport to the Golgi). This was expected as Kex2p is
reported to be a resident of the Golgi apparatus. The y subunit of the killer toxin does
not appear to have become covalently attached to the a|3 precursor before the position
in the secretory pathway at which sec 18 exerts its effect (a question that has not
previously been examined), although there is some doubt as to whether this result
is real or an artifact due to the experimental techniques used. Analysis of
intermediates of processing and assembly of the killer toxin accumulated in Golgi and
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As secretory proteins proceed through the secretory pathway they are processed in
an ordered fashion by a variety of specific enzymes in distinct compartments of the
pathway. What is the reason for this sequential modification of secretory proteins in
separate compartments and is the order in which the processing events occur
important for the correct biogenesis and secretion of secretory proteins? Because of
the complexities of the secretory pathway and the processes that take place in it
there may not be a simple explanation for the compartmentalised processing of
secretory proteins but the following or a combination of the following may provide
some of the answers:- The order of processing events may be important in helping a
protein attain its final folded configuration. On the other hand the ordered processing
may be a consequence of the processing enzymes needing to be in separate
compartments with different environments in order to function efficiently. It is also
possible that some processing events require another processing event to have taken
place previously in order for them to occur. For example modifications to N-linked
oligosaccharides on polypeptides are dependent on the core oligosaccharide having
being transferred to the polypeptide in the first place. It is not so clear cut whether
other processes are dependent on other events having occurred or not. For example it
is quite possible that proteolytic processing events are completely independent of
processes such as glycosylation. Alternatively glycosylation could mask potential
processing sites, or it is possible that glycosylation causes a protein to fold in such a
way that sites not normally exposed are exposed to proteolytic processing enzymes,
thus in these cases proteolytic processing is not independent of glycosylation.
Much experimental work has been carried out on the order of events that take place
in the secretory pathway during the biogenesis of secretory proteins. Our aim was to
alter the order of events in the secretory pathway of yeast and see what effect that
this had on the biogenesis and secretion of secretory proteins. The particular event
that we were interested in altering was the proteolytic processing of secretory
proteins by Kex2p. We aimed to do this by relocating the Golgi enzyme Kex2p to the
ER, hoping to get premature cleavage of secretory proteins in the ER by this
relocated Kex2p. In this chapter I will describe the strategy chosen to localise Kex2p
to the ER and the construction of plasmids that will hopefully enable the relocation of
Kex2p in yeast.
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4.1 The strategy used to localise Kex2p to the ER
The Kex2 endoprotease of S.cerevisiae is membrane-bound and resident in the Golgi
apparatus. It has been shown that the removal of 200 amino acids from the
C-terminus of the Kex2p which removes the transmembrane domain does not effect
the specificity of the enzyme in an in vitro assay (Fuller et al 1988). Our strategy
was to attach specific amino acid sequences that have been used to localise proteins to
the ER (Pelham et al 1988) to the C-terminus of a truncated Kex2p with the
transmembrane domain removed. These truncated polypeptides with the different
C-termini would then be expressed in yeast to look at their effects on the biogenesis
of secretory proteins. During the course of this project we were encouraged by an
observation that expression of a soluble CD4 receptor (normally a membrane bound
protein) mutated to contain a specific retention signal for the ER, blocks the
secretion and surface expression of the envelope glycoprotein (gp20/41) of human
immunodeficiency virus (HIV-1) (Buonocore and Rose 1990). These observations
may have implications in Aids research (discussed by Buonocore and Rose 1990) but
our interest was that a soluble version of a protein that was normally membrane
bound had apparently been specifically retained in the ER by the attachment of
retention signals.
4.2 Construction of vectors enabling the expression of a truncated
Kex2p with different C-termini in veast
The full length KEX2 gene including promoter regions was obtained as a Bam Hl/Sph I
fragment (fig. 4.1) cloned into YEp13 (This plasmid, pGA714 was supplied by Dr. G
Ammerer). The first step in the construction was to clone an Eco Rl/Pvu II fragment
from pGA714 (fig. 4.1) into pK19. The Eco Rl/Pvu II fragment (kex2") codes for a
truncated Kex2 polypeptide (Kex2'p) (fig. 4.1) and was cloned into pK19 (fig. 4.2).
The resulting plasmid was called pKkex' (fig. 4.2).
Oligonucleotides were designed (fig. 4.3) that would place the amino acid sequences
HDEL and KDEL in frame at the extreme C-terminus of Kex2'p. HDEL has been shown
to localise proteins to the ER in yeast when placed at the extreme C-terminus and
KDEL does the same in animal cells. The KDEL signal is not thought to be an efficient
signal for localising proteins to the ER in yeast. The oligonucleotides were designed
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Fig. 4.1 The KEX2 aene the kex2' aene and the polypeptides that thev
encode
(A) The diagram shows the Sphl (S)/BamHI (B) fragment from pGA714, the other
sites shown are Eco Rl (E), Hind ill (H), Pvu II (P) and Bgl II (Bg). The fragment is
approximately 5 kb and encodes a polypeptide (Kex2p) 814 amino acids in length.
Features of the deduced amino acid sequence are:- (1) A signal sequence. (2) A
domain of homology to subtilisin that is thought to be the catalytic site. (3) A
Ser/Thr rich domain thought to be an area of extensive O-linked glycosylation. (4) A
transmembrane domain.
(B) The diagram shows the Eco Rl/Pvu II fragment of pGA714. This fragment
contains all of the promoter regions needed for the expression of Kex2p in yeast but
only encodes a truncated Kex2p (Kex2'p) of 614 amino acids in length. The Kex2'p
still contains the predicted signal sequence and the domain of homology to subtilisin,




The truncated Kex2 polypeptide (Kex2'p)
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Fig. 4.2 Construction of the intermediate plasmid pKkex'
For this construction the source of Kex2p-coding DNA was pGA714. The Eco Rl/Pvu
II fragment from pGA714 was purified: this contains the promoter regions needed for
the expression of Kex2p in yeast and the coding sequence for the first 614 amino
acids of Kex2p. Plasmid pK19 was digested with Bam HI and the ends were made blunt
by filling in. This DNA was then digested with EcoRI. The Eco Rl/Pvu II fragment
from pGA714 was ligated with the Bam HI (filled in) Eco Rl digested pK19 and
transformed into NM522. The resulting plasmid was named pKkex". The Pvu II site
ligated to the Bam HI filled in site re-creates the BamHI site. Plasmid pKkex'
contains the coding sequence for a truncated Kex2p along with the promoter regions
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Fia. 4.3 Attachment of the C-terminal tetrapeptides HDEL and KDEL
onto Kex2'p
Attachment of the HDEL and KDEL sequences to the C-terminus of Kex2'p was
achieved by cloning oligonucleotides into plasmid pKkex'. The HDEL and KDEL
oligonucleotides were designed to have Bam HI and Sph I compatible ends. Plasmid
pKkex' was digested with Bam HI and Sph I, ligated with the HDEL or KDEL
oligonucleotide and then transformed into NM522. Cloning of the oligonucleotides into
the Bam Hl/Sph I sites of pKkex' re-creates Bam HI and Sph I sites and removes a
Sal I site (the Sal I site is in the pK19 polylinker between the Bam HI and Sph I
sites: this region of the polylinker is removed when the vector is digested with Bam
HI and Sph I). Recombinant plasmids were screened for (by restriction digest
analysis) that had lost the Sal I site. The resulting plasmids pKKH and pKKK contain
the HDEL and KDEL coding sequences in frame with the Kex2p coding sequence. Thus
plasmid pKKH and pKKK encode Kex2" polypeptides with HDEL and KDEL
(Kex2'-HDEL and Kex2'-KDEL) at their extreme C-termini.
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with a Bam HI compatable end and an Sph I compatable end so that they could be
cloned into the Bam HI, Sph I sites of pKkex' to create pKKH or pKKK (fig. 4.3),. The
constructs pKKH and pKKK were confirmed to be correct by DNA sequencing (see
materials and methods) of suitable fragments from these plasmids cloned into
M13mp18 (fig. 4.4).
At this stage oligonucleotides coding for the HDEL and KDEL tetrapeptides had been
cloned in frame with the coding sequence for Kex2'p at its C-terminus. However the
plasmids pKKH and pKKK cannot be used to express the Kex2' polypeptides with the
different C-teminal sequences in yeast. Therefore it was necessary to move the kex2'
genes possessing the HDEL and KDEL coding oligonucleotides into vectors that could be
transformed into yeast. The Eco Rl/Sph I fragments from pKKH and pKKK contain the
Kex2 promoter region, the coding region for the first 614 amino acids of Kex2p and
the oligonucleotides coding for HDEL or KDEL respectively. The Eco Rl/Sph I
fragments from pKKH and pKKK were cloned into the Eco Rl, Sph I sites of two
different plasmids YEplac112 and YCplac22 (fig. 4.5) (Gietz and Sugino 1988).
Both YEplac112 and YCplac22 are useful shuttle vectors as they contain the pUCl9
polylinker in which all the restriction sites can be used because any duplicate sites
in the vectors have been mutated out. Both vectors possess the ampicillin resistance
gene as a selective marker in E.coli. The screening for foreign DNA cloned into
YEplac112 and YCplac22 polylinkers is made easier as the blue/white colour test on
X-Gal plates can be used. YEplac112 is an episomal plasmid (multicopy in yeast)
and possesses the TRP1 gene as a selectable marker in yeast. YCplac22 is a
centromere plasmid (essentially single copy in yeast) and also possesses the TRP1
gene as a selectable marker.
The plasmids resulting from the cloning of the Eco Rl/Sph I fragments from pKKH
and pKKK into YEplac112 were called YEpKH and YEpKK respectively (fig. 4.5). The
plasmids resulting from the cloning of the Eco Rl/Sph I fragments from pKKH and
pKKK into YCp Iac22 were called YCpKH and YCpKK respectively (fig. 4.5). It was
also decided to construct vectors from which Kex2'p with no specific C-terminal
retention signals could be expressed in yeast. These vectors were constructed by
cloning a stop oligonucleotide into the Bam HI sites of YEpKH and YCpKH to create
plasmids called YEpKS and YCpKS respectively (fig. 4.6).
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Fig. 4.4 DNA sequence analysis of the Kex2'-HDEL and Kex2'-KDEL
constructs
To check whether plasmids pKKH and pKKK were the correct constructs it was
decided to partially sequence the constructs in order to see if the HDEL and KDEL
oligonucleotides had been cloned into pKkex' correctly. The Bgl ll/Hind III fragments
from pKKH and pKKK were cloned into the Bam Hi/Hind III sites of M13mp18 (Bgl II
creates ends compatible with Bam HI). These M13 recombinants were sequenced as
descibed in Materials and Methods. The sequences (A) and (B) confirm that the
correct oligonucleotides have been cloned in at the correct position. Thus pKKK and




















Fig. 4.5 Construction of vectors for the expression of the Kex2'-HDEL
and Kex2'-KDEL polypeptides in veast
Plasmids pKKH and pKKK were the sources of DNA encoding for Kex2'-HDEL and
Kex2'-KDEL respectively. The Eco Ri/Sph I fragments from pKKH or pKKK were
ligated with EcoRI/Sphl digested YCplac22 or Eco Rl/Bam HI digested YEplac112 and
transformed into NM522. Recombinant plasmids were screened for by a blue/white
colour test on X-Gal plates. The resulting plasmids were called YCpKH, YCpKK,
YEpKH and YEpKK respectively. YCpKH and YEpKH contain the promoter region of
Kex2 and when transformed into yeast should express the Kex2'-HDEL polypeptide.
YCpKK and YEpKK contain the promoter region of Kex2 and when transformed into
yeast should express the Kex2'-KDEL polypeptide. Plasmids YCpKH and YCpKK can be
transformed into yeast and should be present in a single copy per cell. Plasmids
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Fig. 4.6 Construction of vectors for the expression of Kex2'-S in veast
To construct plasmids for the expression of a Kex2'p (Kex2'-S) with no additional
amino acids at the C-terminus an oligonucleotide was designed that could be cloned
into the Bam HI site of YCpKH and YEpKH. The oligonucleotide has stop codons in all
three of its reading frames but in the case of this cloning the first stop codon is in
frame with the Kex2 reading frame. The oligonucleotide also has a Nhe I restriction
site in it which makes screening for insertion of the oligonucleotide possible by
restriction analysis. Plasmid YCpKH or YEpKH were digested with Bam HI, ligated
with the stop oligonucleotide and then transformed into NM522. Recombinant
plasmids were screened for by restriction analysis for the introduction of an extra
Nhe I site. The resulting plasmids were called YCpKS and YEpKS respectively.
Plasmid YCpKS and YEpKS encode Kex2'-S that has no additional amino acids at the
C-terminus along with the Kex2 promoter regions needed for its expression in yeast.
Plasmid YCpKS and YEpKS can be transformed into yeast and should be present in a








































Table 4.1 Plasmid constructs for the expression of truncated Kex2






YCpKH (single copy in yeast) PGSHDEL* Kex2'-HDEL
YCpKK (single copy in yeast) .PGSKDEL* Kex2'-KDEL
YCpKS (single copy in yeast) PGS* Kex2'-S
YEpKH (multi-copy in yeast) PGSHDEL* Kex2'-HDEL
YEpKK (multi-copy in yeast) PGSKDEL* Kex2'-KDEL
YEpKS (multi-copy in yeast) PGS* Kex2'-S
The truncated Kex2 polypeptides with the different C-termini, expressed from
the different plasmids will be referred to in future chapters by the nomenclature
shown in this table.
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4.3 Summary
In this chapter I have described the construction of six vectors (see table 4.1) that
can be used to express truncated Kex2 polypeptides with the different C-termini in
yeast. Experiments to look at the retention of the different constructs, their
localisation in the cell and their effect on the processing and secretion of secretory
proteins in yeast will be described in following chapters.
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Chapter five.
In vitro and in vivo assays for Kex2 activity in strains
of yeast expressing the truncated Kex2 polypeptides
possessing the different ER retention signals.
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5.0 Introduction
In the previous chapter the construction of vectors for the expression in yeast of
truncated Kex2p's with different C-termini in was described. In this chapter I will
describe in vivo and in vitro methods for comparing the properties of the different
constructs with respect to their ability to be retained within the cell and their
ability to process proteins in yeast. All of the yeast plasmids (episomal and
centromere) containing the various Kex2 constructs carried the TRP1 gene as a
selective marker. It was therefore necessary to transform these plasmids into a
strain of yeast lacking a functional TRP1 gene. Also the strain of yeast to be
transformed had to lack a functional KEX2 gene in order that the properties of the
truncated Kex2p's could be assessed without interference from the native KEX2 gene.
5.1 The disruption of the functional KEX2 aene in Saccharomvces
cerevisiae strain JRY188.
JRY188 is a strain of yeast regularly used in our laboratory (For genotype see
strain list table 2.1). The KEX2 gene of JRY188 was disrupted by a gene replacement
method in which the chromosomal KEX2 gene was replaced by a gene that could easily
be selected for (in this case the LEU2 or URA3 genes). The plasmids pGA1070 and
pGA1320 (supplied by Dr Gustav Ammerer) were digested with BamHI and Sphl, and
fragments of DNA containing the majority of the KEX2 gene replaced with the LEU2
(kex2::LEU2) or URA3 (kex2::URA3) genes respectively were purified (figs 5.1 and
5.2). The fragments still contained the flanking regions of the KEX2 gene and some of
the C-terminal coding sequences of the KEX2 gene. These purified fragments were
introduced into JRY188 by transformation with selection for Leu+ (when
transformed with kex2::LEU2) or Ura+ (when transformed with kex2::URA3)
transformants (untransformed JRY188 is Leu",Ura"). Such Leu+ or Ura+
transformants are expected to have the chromosomal copy of KEX2 replaced with the
kex2::LEU2 or kex2::URA3 gene disruptions respec tively, by homologous
recombination of the flanking regions (fig. 5.1 and 5.2). Transformants were
checked for the replacement of the KEX2 gene with the disrupted KEX2 genes by
Southern analysis of the chromosomal DNA of the transformants (fig. 5.3). The
Southern confirmed replacement of the KEX2 gene with the disrupted KEX2 genes.
The resulting strains were named PWYS2 (JRY188 kex2::LEU2) and PWYS3
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Fig5.1 Replacement of the chromosomal copy of KEX2 in JRY188 with
a non functional disrupted KEX2 aene (kex2::LEU2T
The Bam Hl/Sph I fragment of pGA1070 (supplied by Dr. G. Ammerer) has most of
the KEX2 gene replaced with the LEU2 gene (kex2::LEU2), but the flanking regions
are intact. Yeast strain JRY188 was transformed with the kex2::LEU2 disruption
from pGA1070 with selection for Leu+transformants. Homologous recombination of
the regions flanking the kex2::LEU2 disruption in the Bam Hl/Sph I fragment and the
regions flanking the chromosomal copy of the KEX2 gene results in the replacement
of the chromosomal copy of the KEX2 gene with the kex2::LEU2 disruption. The
resulting strain PWYS2 does not contain a functional KEX2 gene. The restriction



























Fig 5.2 Replacement of the chromosomal copy of KEX2 in JRY188 with
a non functional disrupted KEX2 gene (kex2::URA3).
The Bam Hl/Sph I fragment of pGA1320 (supplied by Dr. G. Ammerer) has most of
the KEX2 gene replaced with the URA3 gene (kex2::URA3), but the flanking regions
are intact. Yeast strain JRY188 was transformed with the kex2::URA3 disruption
from pGA1070 with selection for Ura+ transformants. Homologous recombination of
the regions flanking the kex2::URA3 disruption in the Bam Hl/Sph I fragment and the
regions flanking the chromosomal copy of the KEX2 gene results in the replacement
of the chromosomal copy of the KEX2 gene with the kex2::URA3 disruption. The
resulting strain PWYS3 does not contain a functional KEX2 gene. The restriction
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Fig. 5.3 Southern analysis of JRY188 and JRY188 transformants.
Total DNA from JRY166 and JRY188 transformed with the kex2::LEU2 or
kex2::URA3 disruption fragments were digested with Eco Rl and electrophoresed on a
0.8. agarose gel. The DNA was blotted onto nitrocellulose. Southern analysis was
performed using a radiolabeled DNA probe. The DNA fragment used as the probe is
shown in the figure and consists of a 3.6 kb Eco Rl fragment of the KEX2 gene
(purified from plasmid pGA714, supplied by Dr. G Ammerer). The lanes of the
autoradiograph are as follows:-
1. JRY188
2. JRY188 transformed with kex2::LEU2 disruption fragment (n°1).
3. JRY188 transformed with kex2::LEU2 disruption fragment (n°2).
4. JRY188 transformed with kex2::LEU2 disruption fragment (n°3).
5. JRY188 transformed with kex2::LEU2 disruption fragment (n°4).
6. JRY188 transformed with kex2::URA3 disruption fragment (n°1).
7. JRY188 transformed with kex2::URA3 disruption fragment (n°2).
8. JRY188 transformed with kex2::URA3 disruption fragment (n°3).
The 3.6 kb band on the autoradiograph is indicative of the KEX2 gene. The 2.8 kb and
2.6 kb bands are indicative of the kex2::LEU2 disruption fragment being present
(when kex2::LEU2 is digested with Eco Rl, two fragments of 2.8 kb and 2.6 kb are
released; Both of them are recognised by the KEX2 probe). The 3.7 kb band is
indicative of the kex2::URA3 disruption fragment being present.
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(JRY188 kex2::URA3). PWYS3 was the strain which was to be transformed with the
following plasmids:- YCpKH, YCpKK, YCpKS, YEpKH, YEpKK and YEpKS. These
plasmids were introduced into PWYS3 with selection for Trp+ transformants.
5.2 Assay for Kex2 activity in vitro
The enzymic activity of Kex2p can be assayed directly by measuring the amount of a
fluorescent molecule (AMC) released as a result of cleavage of a synthetic peptide
(bQRR-MCA) at the C-teminal side of the pair of basic amino acids (see Materials
and Methods). It was decided to look at the intracellular and extracellular Kex2
activities in the different transformed yeast strains to determine whether the
different C-termini on the truncated Kex2p's had any effect on their retention within
the cell. If there is specific retention within the cell due to the different C-termini,
comparison of the relative amounts of intracellular and extracellular activity in the
different strains should give an indication of this.
The yeast strains to be assayed for intracellular and extracellular Kex2 activities
were grown in their respective selective media for 16 hours. The optical densities
of the different cutures were measured at 600nm. The cells were harvested and the
supernatants were kept for the assay of extracellular Kex2 activities. The cells that
had been harvested were washed and the cells were permeabilised by treatment with
Brij 58 (see Materials and Methods). These Brij-permeabilised cells were the
source of intracellular Kex2p for the different strains. The assays for Kex2 activity
were carried out on 5pl samples of each of the Brij-permeabilised cells and 5^1
samples of the supernatants to give a measure of the relative amounts of
intracellular and extracellular Kex2 activities in the different strains. The results
were corrected for cell density as the different strains had grown to different
densities when grown in their respective selective medias for 16 hours. The results
of the assays are represented in Table 5.1 and fig. 5.4.
The results of the direct assay for intracellular and extracellular Kex2 activity in
the different strains of yeast show a number of interesting features. As expected
there is hardly any detectable Kex2 activity in PWYS3. The small amount of
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Table 5.1 The intracellular and extracellular Kex2 activities of veast
strains expressing the different Kex2' polypeptides




PWYS3 7.2 x 10* (-) o (-)
PWYS3 (YCpKH) 1.3 x 10* (1.6 x 10* ) o (-)
PWYS3 (YCpKK) 6.7 x 103 (2.2 x 103 ) 5.1 x 103 (4.3 x 10X )
PWYS3 (YCpKS) 2.5 x 103 (7.0 x 10*") 3.0 x 103 (3.4 x 10X)
PWYS3 (YEpKH) 4.0 x 10* (2.1 x 103) 5.8 x 10* (4.6 x 10x)
PWYS3 (YEpKK) 4.7 x 10* (2.5 x 103) 5.2 x 10* (3.2 x 103 )
PWYS3 (YEpKS) 1.8 x 10* (3.6 x 103) 7.7 x 103 (5.2 x lO2")
The Kex2 activities are in picomoles of AMC released from bQRR-MCA per minute,
per OD unit of cells. The results are an average of three separate Kex2 assays carried
out in standard conditions (see Materials and Methods), and the standard deviations from
the mean are shown in brackets. Intracellular Kex2 activities were obtained by assaying
Brij-permabilised cells (see Materials and Methods) of cells from each strain. Extracellular
activities were obtained by assaying the supernatants of each strain grown in selective media.
104
Fig 5.4. A graph showing the intracellular and extracellular Kex2
activities of veast strains expessina the different Kex2' polveptides
(JUL
The in vitro intracellular and extracellular Kex2 activities (shown in Table 5.1) for
the strains expressing the different Kex2' polypeptides are plotted. The Kex2
activities are in picomoles of AMC released from the synthetic peptide bQRR-MCA
per minute, per OD unit of cells (pmol of AMC/min/OD unit).
There is some variability in the activities of individual strains in separate
















































intracellular activity detected may be due to other proteases in the cell cleaving the
synthetic peptide non-specifically. In general the overall Kex2 activities in strains
bearing the episomal plasmids is higher than those bearing the centromere plasmids
which is consistent with the episomal plasmids being present in higher number of
copies per cell than the centromere plasmids, which are single copy per cell. The
strains bearing the centromere plasmids expressing the different Kex2'p's show
some interesting differences. The strain expressing the Kex2'-HDEL has the highest
internal Kex2 activity but there is no detectable external Kex2 activity. The strain
expressing Kex2'-KDEL contains the next highest level of intracellular Kex2
activity but it also appears to secrete Kex2p as there is extracellular Kex2 activity
detectable in the medium. The strain expressing the Kex2'-S has the least amount of
intracellular Kex2 activity but also the least amount of total Kex2 activity. These
results suggest that the HDEL sequence at the C-terminus is preventing the Kex2p
from being secreted as all of the detectable Kex2 activity is intracellular. The KDEL
sequence may have some ability to prevent secretion of Kex2p from the cell as there
is more intracellular Kex2 activity than when the stop codon is at the C-terminus of
Kex2'p which should not have any specific retension sequences in it. The reason for
the different total Kex2 activities (ie the sum of intracellular and extracellular
activities) in the different strains is difficult to explain as all the strains should
express Kex2' polypeptides at the same level even though the amounts retained may
be different. We have assumed that the addition of different C-temini will not affect
the specific activity of the truncated polypeptides, although this assumption has not
been tested. If the assumption is not correct the different total activities could be due
to differing catalytic activities of the different Kex2' constructs. Another possibility
is that the different Kex2' constructs are differentially degraded or denatured either
intracellular^ or extracellularly.
As has been mentioned already the cells harbouring the episomal plasmids all have
relatively high levels of intracellular and extracellular Kex2 activities in
comparison to the centromere plasmid bearing strains. Even the strain expressing
Kex2'-HDEL has a high level of extracellular Kex2 activity suggesting that
Kex2'-HDEL is not efficiently retained within the cell. As with the centromere
plasmids the strain expressing Kex2'-S has the lowest total Kex2 activity which is
again difficult to explain. A reason for the high extracellular Kex2 activity in all of
the strains including the strain expressing Kex2'-HDEL could possibly be that the
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retention system is being saturated, which has been shown to be possible in yeast
(Pelham et al 1988, Dean and Peiham 1990). However, as wild type Kex2p is very
inabundant in yeast when expressed from its own promoter (Fuller et al 1989) and
all of the Kex2' polypeptides are expressed from this same promoter we would not
expect the levels of the Kex2' polypeptides being produced, even from multicopy
plasmids to be enough to saturate a retention system that can supposedly retain
abundant proteins such as BiP and PDI in yeast. Another explanation could be that the
sequences attached to the C-termini of the different Kex2' polypeptides are not
efficiently recognised by the retention system because of the way in which the
proteins are folded. This does not explain why the Kex2'-HDEL is apparently
efficiently retained in the cell when expressed at lower levels in cells containing the
centromere plasmids.
5.3 Assay for Kex2 activity in vivo
The Kex2' polypeptides with the different C-termini all appear to be active, as they
cleave the synthetic peptide bQRR-MCA in the in vitro assay for Kex2 activity. It
still remained to be seen however, whether these Kex2' polypeptides could process
proteins in vivo and if so, what might be the effect the different C-termini upon this
processing. It was decided to look initially at the processing of the yeast mating
pheromone a factor in strains expressing the different Kex2' polypeptides. The way
in which a factor is normally processed and the involvement of wild type Kex2p in
this processing is described in the Introduction. We wanted to determine how
efficiently strains transformed with the plasmids for expression of the Kex2'
polypeptides processed and secreted a factor, and if the C-terminal sequences
affected this efficiency.
5.4 The assay for secreted a factor
It is possible to detect the presence of mature a factor secreted from a strain of yeast
using a bioassay which relies on the inhibition of growth of a pheromone-sensitive
strain of yeast. The sensitive strain of yeast used for all of the a factor bioassays in
this thesis was yeast strain RC631 which is an sst2 mutant (super sensitive to a
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factor; Chan and Otte 1982). It was decided initially to look at the levels of secretion
of mature a factor from strains of yeast expressing the different Kex2' constructs
from centromere plasmids as these plasmids are present and in single copies per
cell. Thus the level of expression should be > the same as the level of expression of
the full length Kex2p expressed from the chromosomal KEX2 gene in wild type cells.
A halo assay (see Materials and Methods) was initially used to detect the presence of
a factor secreted from different strains of yeast (fig. 5.5).
The results of the halo assay show that the halo of inhibition of growth of RC631 is
largest around JRY188 which suggests that it secretes the most active a factor. This
was expected as JRY188 expresses the full length Kex2p which should process a
factor efficiently. The halo of inhibition of growth of RC631 around PWYS3 is the
smallest, also as expected as this strain does not express a functional Kex2p. The
reason for the slight halo around PWYS3 will be discussed later in the chapter. The
halos around the strains expressing the different Kex2' polypeptides from the
centromere plasmids are all larger than the halo around PWYS3 but smaller than the
halo around JRY188. This suggests that these strains do process pre-pro a factor
and mature a factor is secreted but the processing is not as efficient as by the wild
type Kex2p. The halo around PWYS3 (YCpKH) is slightly larger than around PWYS3
(YCpKK) and PWYS3 (YCpKS). This could possibly be because the HDEL C-terminus
on the Kex2'p expressed in this strain allows retention of more Kex2'-HDEL in the
cell and thus there is more a factor processed due to a greater amount of
intracellular processing enzyme. We know from the in vitro Kex2 assays that
PWYS3 (YCpKK) and PWYS3 (YCpKS) secrete Kex2 polypeptides. Thus some of the
processing enzyme in these strains (that which is secreted) may not contribute to
the processing of a factor or may only have a reduced contribution during the time it
is in transit through the secretory pathway. The differences in the sizes of the halos
around the three strains transformed with the centromere plasmids, however is only
slight and may not be due to the influence of the different C-termini on the Kex2'
constructs. These halo assays are essentially qualitative and a more sensitive assay
that can be readily quantified was required to look at the effects that the different
C-termini on the Kex2' polypeptides had on the processing of a factor.
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Fia. 5.5 Halo assay for secreted a factor
The figure shows the inhibition of growth of RC631 cells (sensitive to a factor) by
different strains patched onto the lawn. The halo assay was performed as described in








5.5 Microtitre assays for secreted « factor
In order to look at the effects of the different Kex2' polypeptides on the processing of
a factor it was decided to use an assay similar to that described for the
Kluyveromyces lactis killer toxin. This assay still relied on the inhibition of growth
of RC631, but the inhibition of growth was to be measured by the density that the
sensitive cells grew to in media containing a factor (or not, as the case may be) in
microtitre assay plates. The greater the concentration of a factor in the media the
lower the density to which the sensitive cells would grow.
The strains of yeast to be assayed for a factor secretion were grown in their
respective selective media at 26°C until they reached stationary phase of growth.
Cells from each of the cultures were pelleted by centrifugation at low speed, washed
in YPD, pelleted again and resuspended in fresh YPD to a density of approximately
107 cells per ml. The cells were grown in YPD for 4 hrs and a sample of cells was
taken every hour from the cultures. The cells from the samples taken each hour were
immediately removed by centrifugation at high speed in a microfuge for 5 mins. The
supernatants were removed, taking care not to disturb the cell pellet and transferred
to a clean eppendorf tube. The supernatarits from each of the strains taken at the
different times were used in the assay for a factor (see Materials and Methods).
The results of the a factor assays are shown in Table 5.2. The results are expressed
as growth percentage relative to an untreated control (ie YPD). Thus a result of
100% indicates no inhibition of growth of RC631 due to no detectable a factor in the
media. Lower percentages indicate larger inhibitions of growth due to greater
concentrations of a factor being present in the supernatants assayed.
The results show that JRY188 secretes the most a factor, as it inhibits the growth
of RC631 to the greatest extent. After only 1 hr enough a factor has been secreted to
inhibit the growth of RC631 to 20% of that of the control value. Supernatants from
strain PWYS3 showed the lowest inhibition effect, as expected as this strain lacks a
functional Kex2p, although there does nevertheless appear to be a slight inhibition of
growth. After 4 hrs strain PWYS3 (YCpKH) appears to have secreted a greater
1 1 2
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amount of a factor than PWYS3 (YCpKK). Also after 4 hrs PWYS3 (YCpKK) appears
to have secreted more a factor than PWYS3 (YCpKS). Thus it appears that
Kex2'-HDEL is more efficient at processing pre-pro a factor than Kex2'-KDEL and
Kex2'-S. This is consistent with the presence of a greater amount of intracellular
Kex2* polypeptide in strains expressing Kex2'-HDEL in comparison to the other
strains expressing Kex2'-KDEL and Kex2'-S, and may reflect the specific retention
of Kex2'-HDEL. In general the strains bearing the episomal plasmids secrete more a
factor than those bearing the centromere plasmids. This suggests that the centromere
plasmid bearing strains are not processing pre-pro a factor as efficiently as
JRY188 or the episomal plasmid bearing strains.
The results obtained from the strains expressing the various Kex2' polypeptides
from the episomal plasmids are very different from those of the centromere
plasmids. Strain PWYS3 (YEpKH) appears to secrete less a factor than strains
PWYS3 (YEpKK) or PWYS3 (YEpKS). This is the opposite from what was found in
strains expressing the same polypeptide from the centromere plasmids. A possible
explanation for the results obtained from episomal plasmid bearing strains is that
the copy number of the plasmids per cell is variable between PWYS3 (YEpKH),
PWYS3(YCpKK) and PWYS3 (YEpKS). This sort of copy number difference could
possibly occur if the Kex2' polypeptide expressed from one of the plasmids were
deleterious to the cell. In this case the Kex2'-HDEL may be deleterious to the cell if
expressed at high levels, and thus the copy number of YEpKH may drop to help
overcome this effect. Because of the possible copy number effects in strains
transformed with the episomal plasmids it was decided to repeat the experiment with
the centromere plasmid bearing strains only. Samples in the repeated experiment
were taken at 1,2,4,6 and 8 hrs. The results of the a factor assays are shown in
Table 5.3. Again the results are expressed as a percentage of a control in which no a
factor is present. As with the previous assays PWYS3 (YCpKH) secretes more a
factor than PWYS3 (YCpKK) which in turn secretes more a factor than PWYS3
(YCpKS).
A possible problem with these assays is that the Kex2 processing of pre-pro a factor
is occuring extracellularly. This would not be a problem if it were not for the final
1 1 4

































ThegrowthoftsensitiveRC631cellsi acft ealp afactorsaysllsupern tants representedape centageofthd nsityatRC631growswh noalphaf rip t
inthemedia.Thresultsarenaver geoft r es paratea s ysdsta d rdde i tionfrom themeanaregiveinbr ck ts.
copy of the a factor pheromone in the precursor polypeptides. Cleavage by Kex2p of
all but the last copy of a factor in the precusor polypeptides results in the release of
Glu/Asp-Ala-Glu-Ala-a factor-Lys-Arg (see fig. 1.2). The Lys-Arg sequence at the
C-terminus renders this immature a factor polypeptide at least 100-fold less active
at inhibiting the growth of an sst2 mutant (Dmochowska et al 1987). However the
last copy of a factor (Glu-Ala-Glu-Ala-a-factor) cleaved from the precursor
polypeptide does not have Lys-Arg at the C-terminus, and is active (although not to
the same extent as fully mature a factor) at inhibiting the growth of an sst2 mutant
(Julius efa/ 1983). Thus if cleavage of pre-pro a factor by Kex2p were to occur
extracellularly, active Glu-Ala-Glu-Ala-a factor that inhibits the growth of the
sst2 mutant to some extent would be released from the precursor. Only the last copy
of a factor in the precursor would cause this problem as all the other copies of a
factor cleaved extracellularly would have Lys-Arg at the C-terminus rendering them
essentially inactive. For all other copies of a factor apart from the final copy,
cleavage by Kex2p has to occur before the removal of the Lys-Arg residues by Kexlp
in order for them to mature into active a factor. As the Kex1 cleavage is
intracellular, the Kex2 cleavage must also be intracellular in order for the copies of
a factor other than the final copy to be able to mature into an active form.
We wanted to determine the level of processing of the a factor precursor that was
taking place intracellular^. To be sure that the a factor active in inhibiting the
growth of the sst2 mutant had been processed intracellular^ and not extracellularly
by secreted Kex2p we made use of a plasmid called pJK6-4 (Dmochowska et al
1987). Plasmid pJK6-4 is a centromere plasmid that contains an altered MFa1 gene
under the control of the GAL1 promoter. This altered MFa1 gene essentially has the
last copy of the a factor mating pheromone destroyed. Therefore only the first three
copies of a factor can possibly be processed to give mature a factor capable of
inhibiting the growth of RC631. Thus in order to get active a factor from the
precursor encoded for in pJK6-4, cleavage by Kex2p must be intracellular before
the removal of the C-terminal Lys-Arg residues by Kexlp. As this altered MFa1 is
under control of the GAL1 promoter, expression of the altered a factor precursor
1 1 6
only occurs in yeast cells transformed with pJK6-4 when grown on galactose media.
In order to ensure that expression from the chromosomal copies of MFa1 and MFa2
did interfere with the results not use was made of the fact that JRY188 is a sir3
mutant (Brake et al 1984); thus when grown at 37°C, MFa1 and MFa2 are not
expressed, so that JRY188 and strains derived from JRY188 transformed with
pJK6-4 and grown at 37°C on galactose medium will only express the altered MFa1
gene from the GAL1 promoter. Expression from the chromosomal a factor genes will
be switched off. When the pJK6-4 transformed strains of yeast were grown on
glucose media at 37°C no detectable a factor was secreted from any of the strains
(data not shown).
The pJK6-4 transformed strains were grown in their appropriate selective media
with galactose as the sole carbon source at 37°C. The cells were harvested, washed in
YPG and resuspended in YPG to a final density of approximately 107 cells per ml. The
cells were incubated at 37°C in this medium for 14 hrs and then harvested. The
supernatants were removed and different dilutions of the supernatants (diluted with
YPG) from each of the strains were used to assay for a factor using the microtitre
assay. The results of the assay are shown in Table 5.4 and fig 5.6.
JRY188 (pJK6-4) appears to secrete the most active a factor as shown by the
greatest inhibition of growth of RC631. This is consistent with the results of the
previous a factor assays. The strain PWYS2 (pJK6-4) appears to secrete the least a
factor which is also consistent with the previous a factor assays. The strains PWYS2
(YCpKH, pJK6-4) and PWYS2 (YCpKK pJK6-4) secrete similar amounts of active a
factor, but more than PWYS2 (YCpKS pJK6-4). The lower amount of a factor
secreted from the YCpKS harbouring strain is consistent with previous results but
in previous assays the YCpKH harbouring strain has always secreted more a factor
than the YCpKK harbouring strains. These results suggest that the Kex2* polypeptides
with the different C-termini can all process a factor intracellular^ to different
extents.
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Fig. 5.6 A graph to show the growth inhibition of RC631 exposed to
culture supernatants of different strains of veast (IT
The results of microtitre assays for a factor in the culture supernatants of different
strains of yeast, processed from the pJK6-4 encoded precursor (shown in Table
5.4) are plotted. The dilution of culture supernatant (culture supernatant/diluent)
from the different strains is plotted against the growth of RC631 (the a factor
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The results of the in vitro and in vivo assays for Kex2 activity show some
interesting trends especially when the different truncated Kex2p's are expressed
from the centromere plasmids. The apparently efficiently retained Kex2'-HDEL
polypeptide processes pre-pro a factor to a greater extent than the secreted Kex2'-S
polypeptide. The Kex2'-KDEL polypeptide although not as efficiently retained within
the cell as Kex2'-HDEL does appear to be retained to a greater extent than Kex2'-S;
this could possibly be due to weak recognition of the KDEL signal by the yeast
retention system. It has been reported (Lewis et al 1990) that the S. cerevisiae
ERD2 gene product (the putative HDEL receptor) weakly recognises the KDEL
sequence, therefore it is not suprising that we see some apparent retention of
Kex2'-KDEL in yeast. Another observation was that in the Kex2" mutants there was
still a very low level of Kex2 activity, both in the in vitro assays and the in vivo
assays. This "background" activity could possibly be due to non-specific proteases or
alternatively due to an aspartyl protease that reportedly allows the KEX2
independent processing of pre-pro a factor in yeast (Egel-Mitani et al 1990). In
either case the "background" activity is very low in the in vitro and in vivo assays
and does not affect our interpretation of the effect of the different Kex2' constructs.
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Chapter six.
Construction of plasm ids for the expression of a
Kex2-Protein disulphide isomerase fusion protein in




In the previous chapter the addition of the tetrapeptide HDEL at the C-terminus of
Kex2'p appears to have some effect on the efficiency of retention within the cell of
Kex2' polypeptides when compared with the other C-termini. However, the HDEL
signal does not result in full retention of Kex2' polypeptides as Kex2'-HDEL is
secreted when expressed from an episomal plasmid. One possible explanation for this
would be saturation of the retention system when Kex2'-HDEL is expressed from an
episomal plasmid. Alternatively it is possible that Kex2'-HDEL is not efficiently
recognised by the retention system because the HDEL signal is buried in the
structure of the polypeptide. It has been reported that the yeast retention system is
quite leaky and easily saturable in comparison to the mammalian retention system
(Pelham efa/ 1988, Dean and Pelham 1990). It has also been reported that the
C-terminal HDEL signal may not be recognised by its putative receptor in at least
some protein constructs due to masking of the C-terminus (Pelham et al 1988). If
the retention system is easily saturable it is difficult to explain how abundant
HDEL-containing proteins such as BiP and PDI are not normally secreted from the
cell if the HDEL recognition system is the only method of retention. It is important to
note that the levels of expression of the Kex2' polypeptides with the different
C-termini are expected to be low, even in cells transformed with the episomal
plasmids, since the Kex2 promoter is a weak promoter; we would not therefore
expect to saturate a retention system that can reportedly retain abundant proteins
such as BiP and PDI in the cell with the comparatively low levels of Kex2'-HDEL
expected to be expressed in PWYS3 (YEpKH). It therefore seems most likely that the
secretion of Kex2'-HDEL from PWYS3 (YEpKH) results not from saturation of the
retention system but rather from inefficient recognition of the HDEL signal by its
putative receptor because of masking.
6.1 Attachment of the PDI C-terminus to a Kex2' polypeptide.
Because of this possibility that the HDEL signal on Kex2'-HDEL was not being
recognised efficiently due to masking, I decided to attach a C-terminal domain derived
from a protein known to be efficiently retained in the ER to Kex2\ Specifically I
decided to attach the C-terminus of PDI to make a Kex2'-PDI fusion protein with the
HDEL sequence of PDI at the extreme C-terminus of the hybrid protein. The yeast
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PDI gene and sequence were made available by Dr. M. Tuite and Dr. R. Freedman. The
PDI gene was supplied in a plasmid named pRF16. It was decided, because of
convenient restriction sites to attach a DNA fragment coding for the 60 C-terminal
amino acids of yeast PDI (fig. 6.1) to the truncated KEX2 gene in both centromere
and episomal plasmids (fig. 6.2). The resulting plasmids named YCpKP and YEpKP
respectively both encoded the same Kex2'-PDI fusion protein. The plasmids were
transformed into the strains PWYS2 and PWYS3.
6.2 Assays for Kex2 activity in vitro
The assays for Kex 2 activity were performed as in the previous chapter with the
additional strains of yeast PWYS3 (YCpKP) and PWYS3 (YEpKP) included. The
results of the assays are shown in Table 6.1 and fig. 6.3. These results show that as
before there is essentially no detectable Kex2 activity in PWYS3. The overall Kex2
activities in the strains bearing the episomal plasmids was again higher than those
bearing the centromere plasmids as expected. It is interesting to note that strain
PWYS3 (YCpKP) does not secrete any detectable Kex2'-PDI into the supernatant as
is the case with PWYS3 (YCpKH) not secreting any detectable Kex2'-HDEL into the
supernatant. There was, however detectable intracellular Kex2 activity in PWYS3
(YCpKP) suggesting that the Kex2'-PDI hybrid protein is active. These results
suggest that the Kex2'-PDI hybrid protein is retained within the cell when expressed
from a centromere plasmid. There was detectable Kex2 activity in the supematants
of PWYS3 (YCpKK) and PWYS3 (YCpKS) as had been observed previously which
suggests that the KDEL and stop sequences at the C-terminus of the truncated Kex2p
do. not have as great an effect as the HDEL and PDI sequences at retaining Kex2'
polypeptides in the cell.
The internal and external Kex2 activities of the strains transformed with the
episomal plasmids also show some interesting features. Strain PWYS3 (YEpKP) has
a much higher internal Kex2 activity than any of the other strains, but also the
lowest external Kex2 activity. Thus it seems that the addition of the 60 C-terminal
amino acids of PDI to the C-terminus of the Kex2' polypeptide increases the ability
of this protein to be retained within the cell. This could be because the addition of
these extra amino acids allows the HDEL sequence to be presented in such a way that
it is more efficiently recognised by the putative HDEL receptor than when these
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Fig. 6.1 The DNA fragment encoding the 60 C-terminal amino acids of
veast protein disulphide isomerase.
The diagram shows the Sau 3A fragment from plasmid pRF16 (obtained from Dr. M.
Tuite and Dr. R. Freedman) and the 60 C-terminal of yeast PDI that it encodes. This
fragment of DNA was used to create a gene fusion with the DNA encoding Kex2' that
codes for a Kex2'-PDI hybrid polypeptide (fig. 6.2).
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S a u 3 fl
RGR TCC TTG GRC TCT TTR TTC GRC TTC RTC RRG
RSLDSLFDF I K
Sa 11
GRR ARC GGT CRC TTC GRC GTC GRC GGT RRG GCC
ENGHF DUDGKfl
TTG TRC Gflfl GRR GCC CRG Gflfl RflR GCT GCT GRG
LVEERQEKRRE
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RTT CRC GRT Gflfl TTG TRR TTC CTG RTC
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Fig. 6.2 Construction of vectors for the expression of Kex2'-PDI in
yeast
Plasmids YcpKH and YEpKH were digested with Bam HI. The purified Sau 3A fragment
from plasmid pRF16 (see fig. 6.1) was ligated with the Bam HI digested YCpKH or
YEpKH and then transformed into E. coli strain NM522. Recombinant plasmids were
screened for by the introduction of a Sal I site into the vectors. Recombinant
plasmids then had to be checked to deduce in which orientation the Sau 3A fragment
had been cloned. The orientation was determined making use of the assymetric Sal I
site and also the fact that one of the Sau 3A sites when cloned into the Bam HI site
re-created a Bam HI site. In the correct orientation the PDI open reading frame is in
frame with the Kex2' open reading frame and thus a Kex2'-PDI hybrid protein is
encoded for. The resulting plasmids for the expression of Kex2'-PDI were called































Table 6.1 The intracellular and extracellular Kex2 activities of veast






JRY 188 5.5 x 103 (4.1 x 10X) 0 (-)
PWYS3 8.8 x 101 (3.5 x 10* ) 0 (-)
PWYS3 (YCpKH) 9.3 x 103 (1.7 x 10*) 0 (-)
PWYS3 (YCpKK) 5.4 x 10* (1.2 x 103) 1.5 x 103 (1.0 x 10X)
PWYS3 (YCpKS) 7.9 x 103 (1.1 x 103) 3.9 x 10* (1.8 x 101)
PWYS3 (YCpKP) 7.8 x 10* (6.7 x 10X) o (-)
PWYS3 (YEpKH) 1.8 x 10* (1.1 x 103) 7.9 x 10* (9.5 x -\0Z )
PWYS3 (YEpKK) 2.0 x 10* (1.2 x 103) 1.2 x 10S (1.7 x 10*)
PWYS3 (YEpKS) 1.2 x 10* (9.6 x 10X) 6.3 x 10* (8.0 x 103 )
PWYS3 (YEpKP) 4.8 x 10* (1.6 x 103) 5.2 x 10* (1.0 x 10*)
The Kex2 activities are in picomoles of AMC released from bQRR-MCA per minute,
per OD unit of cells. The results are an average of three separate Kex2 assays carried
out in standard conditions (see materials and methods), and the standard deviations from
the mean are shown in brackets. Intracellular Kex2 activities were obtained by assaying
Brij permeabilised cells(see materials and methods) of cells from each strain. Extracellular
activities were obtained by assaying the supernatants of each strain grown in selective media.
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Fig 6.3 A graph showing the intracellular and extracellular Kex2
activities of veast strains expessinq the different Kex2' polveptides
(ID-
The in vitro intracellular and extracellular Kex2 activities (shown in Table 6.1) for
the strains expressing the different Kex2' polypeptides are plotted. The Kex2
activities are in pico-moles of AMC released from the synthetic peptide bQRR-MCA















extra amino acids are not present. It is also possible that there is something
additional in the 60 C-terminal amino acids of PDI that increases the efficiency of
retension of the Kex2'-PDI hybrid protein over the other constructs. Although the
addition of the 60 C-terminal amino acids of PDI to the Kex2' polypeptide appears to
greatly increase the efficiency of retention, there is still Kex2 activity in the
supernatants of strains expressing this polypeptide from episomal plasmids. It
therefore appears that even for this Kex2'-PDI construct the retention system is not
100% efficient.
6.3 Assays for a factor.
The a factor assays were performed as in the previous chapter on the pJK6-4
transformed strains with the additional strain PWYS2 (YCpKP, pJK6-4) also being
assayed. The results of the microtitre assays for a factor are shown in Table 6.2. The
results of the a factor assays show that the strain PWYS2 (pJK6-4) secretes the
least a factor of the strains tested, as expected. The strains PWYS2
(YCpKH/YCpKK/YCpKS, pJK6-4) all show similar trends in a factor processing as
shown in the previous chapter. Suprisingly however, results documented in Table
6.2 show that PWYS2 (YCpKP, pJK6-4) appears to be the least efficient at
processing pre-pro a factor of the strains expressing the Kex2' polypeptides from
centromere plasmids. Therefore although the Kex2'-PDI hybrid protein is
apparently more efficiently retained within the cell than the other Kex2' constructs
it is not able to mature a factor as efficiently as the other constructs. There are a
number of possible explanations for this. Firstly it is possible thst the Kex2'-PDI
hybrid protein is able to cleave the synthetic peptide bQRR-MCA in the in vitro assay
but not process the a factor precursor efficiently in vivo ; if this hybrid protein is
efficiently localised to the ER it may not be able to process the a factor precursor
because of the intraorganellar environment in the ER (processing by Kex2p in wild
type cells occurs in the Golgi). A second possibility is that if a factor precursor is
processed in the ER, the a factor peptide cannot be matured into its active secreted
form. In other words premature processing by Kex2 may effect subsequent
processing events and/or secretion of a factor.
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Fig. 6.4 A graph to show the growth inhibition of RC631 exposed to
culture supernatants of different strains of veast (II).
The results of microtitre assays for a factor in the culture supernatants of different
strains of yeast, processed from the pJK6-4 encoded precursor (shown in Table
6.2) are plotted. The dilution of culture supernatant (culture supernatant/diluent)
from the different strains is plotted against the growth of RC631 (the a factor
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Attachment of the 60 C-terminal amino acids of PDI to the Kex2' polypeptide greatly
increases the efficiency of retention of Kex2 activity within the cell. The increased
retention of the Kex2' polypepeptide due to the PDI C-terminus being attached to it
results in a decrease in secretion of mature a factor.
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In order to further study the location and efficiency of retention of the various Kex2'
constructs with the different C-termini it was decided to use immunological
techniques. These techniques require antibodies that will specifically recognise
Kex2p in the presence of other yeast proteins. The first step in raising specific
antibodies is the preparation of an antigen that contains Kex2p epitopes. Kex2p is a
membrane protein and is present in low abundance in S.cerevisiae, therefore it is
not feasible to purify the wild type protein in sufficient abundance to use it as an
antigen. However, as the KEX2 gene was available and the sequence known it was
decided to use recombinant DNA technology to produce a specific Kex2 antigen that
could be used to immunise rabbits.
Using recombinant DNA technology it is possible to construct hybrid in-frame gene
fusions that can be expressed in E.coli at high levels to produce hybrid fusion
proteins that can be purified and used as immunogens. It was decided to make a hybrid
Staphylococcal aureus protein A-Kex2 fusion protein to raise antibodies, as protein
A fusion proteins offer a number of practical advantages (Lowenadler efa/1986):-
Fusion with the protein A moiety allows affinity purification of the fusion protein
with IgG linked to a solid matrix with a good yield (Nilsson et al 1985). The protein
A moiety probably enhances the immune response due to its repetitive structure
(Lowenadler efa/1986). Also, the recombinant protein produced in E.coli can easily
be identified and checked with respect to predicted size by Western blotting because
of the ability of the protein A portion to bind IgGs.
In this chapter I will describe the construction and purification of a protein A-Kex2
fusion protein and its use as an immunogen. Also the construction and use of a
(B-galactosidase-Kex2 fusion protein in affinity purification of specific anti-Kex2
antibodies from crude rabbit immune serum will be described.
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7.1 The Protein A fusion vector
There are several protein A fusion vectors commercially available for the production
of fusion proteins in E.coli, with different multiple cloning sites allowing fusions of
different open reading frames with protein A. However for the purpose of producing a
protein A-Kex2 fusion protein a plasmid called pKPRA was used (constructed by Alan
Boyd). The plasmid pKPRA (see fig. 7.2) carries:- a kanamycin resistance gene and a
segment of DNA encoding two and a half repeats of the five IgG binding domains of
protein A (fig. 7.1), placed in-frame with the ATG of lacZ to put it under control of
the lac promoter. Also the 3' end of the protein A portion is in frame with the lacZ
gene thus creating a protein A-lacZ fusion. When suitable strains of E.coli (eg
NM522) are transformed with pKPRA and plated onto X-Gal plates, blue colonies are
produced. Cloning of an in frame open reading frame (ORF) into the 3' end of the
protein A segment of DNA usually disrupts the open reading frame of the protein
A-lacZ fusion (a protein A-ORF fusion protein is produced instead) and therefore
white colonies of E.coli are produced on X-Gal plates. This vector can be used for
making protein A fusion proteins in large amounts and has the advantage of a colour
test on X-Gal plates to aid in screening for the correct recombinant constructs. The
construction of pKPRA is shown in (fig. 7.2).
7.2 The fusion of Kex2 to the 3' end of protein A in dKPRA.
The protein A-Kex2 hybrid protein was created by cloning a portion from the
N-terminal coding region of the kex2' gene from YCpKS into pKPRA. The portion of
the gene used extended from the Hind III site in kex2' to the Hind III site in the
remainder of the polylinker in YCpKS (see fig. 7.3). The Hind III fragment was made
blunt ended by filling in the Hind III ends. This filled-in fragment was cloned into the
filled-in Bam HI site of pKPRA to create pKPRA Kex. As the fragment could be cloned
in either orientation, and the orientation of the fragment is important, the
constructs were checked for the correct orientation with suitable restriction digests.
The Hind III filled-in fragment cloned into the BamHI filled in site of pKPRA in the
correct orientation creates a hybrid gene that encodes a 75K predicted molecular
weight protein A-Kex2 fusion protein. Analysis of pKPRA Kex by restriction
analysis revealed (as far as it is possible to tell) that the correct construct had been
made, but it still remained to be seen whether a fusion protein of the predicted size
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Fig 7.1 A schematic map of pRITH. showing the protein A gene and
the domain structure of protein A.
pRIT11 contains the protein A gene from Staphylococcus aureus with a polylinker at
the C-terminal coding region of the gene. The domains of the protein shown are: S a
signal sequence, A-D which are IgG domains, E which is a region homologous to A-D
and X which is the C-terminal part of protein A that lacks IgG binding activity. In the
construction of pKPRA (fig. 7.2) the Hind Ill/Bam HI fragment of pRIT11 coding for
two and a half IgG binding domains and the C-terminal region of protein A was used.
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Fig. 7.2 Construction of plasmid pKPRA
This plasmid was constructed by Dr Alan Boyd and is presented in this thesis for
completeness. For this construction plasmid pRIT11 (Lowenadler et al 1986) was
used as a source of protein A DNA. The pRIT 11 DNA was digested with Hind III and
Bam HI which releases a fragment of DNA coding for two and a half repeats of the five
IgG binding repeats of protein A. This Hind Ill/Bam HI fragment was ligated with
pK19E DNA which had been Hind Ill/Bam HI digested. Plasmid pK19E was made by
Eco Rl digesting pK19-filling in the EcoRI ends to make them blunt ended, and the
re-ligating the vector. The reason for cloning into pK19E and not pK19 was so that
the LacZ gene is in frame with the protein A gene portion being cloned in. Plasmid
pKPRA encodes a protein A-LacZ fusion protein of approximately 26K and E.coli























Fig. 7.3 Construction of the protein A-KEX2 fusion plasmid
pKPRA-Kex
For this construction, plasmid YCpKS was used as a source of KEX2 DNA. YCpKS was
digested with Hind III and the ends made blunt by filling in. Plasmid pKPRA was
digested with Bam HI and the ends made blunt by filling in. The DNA's were ligated
together, transformed into NM522 and transformants harbouring a plasmid with the
Kex2 insert in the correct orientation were selected. The resulting plasmid
pKPRA-Kex encodes a protein A-Kex2 gene fusion in which the protein A and Kex2
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was produced. The E.coli strain NM522 was transformed with pKPRA as a control and
pKPRAKex: both transformed strains NM522 (pKPRA) and NM522 (pKPRA Kex)
were induced to produce the protein A fusion protein (see Materials and Methods). On
induction these strains overproduce the protein A fusion proteins to such an extent
that insoluble aggregates of the fusion proteins (inclusion bodies) form in the cell.
Preparations of inclusion bodies were made (see Materials and Methods) and
analysed on Coomassie stained SDS-PAGE (fig. 7.4) and also by Western blotting
(fig. 7.4).
The Coomassie stained gel (fig. 7.4) shows quite clearly that a protein is present in
the preparation of inclusion bodies from NM522 (pKPRA Kex) that is not present in
the preparation of inclusion bodies from NM522 (pKPRA). The protein has an
approximate molecular weight of 75K which agrees with the predicted molecular
weight of the protein A-Kex2 fusion protein. The same samples analysed by Western
blotting (fig. 7.4) and using pre immune sera from rabbit as a source of first
antibody, reveals that the protein from the preparation of inclusion bodies from
*
NM522 (pKPRA Kex) contains a protein A moiety that is larger than the protein A
containing protein in the preparation of inclusion bodies from NM522 (pKPRA). The
protein A containing protein from NM522 (pKPRAKex) is approximately the same
size as the predicted protein A-Kex2 fusion protein. Because of the fact that pKPRA
Kex appeared to be the correct construct and the fact that a protein A containing
fusion protein of the predicted size was produced in NM522 (pKPRA Kex) under
inducing conditions, it was assumed that the protein was in fact the protein A Kex2
fusion protein.
7.3 Purification of protein A-Kex2 fusion protein for use as an
immunoaen
The original intenbion was to purify the protein A-Kex2 fusion protein from the
other proteins in E.coli by an affinity purification method using its affinity for IgGs.
However other members of the lab experienced problems in affinity purifying
protein A fusion proteins for a number of reasons, including the insolubility of the
fusion protein inclusion bodies and the co-purification of other proteins with the
affinity purified fusion protein. Because of the large amount of protein A-Kex2
fusion protein in ihclusion bodies produced in induced cells it was decided to purify
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Fig 7.4 Analysis of the preparations of inclusion bodies from NM522
fpKPRAI and NM522 (dKPRA Kexl
The preparations of inclusion bodies from NM522 (pKPRA) and NM522 (pKPRA
Kex) were separated on a 10% polyacrylamide gel. Half of the gel was stained with
Coommassie blue and the other half containing duplicate samples was blotted onto
nitrocellulose. The half blotted onto nitrocellulose was analysed by Western analysis
as described in Materials and Methods using pre-immune rabbit serum (1/2000
dilution) as the primary antibody. The Coomassie stained gel (A) and the Western
blot (B) are shown. The numbering of the lanes is the same for the Coomassie stained
gel and the Western blot.
Lane 1. Prestained marker proteins.
Lane 2. Inclusion bodies from NM522 (pKPRA).
Lane 3. Inclusion bodies from NM522 (pKPRA Kex).
147
A B
1 2 3 3 2
1LvIII ifcwi ' 1
148
the fusion protein from SDS-PAGE of inclusion body preps from induced pKKex
transformed cells (see Materials and Methods). The purified fusion protein was
analysed by SDS-PAGE and western blotting as before and shown to be the correct
protein. The purified fusion protein was used to immunise rabbits and obtain sera
hopefully containing antibodies specific to Kex2p (see Materials and Methods).
7.4 Construction of a fl-aalactosidase-Kex2 fusion protein.
When using polyclonal antiserum it is desirable to be able to purify the antibodies
specific to the desired antigen from the other (non specific) antibodies in the serum.
This is because the non specific antibodies tend to bind to proteins other than the
desired antigen, causing problems in the interpretation of results. This seems to be
particularly a problem when studying yeast antigens. In order to be able to affinity
purify the antibodies specific for epitopes in Kex2p from other antibodies in the
immune sera, we therefore decided to make a p-galactosidase-Kex2 fusion protein. In
order to do this the p-galactosidase fusion vector has to contain the same portion of
DNA (or part of the same piece of DNA) as pKPRA Kex, in the same reading frame so
that the protein A-Kex2 fusion protein and the J3-galactosidase-Kex2 fusion protein
share Kex2p epitopes.
As with vectors for making protein A fusion proteins, many vectors for making
p-galactosidase fusion proteins are also commercially available. Stanley and Luzio
(1984) designed vectors (called pEX) that harbour a gene fusion of the cro gene of
bacteriophage lambda and the lacZ gene of E.coli that directs the production of a
117kD Cro-p-galactosidase fusion protein. For the purpose of Kex2 fusion an
improved plasmid called pEX11 was used (Kusters et at) which carries an improved
polylinker at the 3" end of the lacZ gene. The plasmids pEX12 and pEX13 along with
pEX11, between them allow the fusion of any open reading frame with convenient
restriction sites, to be in frame with lacZ and thus produce a fusion protein.
Transcription of the hybrid gene of pEX11 is under control of the Pr promoter of
bacteriophage lambda. Regulated expression can be achieved in a host strain of E.coli
that harbours a lysogenised phage lambda carrying the thermosensitive cl857 allele
(eg pop2136). At 30°C the repressor is functional but at 42°C it is not. Therefore a
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shift to 42°C causes the fusion protein to be produced at high levels.
The p-galactosidase-Kex2 hybrid was created by cloning an Eco Rl/Bam HI fragment
from pKPRAKex into the Eco Rl/ Bam HI sites of pEX11 to create pEX Kex (fig. 7.5).
This cloning put the ORF of Kex2 in frame with the ORF of p-galactosidase and
therefore a p-galactosidase-Kex2 fusion protein should be expressed of expected size
170 K.
The plasmid pEX Kex was transformed into E.coli strain pop2136. Transformants
were grown in selective media, induced for 4 hours to express fusion protein (see
Materials and Methods) and whole cell extracts were made by boiling harvested cells
in SDS sample buffer. The whole cell extracts were run on a 10% SDS-PAGE and
Western blotted using immune and pre-immune sera from rabbits immunised with
the protein A-Kex2 fusion as the source of first antibody.
The immune serum recognised a protein which corresponded to the expected size of
the p-galactosidase fusion protein (fig. 7.6) and was not recognised by pre-immune
serum. Therefore this protein was assumed to be the p-galactosidase fusion protein.
Because the antibodies in the immune serum were raised against protein A-Kex2
fusion protein and the only shared region of the two fusion proteins is the Kex2
portion, the antibodies recognising the p-galactosidase fusion protein were assumed
to be Kex2 specific. It was decided to proceed in using the p-galactosidase fusion
protein to affinity-purify Kex2p specific antibodies from the immune serum.
7.5 Affinity purification of antibodies
E.coli strain pop2136 tranformed with pEX Kex was grown in selective medium,
induced to produce fusion protein and inclusion body preps were made (see materials
and methods). The inclusion body prep was ran on a 10% preparative SDS-PAGE and
blotted onto nitrocellulose. The nitrocellulose was stained with Ponceau-S and a strip
containing the fusion protein, which could be clearly seen (not shown) was cut from
the nitrocellulose. This affinity strip was used to affinity purify antibodies specific
to Kex2p (see Materials and Methods). The affinity purified antibodies were tested to
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Fig. 7.5 Construction of the p-aalactosidase-Kex2 fusion plasmid
pEX-Kex
For this construction, plasmid pKPRA Kex was used as a source of KEX2 DNA.
Plasmid pKPRA Kex was digested with Eco Rl and Bam HI and the resulting fragment
was purified. Plasmid pEX11 (Kusters et al 1989) was digested with Eco Rl and
BamHI and was ligated with the Eco Rl/Bam HI fragment from pKPRA Kex. This
ligation was transformed into pop2136 and transformants harbouring plasmids with
the Kex2 insert were selected. The resulting plasmid pEX-Kex encodes a
p-galactosidase-Kex2 gene fusion in which the p-galactosidase and Kex2 coding

























Fig. 7.6 Analysis of the preparation of inclusion bodies from pop2136
(pEX-Kex).
The preparation of inclusion bodies (duplicate samples) from pop2136 (pEX-Kex)
was separated on a 10% polyacrylamide gel. The gel was blotted onto nitrocellulose
and analysed by Western analysis using either (A) Kex2-immune serum
(anti-serum raised against the protein A-Kex2 fusion protein 1/2000 dilution) or
(B) pre immune serum from the same rabbit as the source of primary antibody
(1/2000 dilution).
(A) Kex2 immune serum
Lane 1. Prestained marker proteins
Lane 2. Inclusion bodies from pop2136 (pEX-Kex)
(B) Pre-immune serum
Lane 1. Prestained marker proteins
Lane 2. Inclusion bodies from pop2136 (pEX-Kex)
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see if they would recognise the p-galactosidase fusion protein. The antibodies did
recognise the fusion protein and were assumed to be Kex2 specific, as all other
antibodies in the serum should have been removed during affinity purification.
In this chapter I have described how anti-Kex2 antibodies were raised and purified
using recombinant DNA technology. The use of these affinity purified antibodies will
be described in some of the following chapters.
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Chapter eight.
Western analysis of intracellular and secreted
Kex2-related polypeptides, in strains of yeast
expressing different truncated Kex2 polypeptides.
156
8.0 Introduction
In the previous chapter the production of antiserum against the N-terminal region of
Kex2p and the affinity purification of Kex2-specific antibodies from this serum was
described. In order to test whether these affinity-purified Kex2 antibodies
recognised Kex2 related polypeptides expressed in yeast, I decided to look at the Kex2
polypeptides present in culture supernatants of cells that secreted Kex2p (or at least
Kex2 activity) by Western blot analysis. In an initial experiment supernatants from
PWYS3 (YEpKS) and PWYS3 (YEpKP) cells grown in selective medium overnight to
stationary phase, (which are known to contain Kex2p by the criterion of the in vitro
assay for Kex2) were examined by Western blot analysis (see Materials and
Methods) using affinity-purified Kex2 antibodies as the first antibody. There were
no proteins specifically recognised by the Kex2 antibodies in the supernatants of
either of the strains (data not shown). It was presumed that the concentration of
Kex2p in the supernatants was too low to allow the protein to be detected by Western
blotting, so the supernatants were concentrated and, in addition, crude microsomes
were prepared from the two strains in order to attempt to detect the two forms of
Kex2' polypeptides expressed in these cells (see Materials and Methods). The
concentrated supernatants of were assayed for Kex2 activity and, as expected, the
activity was more than 50-fold greater than in the unconcentrated supernatants of
each strain (data not shown).
8.1 Western blot analysis of Kex2-related polypeptides Ln
concentrated supernatants and microsomes.
The concentrated supernatants and microsome preparations from PWYS3 (YEpKS)
and PWYS3 (YEpKP) were added to equal volumes of protein electrophoresis sample
buffer and boiled for 5 minutes. The samples (20 |al) were separated by SDS PAGE on
a 10% gel and transferred to nitrocellulose. Western analysis (see Materials and
Methods) using affinity-purified Kex2 antibodies as the first antibody was
performed to detect Kex2 related polypeptides in the samples.
The result of the Western analysis (fig. 8.1) shows that the proteins recognised by
the Kex2 antibodies are different in PWYS3 (YEpKS) and PWYS3 (YEpKP), both in
the supernatants and in the preparations of microsomes. This was to be expected as
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Fig. 8.1 Western analysis of concentrated supernatants and
microsomes of two veast strains with anti-Kex2 antibodies
The protein in concentrated supernatants and microsomes of strains PWYS3 (YEpKS)
and PWYS3 (YEpKP) were separated on 10% SDS PAGE and transferred to
nitrocellulose. The nitrocellulose blot was probed with affinity purified anti-Kex2
antibodies (1/100 dilution) and the proteins recognised by the antibodies were
detected using horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG
antibodies (The ECL method of detection was used as described in materials and
methods). The marker proteins in this experiment and all the following Western
analyses are a mixture of protein A fusion proteins of different sizes made in our
laboratory (Dr. J. Zueco)
Lane 1. Marker proteins
Lane 2. PWYS3 (YEpKS) concentrated supernatant.
Lane 3. PWYS3 (YEpKP) concentrated supernatant.
Lane 4. PWYS3 (YEpKS) microsomes.
Lane 5. PWYS3 (YEpKP) microsomes.
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the polypeptides supposedly expressed from these strains, Kex2'-S and Kex2'-PDI
have predicted molecular weights of 70K and 76K respectively. This result therefore
provided further evidence that the antiserum raised against the protein-A-Kex2
fusion protein, and the antibodies affinity purified against the p-galactosidase-Kex2
fusion protein were in fact Kex2-specific. Without this information, only the fact
that the crude antiserum recognised the p-galactosidase-Kex2 fusion protein had
provided evidence that the antibodies in the immune serum were Kex2-specific. Also
the result showed that Kex2' polypeptides expressed in S. cerevisiae could be
recognised by the affinity purified antibodies. As well as confirming the specificity
of the antibodies the fact that Kex2-related polypeptides of different molecular
weights were recognised in PWYS3 (YEpKS) and PWYS3 (YEpKP) provided evidence
that the expected Kex2 polypeptides (ie Kex2'-S and Kex2'-PDI) were being
expressed in their respective strains (the only previous evidence was that the YEpKS
and YEpKP constructs were correct as far as it was possible to tell).
One observation from the blot was that there appears to be some heterogeneity of
polypeptides expressed in the individual cell supernatants and preparations of
microsomes. It is known that the portion of Kex2p in the Kex2' constructs contains a
single N-linked glycosylation group (Fuller et al 1989) and therefore this
heterogeneity was thought possibly to reflect different glycosylation states of the
Kex2' polypeptides. This possibility was examined by treating all of the samples with
endoglycosidase H (Endo H) to remove the N-linked carbohydrate and comparing the
treated samples with untreated samples by Western analysis (fig. 8.2). If the
heterogeneity was due to different N-linked giycosylation states of the Kex2'
polypeptides we would expect that on treatment with Endo H, the Kex2* polypeptides
would migrate as a single protein band on the blot, corresponding to their
unglycosylated forms. The results of the Endo H treatment reveal that the
heterogeneity of polypeptides recognised by Kex2 antibodies in individual samples is
difficult to explain by differences in N-glycosylation alone: treatment of the
supernatant of PWYS (YEpKS) with Endo H causes a shift in mobility of the Kex2
related polypeptide. This is consistent with a single N-linked carbohydrate being
removed from Kex2'-S. However if this is the case, it is difficult to account for the
slower migrating (and less abundant) polypeptides recognised by Kex2 antibodies in
the microsomes of PWYS3 (YEpKS) by differences in N-linked glycosylation. In fact
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Fig 8.2 Western analysis of endoalvcosidase H-treated supernatants
and microsomes of two veast strains using anti-Kex2 antibodies.
The Endoglygosidase H (Endo H)-treated and untreated protein samples (the same
samples as in fig. 8.1) were separated by 10% SDS PAGE and transferred to
nitrocellulose. The nitrocellulose blot was probed with affinity-purified anti Kex2
antibodies (1/100 dilution) and the proteins recognised by the antibodies were
detected using horseradish peroxidase (HRP) conjugated goat anti-rabbit IgG
antibodies (The ECL method of detection was used as described in materials and
methods).
Lane 1. Marker proteins
Lane 2. PWYS3 (YEpKS) concentrated supernatant (untreated)
Lane 3. PWYS3 (YEpKS) concentrated supernatant (Endo H treated)
Lane 4. PWYS3 (YEpKP) concentrated supernatant (untreated)
Lane 5. PWYS3 (YEpKP) concentrated supernatant (Endo H treated)
Lane 6. PWYS3 (YEpKS) microsomes (untreated)
Lane 7. PWYS3 (YEpKS) microsomes (Endo H treated)
Lane 8. PWYS3 (YEpKP) microsomes (untreated)









it is difficult to account the slower migrating forms of Kex2 related protein at all, as
the fastest migrating form of Kex2-related protein recognised in the microsomes has
a change in mobility when treated with Endo H which suggests that it is
N-glycosylated. I have therefore assumed that this most abundant and fastest
migrating species of polypeptide in the microsomes of PWYS3 (YEpKS) is the
Kex2'-S polypeptide with a single N-linked glycosylation group (marked on fig. 8.1)
(the reason for this assumption will be discussed later in the chapter). Thus a
possible explanation for polypeptides larger than singly N-glycosylated Kex2'-S
being present is that they are Kex2'-S polypeptides containing additional post
translational modifications such as O-linked glycosylation.
In the microsomes of PWYS3 (YEpKP), I have assumed again, that the smaller, more
abundant polypeptide is Kex2'-PDI that is contains a single N-glycosyl group
(marked on fig. 8.1), as it has an altered mobility after treatment with Endo H (fig,
8.2); and that the larger, less abundant forms have some additional post
translational modification. An interesting observation is that the major secreted
polypeptide from PWYS3 (YEpKP) appears to be smaller than the intracellular
polypeptide that is assumed to be singly N-glycosylated Kex2'-PDI. This difference
cannot be explained by differences in N-glycosylation as the major secreted
polypeptide also appears to be N-glycosylated as it has an altered mobility after
treatment with Endo H.
The observation that the major secreted form of Kex2 related polypeptide from
PWYS3 (YEpKP) is smaller (by approximately 4K) than the major intracellular
form (Kex2'-PDI) is confirmed in fig. 8.3. The major forms of secreted ana
intracellular Kex2-related protein expressed in PWYS3 (YEpKS), however, have
identical apparent molecular weights (approximately 70K; fig. 8.3). This agrees
with the predicted molecular weight of Kex2'-S, therefore these forms were assumed
actually to be Kex2'-S (singly N-glycosylated as shown by the Endo H experiments;
this was also why the larger forms of Kex2 related protein detected in the
microsomes were assumed to have some additional post translational modification).
One explanation for the secreted polypeptide from PWYS3 (YEpKP) being
approximately 4 K smaller than the intracellular Kex2'-PDI polypeptide is that it
might be a proteolytic cleavage product of Kex2'-PDI (called Kex2'-PDI'). One piece
of evidence for this is that the polypeptide secreted from PWYS (YEpKP) is not
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Fig. 8.3 Western analysis to compare the secreted and intracellular
forms of Kex2p produced in two different strains of veast using
anti-Kex2 antibodies.
The proteins in concentrated supernatants and microsomes from PWYS3 (YEpKS)
and PWYS3 (YEpKP) (the same samples as in fig 8.1) were separated on 10% SDS
PAGE and transferred to nitrocellulose. Supernatants and microsomes from each of
the strains were loaded in adjacent lanes so that secreted and internal proteins could
be compared. The nitrocellulose blot was probed with affinity-purified anti-Kex2
antibodies (1/100 dilution) and the proteins recognised by the antibodies were
detected using horseradish peroxidase (HRP)-conjugated goat anti rabbit IgG
antibodies (The ECL method of detection was used as described in materials and
methods).
Lane 1. Marker proteins.
Lane 2. PWYS3 (YEpKS) concentrated supernatant (secreted).
Lane 3. PWYS3 (YEpKS) microsomes (internal).
Lane 4. Marker proteins.
Lane 5. PWYS3 (YEpKP) concentrated supernatant (secreted).
Lane 6. PWYS3 (YEpKP) microsomes (internal).
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recognised by HDEL antibodies (fig. 8.4) and Kex2'-PDI should have the HDEL signal
at its extreme C-terminus. As this putative cleavage does not apparently occur in
secreted Kex2'-S, it seems reasonable to assume that the cleavage occurs in the PDI
portion of Kex2'-PDI. Evidence for this is that the 60 C-terminal amino acids of PDI
in Kex2'-PDI is the only region of the polypeptide not identical with Kex2'-S and if
the putative cleavage were to occur in the common Kex2' portion of Kex2'-PDI we
would also expect it to occur in Kex2'-S. Also, if this putative cleavage had occurred
in the Kex2' portion of Kex2'-PDI, the polypeptide secreted would be smaller than
Kex2'-S; this is not the case and Kex2'-PDI' is larger than secreted Kex2'-S (fig.
8.1). Autoproteolytic cleavage by Kex2 has been ruled out as there are no Kex2
cleavage sites in the PDI portion of Kex2'-PDI.
If cleavage in the PDI portion of Kex2'-PDI is the explanation for the smaller
secreted Kex2'-PDI' polypeptide, a number of results in previous chapters become
easier to explain. Kex2'-PDI' would not contain the HDEL sequence or a substantial
portion of the PDI C-terminus as Kex2'-PDI' is approximately 4K smaller than
Kex2'-PDI. This would explain the reason for Kex2 activity being secreted into the
growth medium of PWYS3 (YEpKP) even though Kex2'-PDI was expected to be
efficiently retained in the cell. Although Kex2'-PDI is the most efficiently retained
fusion protein, cleavage of a 4K portion from the C-terminus would be expected to
abolish retention due removal of the HDEL signal and amino acids of the C-terminus
of PDI.
8.2 Western analysis of HDEL-containino proteins in concentrated
supernatants and microsomes
Kex2'-PDI and Kex2'-HDEL should both have the C-terminal HDEL sequence whereas
Kex2'-S should not. Microsomes and concentrated supernatants from PWYS3
(YEpKP), PWYS3 (YEpKH) and PWYS3 (YEpKS) were prepared as before (see
Materials and Methods). To detect proteins containing the HDEL sequence at the
C-terminus we decided to use anti-HDEL antibodies (obtained from Dr. H. Pelham)
for Western analysis of the samples from the three strains (fig. 8.4). Western
analysis of the same samples was also performed using the affinity purified
anti-Kex2 antibodies, and the results compared with those obtained using the
anti-HDEL antibodies (fig. 8.4).
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Fig. 8.4 Western analysis gf concentrated supernatants and
microsomes of three veast strains using anti-HDEL and anti-Kex2
antibodies
The proteins in concentrated supernatants and microsomes of strains PWYS3
(YEpKH), PWYS3 (YEpKS) and PWYS3 (YEpKP) were separated on 10% SDS PAGE
and transferred to nitrocellulose (identical samples were loaded onto two gels). The
nitrocellulose blots were probed with either rabbit anti-HDEL antiserum (A)
(obtained from Dr H. Pelham) or affinity purified anti-Kex2 antibodies (B), and the
proteins recognised by the antibodies were detected using horseradish peroxidase
(HRP) conjugated goat anti-rabbit IgG antibodies (The ECL method of detection was
used as described in materials and methods).
Lane 1. Marker proteins
Lane 2. PWYS3 (YEpKH) microsomes.
Lane 3. PWYS3 (YEpKS) microsomes.
Lane 4. PWYS3 (YEpKP) microsomes.
Lane 5. Marker proteins.
Lane 6. PWYS3 (YEpKH) concentrated supernatant.
Lane 7. PWYS3 (YEpKS) concentrated supernatant.



















There are no proteins recognised by the HDEL antibodies in the culture supernatants
of any of the three strains. In the microsomes prepared from the three strains
however, two proteins were recognised by the HDEL antibodies (fig. 8.4). As these
recognised proteins are the same size in each strain and we know that Kex2'-PDI is
larger than Kex2'-HDEL and Kex2'-S (fig. 8.4) it is unlikely that the proteins
recognised by the HDEL antibodies are Kex2 -related. It is likely that the protein
with the approximate molecular weight of 73K is yeast BiP (Rose et al 1989) and it
is possible that the protein with the approximate molecular weight of 45K is yeast
PDI (although the predicted molecular weight of yeast PDI from its DNA sequence is
58K; Dr. M. Tuite, personal communication). Thus it appears that the Kex2*
polypeptides expressed in these strains are not detectable with anti-HDEL antibodies
even though they are recognised by anti-Kex2 antibodies. As both of the Western
blots (figs. 8.4) were identical with respect to the samples loaded, these results
suggest that the anti-HDEL antibodies may not have such a high affinity for their
antigen as the anti-Kex2 antibodies do for their antigen. Therefore the anti-HDEL
antibodies recognise only abundant proteins (ie BiP) and did recognise Kex2'
polypeptides (Kex2'-HDEL or Kex2'-PDI) as they are in too small amounts to be
detectable. The anti-Kex2 antibodies may be more efficient at recognising their
antigen because of their ability to recognise several epitopes in Kex2' and thus
recognise Kex2' polypeptides in amounts that cannot be detected with the anti-HDEL
antibodies. As it was not possible to detect Kex2'-HDEL or Kex2'-PDI in either
microsomes or supernatants it is not possible to test the idea that the HDEL sequence
is not present on secreted Kex2'-PDI' using the HDEL antibodies. Thus although we
suspect that the HDEL sequence has been removed along with some of the PDI sequence
of Kex2'-PDI to yield Kex2'-PDI' it is difficult to prove with the resources
available. The possibility cannot be ruled out that Kex2'-HDEL has the HDEL signal
removed before being secreted although this is less likely as the intracellular and




Immunolocalisation of the different truncated Kex2
polypeptides by immunogoid labelling of yeast cells.
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9.0 Introduction.
From the results described in previous chapters it appears that the addition of the
different C-termini to a truncated Kex2p has an effect on the efficiency of retention
within the cell. The addition of the 60 C-terminal amino acids of yeast PDI to the
C-terminus of the truncated Kex2p to create a Kex2'-PDI fusion protein appears to
result in efficient retension of this protein although some Kex2'-PDI hybrid protein
is secreted in an apparently cleaved form. Although it is known that there are
internal Kex2-related proteins (shown by Western analysis) and ^ Kex2
activity (shown by in vitro Kex2 assays) in the strains expressing the truncated
Kex2 proteins with the different C-termini, the exact location of these proteins
within the cell is not known. To investigate the distribution of the Kex2' polypeptides
within the yeast cell, it was decided to attempt immunogold labelling of the strains.
The affinity-purified anti-Kex2 antibodies appeared to be specific for Kex2 related
proteins (shown by Western analysis) and therefore these antibodies were used in an
attempt to specifically label Kex2-related proteins in immunogold labelling
experiments. The following strains were prepared for immunogold labelling by the
methods described in Chapter2 (Materials and Methods):- JRY 188, PWYS3, PWYS3
(YEpKH), PWYS3 (YEpKK), PWYS3 (YEpKS) and PWYS3 (YEpKP). The reason for
using the episomal plasmid bearing strains was that these strains express more
Kex2'p and therefore detection of the Kex2' polypeptides should be made easier.
9.1 Results of immunolabellina experiments.
In order to be convinced that results of immunolabelling experiments are real and
not artefactual it is necessary to carry out as many controls as possible. The first
control used here was to omit the primary antibody from the immunolabelling
procedure (ie replace first antibody solution with blocking solution) in order to
determine whether the gold labelling in the cells is dependent on the presence of the
first antibody. If the gold labelling is not dependent on the first antibody being
present the labelling must be non specific. Strain JRY 188 was treated as usual for
immunolabelling except that the first antibody solution was replaced with
blocking solution. The electron micrograph in fig 9.1 shows a typical cell from this
experiment. There is virtually no gold labelling in this cell which suggests that any
gold labelling in other strains is most probably due to the specificity of the first
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antibody. A no first antibody control was performed for all the strains with the same
result (ie virtually no labelling with gold. Data not shown).
The second control was performed in order to determine whether labelling when first
antibody is present is only in strains expressing Kex2p in some form. Strain PWYS3
does not contain any Kex2p due to the KEX2 gene being disrupted. Thus any labelling
of this strain with gold is not due to antibody recognising Kex2p but due to non
specific labelling. Strain PWYS3 was treated as described for immunolabeling with
anti-Kex2 antibodies. The electron micrograph in fig 9.2 shows a typical cell from
this experiment. There is virtually no labelling of PWYS3 which suggests that gold
labelling in other experiments is probably due to labelling of Kex2p and not to non
specific labelling. Thus these two controls suggest that gold labelling is due to a
specific labelling of Kex2p by the affinity purified anti-Kex2 antibodies.
Strain JRY188 expresses the full length wild type Kex2p that is reportedly localised
in the Golgi apparatus. Typical results of immunolabelling of this strain with
anti-Kex2 antibodies are shown in fig 9.3 and fig 9.4. Labelling with gold appears to
be dispersed throughout the cell and not localised in a particular area. The yeast Golgi
apparatus is not well-defined cytologically especially in wild type cells and
therefore it is not possible to say whether the labelling is typical of a yeast Golgi
protein or not.
Typical results of immunolabeiling with anti-Kex2 antibodies of the episomal
plasmid bearing strains expressing the truncated Kex2p's with the different
C-termini are shown in fig. 9.5 {PWYS3 (YEpKH)}, fig. 9.6 {PWYS3 (YEpKK)}, fig.
9.7 {PWYS3 (YEpKS)}, figs 9.8 and 9.9 {PWYS3 (YEpKP)}. Labelling of all of these
strain with gold also appears to be dispersed throughout the cell as with JRY 188. It
is not possible to say whether the gold labelling is associated with particular
organellar structures as we had hoped would be the case. Large clumps of gold
particles are common in strains PWYS3 (YEpKS) and PWYS3 (YEpKP) but less
common in strains PWYS3 (YEpKH) and PWYS3 (YEpKK).
The centromere plasmid bearing strains of yeast:- PWYS3 (YCpKH), PWYS3
(YCpKK), PWYS3 (YCpKS) and PWYS3 (YCpKP) were processed for
immunocytochemistry as descibed and immunolabelled with anti-Kex2 antibodies the
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Figs. 9.1-9.9 Electron micrographs of different strains of veast
immunolabelled with anti-Kex2 antibodies.
All strains of yeast were processed for immunocytochemistry with LR white resin as
described in Materials and Methods. The strains were typically immunolabelled as
described in this Materials and Methods with anti-Kex2 antibodies (1/50 dilution)
as the primary antibody, although a control in which primary antibody was omitted
is also shown. The electron micrographs were all taken at a magnification of
x17000.
(9.1) JRY 188 (no primary antibody)
(9.2) JRY kex2::URA3-1320 (anti-Kex2 antibody 1/50 dilution)
(9.3) JRY 188 (anti-Kex2 antibody 1/50 dilution)
(9.4) JRY 188 (anti-Kex2 antibody 1/50 dilution)
(9.5) JRY kex2::URA3-1320 (YEpKH)
(9.6) JRY kex2::URA3-1320 (YEpKK)
(9.7) JRY kex2::URA3-1320 (YEpKS)
(9.8) JRY kex2::URA3-1320 (YEpKP)
(9.9) JRY kex2::URA3-1320 (YEpKP)
(anti-Kex2 antibody 1/50 dilution)
(anti-Kex2 antibody 1/50 dilution)
(anti-Kex2 antibody 1/50 dilution)
(anti-Kex2 antibody 1/50 dilution)









same as the episomal plasmid bearing strains. There was very little labelling of any
of the centromere plasmid bearing strains expressing the Kex2' polypeptides with
the different C-termini (Data not shown).
9.3 Conludina remarks.
Labelling in the centromere plasmid bearing strains expressing the Kex2
polypeptides with the different C-termini is much lower than in the episomal
plasmid bearing strains which contain the most label. The controls ie when first
antibody is omitted and labelling of strain PWYS3 contain virtually no gold label.
Thus it appears the cells expressing the most Kex2'p are labelled to the greatest
extent and labelling of cells expressing lower amounts of Kex2'p contain virtually no
label. Therefore the majority of gold labelling seems to be due to recognition of
Kex2p by the first antibody (anti-Kex2 antibody). Unfortunately however, it is
difficult to interpret the results of the immunolabelling experiments with any great
confidence as the amount of gold labelling even in the episomal plasmid-bearing
strains is not very high (although it is higher than in other strains) and does not
appear to be well localised.
There are no striking differences in the labelling of any of the episomal plasmid
bearing strains as we may have expected from the differences in intracellular Kex2
activity, especially between PWYS3 (YEpKP) which has by far the greatest
intracellular Kex2 activity and the other episomal plasmid bearing strains which
have less intracellular Kex2 activity (Chapter 7). Thus although labelling appears
specific to cells expressing Kex2p at relatively high levels in comparison (the levels
of Kex2p in the cell are probably very low in relation to total protein content of the
cell) nothing can be deduced about the location of the Kex2p's in the different strains.
It is possible that the distribution of gold in the cell corresponds to the subcellular
distribution of the different Kex2' polypeptides but it is also possible that the
results are artefactual due to the methods used to process the cells. Clearly these
results are somewhat disappointing and of a preliminary nature: they are included
here for the sake of completeness.
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Chapter ten




In previous chapters the effect of the different Kex2p constructs on the processing of
a factor has been analysed. One of my aims at the start of this project was to
investigate the biogenesis of the K.lactis killer toxin in the secretory pathway of
S.cerevisiae. The Kex2p has been shown to be involved in the maturation of the of the
ap precursor polypeptide into the mature a and p subunits of the toxin most probably
at a late stage in the secretory pathway after the sec18 mutation exerts its effects
(ie in the Golgi complex). It was therefore of interest to investigate the biogenesis of
the toxin when processed by the different Kex2p constructs, some of which possibly
process in the ER. It was proposed to see if functional killer toxin could be
assembled and secreted from strains expressing the different Kex2 constructs and if
not the reason for this (ie the Kex2p may not process the ap precursor, or if it does,
processing at an earlier stage in the secretory pathway may not allow the toxin
subunits to assemble correctly).
In order to study the effect of the different Kex2 constructs on the biogenesis of the
K.lactis killer toxin a suitable strain expressing the toxin had to be used. The strain
would have to have the chromosomal KEX2 gene inactivated and the plasmids encoding
the different Kex2* constructs transformed into it. The only strain expressing the
toxin and possessing auxotrophic markers with which to select transformants was
F102-2 (k1, k2, Ieu2, his4). To inactivate the chromosomal KEX2 gene the only
method available was to replace it with a disrupted Kex2 gene (ie kex2::LEU2 from
plasmid pGA1070 as in Chapter 1). The problem with this was that the resulting
strain would then only possess auxotrophy for histidine. The plasmids for the
expression of the different Kex2' constructs are all TRP1 plasmids and it would not
therefore be possible to select for transformants in F102-2 disrupted with
kex2::LEU2. Although it is possible to move the DNA encoding the different Kex2*
constructs into other plasmids quite easily, suitable plasmids containing the HIS4
gene as selectable marker in yeast do not exist. The possibility of creating a yeast
strain possessing the correct auxotrophies and the linear plasmids k1 and k2 was
also ruled out as standard crossing procedures of p° strains of S.cerevisiae to create
new strains is not possible (p° diploids do not sporulate, and the linear plasmids are
only stable in p° strains of S. cerevisiae). It was therefore decided to disrupt the
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TRP1 gene of F102-2 in order to make it Trp" so that TRP plasmids can be selected
for in transformations.
10.1 Disruption of the chromosomal TRP1 gene of F102-2
In order to disrupt the chromosomal copy of the TRP1 gene, a plasmid was contructed
in which TRP1 or at least part of the TRP1 gene is disrupted. This disrupted gene
should be able to be excised as a linear DNA fragment from its vector and
transformed into F102-2 to disrupt the chromosomal TRP1 gene by homologous
recombination. A portion of the TRP1 gene from YRp7 was cloned into pUC9 (fig.
10.1). The resulting plasmid was named pUC-trp'. The TRP1 portion of pUC-trp'
was disrupted with a fragment of bacteriophage X DNA resulting in a plasmid called
pUC-trp'::A. (fig. 10.2). The linear fragment containing the portion of TRP1
disrupted with X DNA was excised from pUC-trp'::X and used in co-transformation of
F102-2 with the linear piece of DNA from pGA1070 containing the kex2::LEU2
disruption (see fig. 3.1). Initially Leu+ transformants were selected for on SD +
HW plates. Tryptophan was added to the plates so that as well as the Leu+
transformants being able to grow, any cells that had been made Trp" due to
integration of the disrupted portion of the TRP1 gene would also grow. Thus the Leu+
transformants selected should be Kex2" due to integration of the linear DNA encoding
the kex2::LEU2 disruption but a mixture of Trp+ and Trp- colonies. These Leu+
transformants were screened by replica plating onto SD + H and SD +HW plates and
transformants that were Trp" were selected (ie would grow on SD + HW but not SD
+ H). Thus a strain based on F102-2 that was Kex2" and also Trp" was made. This
strain could be transformed with the TRP plasmids encoding the different Kex2*
constructs. The strain was named PWYS4.
10.2 Analysis of toxin production in strains expressing the different
Kex2p constructs
The strain PWYS4 was transformed with the plamids YCpKH, YCpKK, YCpKS and
YCpKP and Trp+ transformants were selected. The resulting strains were called
PWYS4 (YCpKH), PWYS4 (YCpKK), PWYS4 (YCpKS) and PWYS4 (YCpKP)
respectively. An initial experiment on the strain PWYS4 and the transformed strains
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Fig. 10.1 Construction of plasmid pUC-trp'
The Eco Rl fragment (approximately 1.45 kb) from plasmid YRp7 (Parent et al
1986) containing the full length TRP1 gene is shown. The Eco Rl/Hind III fragment
from YRP7 coding for a portion of TRP1 (trp1) was ligated with plasmid pUC9 that
had been digested with Eco Rl/Hind III, and the ligation was transformed into NM522.
White colonies were selected on X-Gal plates, and recombinant plasmids were
screened by restriction analysis for the presence of the Eco Rl/Hind III fragment
from YRP7. The resulting plasmid was named pUC-trp'.
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Fig. 10.2 Disruption of the TRP1 aene
In order to disrupt the chromosomal copy of TRP1 to make a Trp- mutant it was
necessary to first disrupt the TRP1 gene or at least a portion of the gene. It was
decided to disrupt the Eco Rl/Hind III fragment of the TRP1 gene in pUC-trp' by
cloning a piece of disrupting DNA (X DNA) into the Eco RV site. Phage X DNA was
digested with Eco RV and ligated with Eco RV digested pUC-trp'. The ligation was
transformed into NM522 and recombinant plasmids were screened for by restriction
analysis (ie an Eco RV digest that released a fragment of X DNA). A recombinant
plasmid was selected that contained a fragment of approximately 1.5 kb of X DNA
(that did not contain Eco Rl or Hind III sites) in the Eco RV site of pUC-trp'. The
resulting plasmid was named pUC-trp'::A,. The Eco Rl/Hind III fragment of
pUC-trp'::X contained a portion of the TRP1 gene disrupted with X DNA. This fragment
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derived from it was to see whether active toxin is secreted from any of the strains.
Active killer toxin could not be detected in the supernatants of any of the strains
when standard killer toxin assays were performed (see Materials and Methods).
Because of this result it was decided to make sure that the linear plasmids (k1 and
k2) encoding the toxin subunits were present in the F102 derivative strains.
Unfortunately, no linear plasmids were detected by in situ lysis analysis (see
Materials and Methods) in any of the strains (data not shown). Therefore it appears
as if the strain PWYS4 does not possess the linear plasmids and subsequently the
derivatives of this strain will also lack the linear plasmids. In every other respect
PWYS4 appears to be the correct strain (ie a derivative of F102-2) as it possesses
the correct auxotrophies and lacks Kex2 activity as expected. The most likely
explanation for the lack of the linear plasmids in PWYS4 is that the plasmids cannot
be stably maintained in the genetic background of PWYS4. It seems possible that
production of the toxin polypeptides in a Kex2" genetic background is deleterious to
the cells in some way and thus, cells that lose the linear plasmids are selected for.
Cells that have lost the linear plasmids are probably healthier and soon become the
majority in a population by outgrowing the linear plasmid containing cells. When
strain F102-2 had its KEX2 gene replaced (Chapter 3) the strain contained the
linear plasmids. However upon re-examination of the in situ lysis gel (fig. 3.3) it
was apparent that the strains containing the kex2::LEU2 disruption do not appear to
contain as much linear plasmid as the non-disrupted cells. In hindsight this is
possibly due to the linear plasmids not being stably maintained in a Kex2" genetic
background.
10.3 Concluding remarks
Study of the biogenesis of the K. lactis killer toxin in cells expressing the different
Kex2 constructs was made impossible due to difficulties in obtaining a strain
suitable for these studies. The problems were probably due to the instability of the
linear plasmids in Kex2" cells. I suspect that the linear piasmids may also be






The amenability of Saccharomyces cerevisiae to genetic manipulaton has made it a
useful organism for studying many of the basic questions in eukaryote biology. The
aim of this project was to use recombinant DNA technology and the powerful genetics
of S. cerevisiae to facilitate the analysis of the biogenesis of secretory proteins, in
particular the Kluyveromyces lactis killer toxin since it has a number of interesting
features (see Introduction; Chapter 1).
The involvement of the Kex2 endoprotease in the processing of the K. lactis killer
toxin was confirmed since it was found that strains of yeast which contain the linear
plasmids encoding the toxin polypeptides (k1 and k2), but which lack a functional
Kex2p, do not secrete any detectable active killer toxin. Furthermore it appears that
if Kex2 processing does not occur, the toxin polypeptides are not secreted, even in an
unprocessed form (Dr M. Stark personal communication). The Kex2 processing of
the ap toxin precursor was shown to occur at a point in the secretory pathway after
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that at which the sed8 mutation (blocking ER to Golgi transport) exerts its effect.
This is because at the restrictive temperature of 37°C a sec18 mutant strain of yeast
expressing the toxin (MRY101) accumulated an ap precursor polypeptide that had
not been processed by Kex2p. This observation fits well with the generally accepted
view that Kex2p normally processes proteins in the Golgi apparatus.
Another observation was that the toxin subunits do not appear to have been covalently
assembled in the ER. This is suprising since the p and y subunits of the mature toxin
are covalently linked by a single disulphide bond and disulphide bonds are widely held
to be formed exclusively in the ER; thus it was expected that the ap precursor and y
subunits accumulated in a sec18 mutant at the restrictive temperature would
co-precipitate in immunoprecipitation experiments. However, this does not appear
to be the case as immunoprecipitation experiments showed no detectable
co-precipitation of the toxin subunits accumulated in a sec 18 mutant (ie the y
subunit does not appear to be associated with the ap precursor). The simplest
explanation for this observation is that the disulphide bond between the p and y
subunits of the toxin occurs after the point in the secretory pathway at which the
sec 18 mutation exerts its effect (from the experiments performed it was not
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possible to deduce whether the intramolecular disulphide bonds in the a subunit had
been formed or not). The phenomenon of late covalent assembly of polypeptides in the
Golgi apparatus has been reported for the assembly of asymmetric
acetylcholinesterase (Rotundo 1988) and therefore it is possible that the assembly
of killer toxin in yeast may also occur at a late stage in the secretory pathway. The
possibility that co-precipitation of the toxin subunits is not detected because of the
experimental procedures cannot be ruled out, but as non-reducing conditions were
used for extraction and immunoprecipitation of yeast proteins I feel that the
likelihood of disulphide bonds between subunits being broken was minimised as far
as possible. Another possibility that we cannot rule out is that the lack of
co-precipitation of toxin subunits could be a result of the sec18 mutant being
deficient in disulphide bond formation at the restrictive temperature due to changes
in the ER. In summary my results suggest that the toxin accumulated in the ER in a
sec18 mutant has not been proteolytically processed by Kex2p, and that disulphide
bonds between subunits have not been formed.
Processing events in the secretory pathway occur sequentially in order that secreted
proteins are converted into their active secreted form. One of the aims of this project
was to alter the timing of the Kex2 processing event in the secretory pathway by
localising an active Kex2p to the ER and to investigate the effect of premature Kex2
processing on the biogenesis of secretory proteins. In my attempt to localise an
active Kex2p to the ER some interesting observations about retention of proteins in
the ER were made. The yeast HDEL retention sequence alone did not appear to be
sufficient to facilitate the efficient retention of the Kex2p within the cell since
Kex2'-HDEL protein is secreted when expressed at relatively high levels (ie from an
episomal plasmid), although when expressed at lower levels (ie from a centromere
plasmid) it appears to be efficiently retained. This could be due to the Kex2'-HDEL
protein saturating the HDEL retention system when expressed at relatively high
levels. However a Kex2'-PDI hybrid protein appears to be much more efficiently
retained even when expressed at similar levels, although some is secreted in an
apparently clipped form. It is possible that the HDEL element in Kex2'-HDEL is
masked and not efficiently recognised by the putative HDEL receptor, but that the
addition of the 60 C-terminal amino acids of yeast PDI places HDEL in a natural
context and allows the HDEL sequence to be more efficiently recognised. It is also
possible that something in the C-terminus of PDI other than the HDEL sequence is
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responsible at least in part for the efficient retention of the Kex2'-PDI hybrid
protein. Examination of the 60 C-terminal amino acid residues of yeast PDI and yeast
BiP (both luminal ER proteins) reveals that they have a very high net negative
charge (-19 and -18 respectively; see fig. 11.1). It has been suggested that the ER
is made up of a gel matrix of abundant ER proteins (reticuloplasmins; Booth and Koch
1989) and that calcium ions are necessary to stabilise this matrix. It therefore
seems reasonable to suppose that the high negative charges at the C-termini of yeast
reticuloplasmins PDI and BiP (and possibly other reticuloplasmins) may interact
with the positive charge on calcium ions to stabilise a gel matrix. The more efficient
retention of Kex2'-PDI might thus be due to the fact that the Kex2'-PDI protein can
be stabilised in a gel matrix whereas the other Kex2'p constructs including the
Kex2'-HDEL protein cannot. Thus Kex2'-PDI may avoid the normal fate of soluble
secretory proteins by being incorporated into this gel matrix. If, when vesicles bud,
they only entrap proteins present in the fluid phase, the Kex2'-PDI hybrid protein
will not usually be present in the budding vesicles, whereas the other, fully soluble
Kex2 constructs will be. The HDEL retention system has been reported to be easily
saturable (Pelham et al 1988, Dean and Pelham 1990). Therefore the Kex2'-HDEL
protein, when expressed at high levels (ie from the episomal plasmids), will
probably leave the ER in fairly large amounts, perhaps enough to saturate the
putative HDEL receptor that retrieves HDEL-containing proteins from a post ER
compartment. In contrast, if the above argument is true, the amount of Kex2'-PDI
protein leaving the ER even when the protein is expressed at high levels, will
probably be much lower, since most would be present in an immobilised form. This
low amount of Kex2'-PDI hybrid protein would probably not be enough to saturate
the putative HDEL receptor, allowing it to be recycled back to the ER. When
expressed at low levels (ie from the centromere plasmid) the amount of Kex2-HDEL
protein, although it leaves the ER is probably not enough to saturate the putative
HDEL receptor and this is why no detectable Kex2 activity is present in strains
expressing Kex2'-HDEL from centromere plasmids.
Results obtained from the attempts to localise an active Kex2' polypeptide to the ER
are thus consistent with the involvement of a mechanism other than the HDEL
retrieval mechanism for localising reticuloplasmins to the ER. The model I propose
for the retention of reticuloplasmins based on my experimental data is consistent
with the model proposed by Booth and Koch (1989) and is as follows:- The negative
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Fig. 11.1 The C-termini of veast PDI and veast BiP
The C-terminal amino acid (59 residues) sequences of the yeast PDI and yeast BiP
proteins are shown. The asterisks indicate the amino acids, aspartic acid (D) and
glutamic acid (E) that are negatively charged at pH 7.0. The C-terminus of PDI has
24 negatively charged amino acid residues and carries a net negative charge of -19.
The C-terminus of BiP has 22 negatively charged amino acid residues and carries a
net negative charge of -18. The reason 59 C-terminal amino acid residues of each of
the proteins were looked at was that 59 amino acid residues of yeast PDI are present
in the Kex2-PDI hybrid protein.
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charge on the C-terminus of PDI (and other reticuloplasmins) is involved in a bulk
sorting mechanism i.e. the formation of a gel matrix possibly stabilised by calcium
ions. HDEL-containing proteins that escape the bulk sorting and leave the ER are
retrieved by the HDEL receptor recycling mechanism which is a backup to the bulk
sorting that stops the majority of reticuloplasmins from being secreted. The
HDEL-based recycling mechanism probably does not have to deal with large amounts
of HDEL-containing proteins and therefore it does not normally matter that it is not
capable of dealing with large amounts of HDEL-containing proteins. The bulk sorting
model can explain the apparent anomaly that the very abundant proteins BiP and PDI
do not normally get secreted even though the HDEL retention system seems easily
saturable in yeast.
Another interesting observation arising from the attempts to localise the Kex2*
polypeptides to the ER was that although the Kex2'-PDI hybrid protein is the most
efficiently-retained construct by far, there was still Kex2 activity secreted from
strains expressing Kex2'-PDI. When the secreted Kex2'-PDI polypeptide was
compared to the internal (i.e. retained) Kex2'-PDI polypeptide it was discovered to
be approximately 4K smaller. This suggests to me that the Kex2'-PDI secreted has
been specifically cleaved by a proteolytic enzyme as the secreted polypeptide runs as
a distinct band and not as a smear which could possibly arise due to proteolytic
degradation. The most likely explanation for the secreted polypeptide being smaller
than the internal form is that the C-terminus has been removed by a cleavage
somewhere in the PDI portion of the Kex2'-PDI hybrid protein. This cleavage would
remove the majority of the PDI portion involved in the putative bulk sorting
mechanism of retention and also the HDEL sequence. The cleaved protein would
therefore have little or no means of being retained within the cell either by the bulk
sorting proposed above or by the specific HDEL recognition mechanisms, and would
get secreted along with other secretory proteins. One of the questions that arises
from this observation is; what is the enzyme responsible for the cleavage of the
Kex2'-PDI protein? From the experiments performed there is no evidence for a
vacuolar protease being responsible, i.e. in a strain deficient in vacuolar proteases
Kex2'-PDI still gets secreted. Clearly further experiments will be required to
determine the reason for this proteolytic cleavage. One interesting possibility is that
an ER protease normally involved in removal of aberrant proteins is responsible,
analogous to that reported in mammalian cells (see Hurtley and Helenius 1989).
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Finally, it is unfortunate that technical problems prevented the analysis of the
biogenesis of the K.lactis killer toxin processed by the different Kex2' constructs^
However, the analysis of the processing of pre-pro a factor by the different Kex2'p
constructs has yielded some interesting results. The most striking of these results is
that the Kex2'-PDI hybrid protein, which is efficiently retained within the cell and
is most likely to be permanently located in the ER, did not process a factor with
anything near the same efficiency as the other constructs, although it is known that
the Kex2'-PDI protein is fully active in an in vitro assay. It is noteworthy that the
intracellular level of Kex2'-PDI activity (in vitro) is higher than for any of the
other Kex2' constructs. There are a number of possibilties for the relatively low in
vivo activity:- (1) Although the Kex2'-PDI protein can process a small peptide
substrate in an in vitro assay this does not mean that it will be able to process the
larger pre-pro a factor polypeptide efficiently. (2) It is possible that the
environment in the ER with respect to pH, ion concentrations etc is not favourable
for Kex2 protease activity and therefore very little a factor is processed. (3) If
pre-pro a factor is processed in the ER by Kex2p active a factor may not reach the
cell surface due to degradation in the secretory pathway. A final possibility exists
which arises from the suggestion made above that Kex2'-PDI may be incorporated
into the reticuloplasm. If this is the case, pre-pro a factor which is likely to be in
the fluid phase, may only rarely come into contact with the Kex2 enzyme and
therefore may not be as efficiently processed. The other Kex2' constructs are
probably in the fluid phase and can come into contact with the pre-pro a factor
substrate and process it more efficiently. Even the Kex2'-HDEL construct, that may
be being recaptured by the HDEL retrieval mechanism is probably present in the
fluid phase and is in contact with the prepro a factor substrate.
In summary a number of interesting observations have been made regarding the
biogenesis of proteins in the secretory pathway and retention of reticuloplasmins in
yeast. Additional work will be required to re-inforce some of the observations and
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